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Introduction and outline 9
intRoduCtion
Patients with breast cancer are getting older 
Populations around the world are rapidly ageing. In high-income countries, increasing 
longevity is mainly due to rising life expectancy among people aged 60 years and older.1 
Ageing of a population increases the exposure to age-related diseases, such as cancer.1 In 
high-income countries, cancer is now surpassing cardiovascular disease as the leading 
cause of death and it is expected to become the leading cause of morbidity and mortality 
worldwide in the coming decades.2 For this reason, we can expect an exponentially growing 
number of older patients diagnosed with cancer that will pose serious challenges to our 
health care system and resources. 
Breast cancer is the leading contributor to cancer incidence and the second cause of cancer 
death among all cancers in women living in high income countries.3  Breast cancer is oft en 
perceived as a disease that aff ects young women. However, the majority of women diagnosed 
with breast cancer is older than 65 as the probability of developing breast cancer increases 
with age. Among women aged between 50-59 years, one out of 44 will develop breast cancer 
during that age interval while among women aged over 70 years, it rises to one out of 15 
women that will develop breast cancer.4 With the ageing of the population, the number of 
women diagnosed with breast cancer will sharply increase in the coming decades. In the 
United States, it is estimated that the absolute number of women aged between 70 and 84 
years diagnosed with invasive oestrogen positive breast cancer will rise by 4.0% per year 
(Figure 1).5 
Figure 1. Observed and projected incidence of invasive and in situ estrogen receptor (ER)–positive 
breast tumours in Surveillance, Epidemiology, and End Results (SEER) 13 and corresponding forecasts of 
cancer burden in the entire United States. A) Observed and projected incidence of invasive ER+ tumours 
per 100 000 woman-years in SEER 13. B) Predicted burden of invasive ER+ tumours in the United States 
(number of newly diagnosed cases per year) by age group and overall. Adapted from Rosenberg et al.5
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old versus young 
Older patients are more likely to present with estrogen and progesterone receptor posi-
tive tumours. Among patients aged 80-84 years, 85% is diagnosed with oestrogen receptor 
positive cancer compared to 60% among patients aged 30-34.5 The proportion of patients 
presenting with Human epidermal growth receptor (HER2) receptor positive breast cancer 
decreases from 22% among patients younger than 40 years to 10% in patients aged 70 years 
and older.6 Tumour size at diagnosis increases with age and this is most pronounced after 
the age of 80. Above the age of 70 years the proportion of patients with positive lymph nodes 
rises significantly.7-9 Among postmenopausal patients, tumour grade does not appear to 
change with increasing age.6 Although breast cancer survival significantly improved over 
the last three decades for younger patients, such an improvement was not observed among 
older patients.7 This has led to an increasing gap in survival outcomes between younger and 
older patients.    
There are many other aspects than breast cancer itself that distinguish older patients from 
young patients. In older patients, breast cancer occurs on the background of ageing. Due to 
the ageing process, there is a large variety in older individuals with respect to concomitant 
diseases, physical and cognitive functioning and physiological reserve. As a result, life 
expectancy among older patients varies considerably and does not merely depend on breast 
cancer prognosis. Ageing influences treatment decisions in several ways. In patients with a 
short life expectancy, the benefit of treatment might be limited as the patient is not expected 
to be alive long enough to experience that benefit. Moreover, comorbidities or polyphar-
macy can limit the efficacy of treatment or increase the risk of complications or toxicity 
related with treatment.10 For these reasons, it is challenging for a clinician to estimate the 
potential benefits and harms of treatment strategies for an individual older patient. 
Moreover, patient preferences for treatment might vary between younger and older patients. 
For the majority of older patients maintaining or increasing quality of life becomes more 
important than increasing length of life.11 The burden of frequent hospital visits associ-
ated with radiotherapy and the risk of a second surgery are treatment-related aspects that 
withhold some older patients to undergo breast-conserving surgery.12 Although a majority 
of patients would accept adjuvant chemotherapy, older patients are less willing to trade of 
cognitive or physical capacity for survival benefit.13,14 
Research in older patients with breast cancer 
Most international or national clinical guidelines on the treatment of breast cancer do not 
provide specific guidance for the treatment of older patients. Dutch guidelines do provide 
specific recommendations for the administration of chemotherapy in older patient. They 
state that ‘chemotherapy should not be given to patients aged over 70 years, unless the 
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patient is considered very fit’.15 There is no further elaboration on the concept ‘very fit’ nor 
is there any evidence to underline this statement. Instead, they argue evidence for the ef-
fectiveness of chemotherapy among patients aged over 70 years is not available and for this 
reason it should not be given. In 2012, the International Organization for Geriatric Oncol-
ogy (SIOG) published an updated guideline with recommendations for the management 
of older patients with breast cancer.6 Unfortunately, the common thread throughout the 
guideline was the inability to provide evidence based recommendations for this population. 
Indeed, evidence to guide treatment of these patients remains scarce. Clinical trials often 
have inclusion criteria that, either directly or indirectly, preclude older patients from par-
ticipating.16,17 Furthermore, older patients who do participate in breast cancer trials may not 
be representative for the general older population due to selection of fitter older patients 
with a higher socio-economic status and with good cognitive function. These differences 
impair the external validity of a clinical trial and limit the extrapolation of outcomes to the 
wider older population with breast cancer.18
Moreover, it is questionable whether current trials provide endpoints that are adequate 
and relevant for older patients. Most clinical trials assess cancer-related outcomes, such as 
disease-free survival, recurrence-free survival or progression-free survival as their main 
endpoints.16 First, the validity of these endpoints might be problematic among older patients. 
With increasing age, the risk of dying due to other causes than breast cancer, so called com-
peting mortality, increases.19,20 As a result, competing mortality influences cancer-related 
endpoints and this is not adequately addressed in the analyses of current clinical trials.21 
Furthermore, defining cause of death is challenging in older patients because some cancer 
treatments might influence non-cancer related deaths. Misclassification of cause of death is 
more likely to occur among older patients.22 Most importantly, we should ask ourselves if 
cancer-related endpoints fit to the needs and desires of older patients. As described above, 
maintaining quality of life becomes an important aspect of treatment decisions. For older 
patients, side effects of therapy might outweigh the potential survival benefit.
Over the last decade, it was increasingly acknowledged that the lack of evidence based 
medicine in the growing older population with breast cancer should be addressed as this 
may contribute to survival differences between younger and older patients. International 
organizations such as the American Society for Clinical Oncology (ASCO), the European 
CanCer Organization (ECCO), the European Organiasation for Research and Treatment 
(EORTC)  and the SIOG have urged researchers to include older patients in clinical trials 
and to design trials that are specifically focused on older patients.6,21,23 Despite the encour-
agement of these important international organizations to include older patients in clinical 
trials, only 4% of the current clinical trials in breast cancer is focused on older patients.16 
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As current clinical trials will not improve evidence based medicine for the older population 
in the forthcoming years, alternative research methods should be considered. Although 
randomized clinical trials are considered the gold standard in evidence based medicine, 
observational studies could be a reasonable alternative when the adequate methodological 
methods are used.24 Patients included in observational studies are more representative of 
the general population and thereby improve the external validity of research findings. 
outline
The aim of this thesis is to better define which older patients will benefit from treatment 
and to improve our understanding of the impact of breast cancer treatment on both breast 
cancer related and non-breast cancer related outcomes. In Part I,  we investigate the as-
sociation with various treatment strategies on breast cancer related and non-breast cancer 
related outcomes. Part II discusses the long term prognosis of breast cancer among younger 
and older patients in the presence of competing causes of death. Part III elaborates on 
several methods for performing and evaluating research in the older population.
Part i: evaluating treatment of older patients with breast cancer
The lack of evidence to guide treatment decisions and the heterogeneity among the older 
population has led to deviation from standard guidelines among older patients.19 This might 
be justified for frail older patients who have a high chance of dying due to other courses or 
who are at a high risk of adverse events of treatment. In these patients, treatment according 
to guidelines might lead to overtreatment. On the other hand, some patients might not 
have received treatment while they would have gained benefit from this treatment. In this 
case, deviation from guidelines to withhold treatment may contribute to undertreatment. In 
Chapter 2, we use population-based data from European cancer registries to study variation 
in treatment strategies between countries in older patients with non-metastatic breast cancer 
and we assess whether country specific treatment strategies are associated with variation in 
relative survival between these countries. Older patients are often diagnosed with hormone 
receptor positive breast cancer. In this subgroup, several types of adjuvant endocrine treat-
ment strategies are available.25 In Chapter 3, we evaluate long-term outcomes of two types 
of endocrine treatment strategies in postmenopausal patients included in the Tamoxifen 
and Exemestane Adjuvant Multinational (TEAM) trial. Chapter 4 evaluates the influence of 
age on physical functioning at time of diagnosis, one and two years after start of endocrine 
therapy among a subset of patients included in the TEAM trial. 
Part ii: Breast cancer prognosis in the presence of competing mortality
As life expectancy is increasing, older patients remain at risk of dying of breast cancer over 
a long time period. At the same time, the risk of dying from other causes than breast cancer 
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increases substantially with advancing age.26 Survival estimates that take these competing 
causes of death into account are essential for individual decision making to balance between 
benefits and toxicities of cancer therapy.27 As breast cancer can recur until 20 years after 
initial diagnosis,28 it is relevant to investigate how breast cancer mortality and other cause 
mortality compete over a longer time period. In Chapter 5, the impact of age at diagnosis 
on long-term breast cancer mortality and other cause mortality is assessed using competing 
risk analysis. Moreover, comorbidities influence other cause mortality and possibly influ-
ence breast cancer mortality.7,19,29 In Chapter 6, we study the impact of comorbidities and 
age at diagnosis on breast cancer mortality and other cause mortality. 
Part iii: From research setting to clinical practice: improving methodology in 
studies in older patients 
In the world of research, we became accustomed with measurements and outcomes from 
a biomedical perspective. These measurements and outcomes may be disconnected from 
the experience and relevance in clinical practice and the patient itself. As a consequence, 
findings from clinical trials are often not reproducible in clinical practice, especially among 
older patients. In Chapter 7, we investigate how the construct of successful ageing has been 
defined and changed over the last century and how the definition of successful ageing influ-
ences our research methodology in the field of geriatrics and gerontology. In Chapter 8, we 
describe how the use of absolute risks instead of relative risks improves our understanding 
of impact of risk factors in clinical practice and how the use of absolute risks leads to dif-
ferent findings among older patients. In Chapter 9, we propose a new endpoint for clinical 
studies that will enable researchers to adequately include the patients experience in the 
evaluation of effectiveness of treatment among older patients.  
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ABstRACt
Background: Elderly are poorly represented in breast cancer research. We assessed whether 
variance in treatment patterns may be associated with variation in survival. 
Methods: Population-based study including patients aged ≥ 70 with non-metastatic BC 
from cancer registries from the Netherlands, Belgium, Ireland, England and Greater Poland. 
Proportions of local and systemic treatments, five-year relative survival and relative excess 
risks (RER) between countries were calculated. 
Results: 236,015 patients were included. The proportion of stage I breast cancer  receiving 
endocrine therapy ranged from 19.6% (Netherlands) to 84.6% (Belgium). The proportion 
of stage III breast cancer receiving no breast surgery varied between 22.0% (Belgium) and 
50.8% (Ireland). For stage I breast cancer, relative survival was lower in England compared 
to Belgium (RER 2.96, 95%CI 1.30-6.72, P<.001). For stage III BC, England, Ireland and 
Greater Poland showed significantly worse relative survival compared to Belgium.
Conclusion: There is substantial variation in treatment strategies and survival outcomes 
in elderly with breast cancer in Europe. For early stage breast cancer, we observed large 
variation in endocrine therapy but no variation in relative survival, suggesting potential 
overtreatment. For advanced breast cancer, we observed higher survival in countries with 
lower proportions of omission of surgery, suggesting potential undertreatment. 
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intRoduCtion
Cancer is a disease of the elderly; 30% of patients diagnosed with breast cancer are aged 70 
years or older.1 Although this group of older patients is rapidly growing, evidence to guide 
treatment of these patients remains scarce.2 Clinical trials often have inclusion criteria that 
preclude older patients from participating.3 Furthermore, older patients participating in 
trials may not be representative for the wider older population due to selection of fitter older 
patients, those with higher socio-economic status and those with good cognitive function. 
These differences impair the external validity of trials and limit the extrapolation of their 
findings.4 
The American Society of Clinical Oncology (ASCO) and the International Society of Ge-
riatric Oncology (SIOG) have called for age specific clinical trials to improve treatment in 
this patient group.3,5 However, de Glas and colleagues showed that only 4% of the currently 
running trials for breast cancer treatment are specifically including older patients.6 There-
fore, major improvement in the evidence base for treatment in older patients is not likely to 
occur within a short period of time. An alternative way to study treatment in older patients 
is by using observational data. Observational data from cancer registries are highly repre-
sentative of the older population because there is no selection for inclusion.4 Furthermore, 
observational data are currently available and can directly be used for research purposes.7 
They provide better insight into treatment strategies and, when using appropriate methods, 
may be used to evaluate the efficacy of different treatment strategies.8 For these reasons, the 
European Registration of Cancer Care project (EURECCA) Breast Cancer Group, collected 
data from cancer registries on treatment and survival outcomes in older patients with breast 
cancer. 
The aim of this study was to compare differences in locoregional and systemic treatment 
patterns and survival outcomes in older patients with non-metastatic breast cancer across 
five European countries. In addition, this study aimed to assess whether variance in treat-
ment between countries was associated with outcome variation.
MAteRiAls And Methods
This is an observational cohort study with data obtained from four national (The Nether-
lands, Belgium, Ireland and England) and one regional (Greater Poland) population-based 
cancer registry (CR). All patients aged 70 years and older at time of diagnosis with non-
metastatic invasive breast cancer were selected. The International Classification of Diseases 
and Related Health Problems (ICD-10) coding was used for selection of breast cancer.9 In 
case of synchronous or bilateral tumours, the tumour with the highest known TNM stage 
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was selected for analysis. In addition, second primary tumours and patients diagnosed with 
breast cancer only at the time of death were excluded.
Procedures
The protocol specified that data on all consecutive breast cancer cases available between 
2000 and 2013 should be provided with information on stage of disease, treatment and 
vital status. For all national and regional based CRs coverage rate was approximately 100%. 
Quality of the CRs and methods and periods of collection of the data are described in 
Supplementary Table 1.
Stage of disease was defined using the TNM Classification of Malignant Tumours for breast 
cancer, 6th edition.10 Information on tumour stage was based on pathology reports. If the 
pathological T or N category was unknown, clinical stage was used instead. For patients 
with unknown T or N category (both clinical and pathological) stage of disease was 
considered unknown, unless patients with only known T or N category could be reliably 
assigned to a specific stage (for example T4NXMX = stage III). Patients with an unknown 
M-category were assumed to have non-metastatic disease (unless T and N category were 
both unknown). When stage directly derived from patient reports was available but was 
assigned unknown according to the above mentioned stage definition, stage available from 
reports was used instead. If available, data on tumour grade, morphology and hormone 
receptor expression were collected. Tumour grade was classified as grade I (well differenti-
ated), grade II (moderately differentiated), or grade III (poorly differentiated). Morphology 
was classified into ductal, lobular, or mixed/other according to ICD-O-3 classification.11
outcomes
Main outcomes were the proportion of given treatment for locoregional treatment (breast 
surgery, axillary surgery and radiotherapy) and systemic treatment (endocrine therapy, che-
motherapy and primary endocrine therapy) and five-year relative survival for each country. 
Breast surgery was defined as the most extensive breast surgery (no surgery, breast conserv-
ing surgery (BCS), mastectomy, breast surgery not otherwise specified), axillary surgery 
if any breast surgery (yes or no) and radiotherapy if BCS (yes or no). Adjuvant endocrine 
therapy was defined as endocrine therapy if any breast surgery was performed (yes or no). 
Adjuvant chemotherapy was defined as chemotherapy if any breast surgery was performed 
(yes or no). Most registries did not distinguish between adjuvant or neo-adjuvant systemic 
therapy. Therefore, these were combined. Primary endocrine therapy was defined as endo-
crine therapy without receiving surgery (yes or no). Vital status was provided by the CRs 
and defined as alive, dead, or unknown. Follow up time for vital status was defined as time 
in days from diagnosis until death or end of follow up. Vital status and date of last follow-
up were established either directly from the patient’s medical record or through linkage of 
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cancer registry data with mortality or population registries (Supplementary Table 1). All 
outcomes were stratified for stage (I-III). 
statistical analysis
All analyses were performed in Stata/MP. Data from national or regional data registries 
were compared between countries. Proportions of patients undergoing each treatment were 
calculated. Due to the large number of cases, no statistical tests were conducted to assess 
statistical significant proportional differences. Median follow up and interquartile range 
(IQR) were calculated according to the reverse Kaplan-Meier method.12 Relative survival re-
flects the ratio of overall survival of cancer patients compared with survival that would have 
been expected based on the corresponding general population (matched by country, age by 
single year and year of diagnosis). Relative survival for the complete cohort was estimated 
using the Pohar-Perme method.13 National life tables from The Human Mortality Database 
were used to estimate expected survival.14 To model the effect of covariates on relative sur-
vival an additive hazard model was employed. The effect of covariates on the excess hazard 
was estimated using the expectation-maximisation method.15 Estimates of the covariates are 
expressed as relative excess risk of death (RER) and they quantify the relative cancer related 
excess mortality between the categories of the included covariates in the model.16 When 
the excess mortality is low (for instance in a population with a high population mortality 
and generally curable cancer), standard errors become large and hamper the interpretation 
of the RER.15 To compare RER between countries, country was included as a covariate in 
the univariate model. Differences in relative survival between countries were adjusted for 
the following potential confounders in a multivariable model: age (continuous), year of 
diagnosis, stage (not when stratified for stage), grade and morphology. A two-sided p-value 
of <0.05 was considered statistically significant. In Table 3 and Figure 2, countries were 
ranked according to the sum of proportions of given treatment and the country with the 
highest sum was assigned as reference country. 
Multiple imputation was used to account for missing values for each country separately after 
exclusion of tumors diagnosed at time of death, second primary breast cancer and smaller 
synchronous tumours and age younger than 70 years (Figure 1). Multiple imputation by 
chained equation was performed, assuming that data are missing at random. For each 
incomplete variable (stage, grade, morphology, hormone receptor expression), imputation 
models were applied that included the other incomplete variables, as well was complete 
variables (age, year of diagnosis), treatment variables and outcome variables (vital status, 
follow up time in days). When data for a variable was 100% missing it was not imputed. 
Analyses were based on pooled results of five imputed data sets.17
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Additional analyses
A sensitivity analysis was performed to assess the impact of variation in time periods on 
treatment and survival outcomes between the participating countries only including the 
years with data available from all countries (2008 and 2009). Based on expert panel discus-
sion, a proportional difference of 10% or higher between treatment outcomes was defined 
as clinically relevant. 
ethical approval 
Data from cancer registries provided anonymised patient data. Therefore, informed consent 
from patients or ethical approval were not required for this study.
Results 
Patients
The original dataset included 829,131 patients diagnosed with breast cancer between 2000 
and 2013. Patients with synchronous or bilateral tumours, second primary tumours, tu-
mours diagnosed at time of death and patients aged younger than 70 years were excluded 
(Figure 1). 40,448 patients from the Netherlands, 11,305 patients from Belgium, 4,319 
patients from Ireland, 179,239 patients from England and 704 patients from Greater Poland 
were included (Table 1, step 1). Multiple imputation analysis was performed to account for 
missing values (Table 1, step 2) and selected patients stage I-III breast cancer for further 
analyses (Table 1, step 3). Median follow up was 8.8 years (IQR 5.9-12.5 years). 
Primary data 
n=144,308
The Netherlands Belgium Ireland England Greater Poland
Excluded (n=104,870) 
- Bilateral tumors (n=1,649)
- Second primary BC (n=3,760)
- Death certificate only (n=6)
- Age < 70 years (n=99,455)
Excluded (n=25,330) 
- Bilateral tumors (n=0)
- Second primary BC (n=0)
- Death certificate only (n=2)
- Age < 70 years (n=25,328)
Excluded (n=13,254) 
- Bilateral tumors (n=187)
- Second primary BC (n=284)
- Death certificate only (n=10)
- Age < 70 years (n=12,773)
Excluded (n=448,205) 
- Bilateral tumors (n=10,010)
- Second primary BC (n=21,290)
- Death certificate only (n=8,334)
- Age < 70 years (n=408,571)
Excluded (n=2445) 
- Bilateral tumors (n=0)
- Second primary BC (n=0)
- Death certificate only (n=30)
























Figure 1. Flow chart 
Bilateral tumours: in case of synchronous tumours, the smallest stage tumour was excluded.
Patient characteristics 
Stage distribution varied slightly across countries; patients from the Netherlands were more 
frequently diagnosed with stage I breast cancer compared to other countries (Table 1, step 
3). Overall, tumour characteristics were broadly comparable across countries (Table 1, step 
3). Patients from the Netherlands and Greater Poland were more likely to have grade I breast 
cancer. 
Treatment and survival of older patients in Europe 25
locoregional treatment
As shown in Table 2, the majority of patients with stage I breast cancer received BCS (be-
tween 48.9% (England) and 65.1% (Belgium), except for Greater Poland (21.1%)). Omis-
sion of surgery was commonly used in England (24.2%) and Ireland (17.8%) compared to 
other countries. For stage II breast cancer, the majority of patients received a mastectomy 
(between 44.0% (Ireland) and 66.1% (Greater Poland)). The proportions of patients not 
receiving any surgery showed a similar pattern as seen in patients with stage I breast cancer 
(Table 2). For stage III breast cancer, the proportion of patients not receiving any surgery 
increased compared to lower stages of breast cancer: this is most pronounced in The Neth-
erlands (30.1%), England (44.1%) and Ireland (50.8%). The majority of patients who had 
breast surgery received axillary treatment with no clinically relevant differences between 
countries and across stages (Figure 2, Supplementary Table 2). In England (across all stages) 
and Greater Poland (for stage III), the proportion of patients receiving radiotherapy after 
breast conserving surgery was lower (Figure 2, Supplementary Table 2). 
systemic treatment 
Use of adjuvant endocrine therapy differed considerably between countries: for stage I 
breast cancer the proportion was substantially lower in the Netherlands (20%), compared to 
the other countries (Belgium 84.6%; Ireland 79.5%; England 47.5%; Greater Poland 68.9%, 
Figure 2A, Supplementary Table 2). In England, systemic therapy was not registered for 
a large proportion of patients but this could not be considered as not given, hence this is 
considered as unknown (Figure 2). For higher stages of breast cancer, variation was less 
pronounced between countries (Figure 2B and 2C, Supplementary Table 2). In addition, 
substantial variation in the administration of chemotherapy across countries was observed. 
The proportion of patients with stage I breast cancer receiving chemotherapy was very low 
across all countries but showed marked variation (range from 0.5% (the Netherlands) to 
6.0% (Ireland) and 11.4% (Greater Poland), Figure 2A, Supplementary Table 2). For stage II 
breast cancer, chemotherapy use was higher but again varied markedly between countries 
(range from 2.2% (the Netherlands) to 19.4% (Ireland) and 23.1% (Greater Poland), Figure 
2B, Supplementary Table 2). For stage III breast cancer, chemotherapy use increased further 
but still varied markedly, from 10.3% of patients in the Netherlands to 35.2% in Belgium and 
42.7% in Greater Poland (Figure 2C, Supplementary Table 2). As shown in Figure 2, use of 
primary endocrine therapy (PET) was a commonly used strategy among older patients with 
breast cancer (Figure 3, Supplementary Table 3). In stage III disease differences between 
countries were most pronounced; in Ireland 39% of the patients received primary endocrine 
therapy, compared to 23.6% in the Netherlands, 24.9% in England, 15.1% in Belgium and 
1.8% in Greater Poland (Figure 3, Supplementary Table 3). 
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Table 1. Distribution of patient and tumour characteristics by country, before and after imputation (Step 1 and 
2) and after selection of patients with stage I-III breast cancer (Step 3)
Netherlands Belgium Ireland England Greater Poland
Step 1 Step 2 Step 3 Step 1 Step 2 Step 3 Step 1 Step 2 Step 3 Step 1 Step 2 Step 3 Step 1 Step 2 Step 3
N  %  % % N  %  % % N  %  % % N  %  % % N  %  % %
Total N 40,448 11,305 4,319 179,239 704
Year of diagnosis
2000 3745 9.3 9.3 9.2 0 0.0 0.0 0.0 0 0.0 0.0 0.0 11837 6.6 6.6 6.4 0 0.0 0.0 0.0
2001 3688 9.1 9.1 9.1 0 0.0 0.0 0.0 0 0.0 0.0 0.0 12073 6.7 6.7 6.6 0 0.0 0.0 0.0
2002 3555 8.8 8.8 8.7 0 0.0 0.0 0.0 0 0.0 0.0 0.0 11995 6.7 6.7 6.7 0 0.0 0.0 0.0
2003 3553 8.8 8.8 8.7 0 0.0 0.0 0.0 533 12.3 12.3 12.4 12409 6.9 6.9 6.9 0 0.0 0.0 0.0
2004 3656 9.0 9.0 9.0 0 0.0 0.0 0.0 566 13.1 13.1 13.1 12302 6.9 6.9 6.8 0 0.0 0.0 0.0
2005 3609 8.9 8.9 8.9 0 0.0 0.0 0.0 567 13.1 13.1 12.7 12935 7.2 7.2 7.1 0 0.0 0.0 0.0
2006 3590 8.9 8.9 8.9 0 0.0 0.0 0.0 638 14.8 14.8 14.6 12666 7.1 7.1 7.0 0 0.0 0.0 0.0
2007 3771 9.3 9.3 9.5 2763 24.4 24.4 24.7 641 14.8 14.8 15.0 12645 7.1 7.1 7.0 0 0.0 0.0 0.0
2008 3797 9.4 9.4 9.4 2805 24.8 24.8 24.7 662 15.3 15.3 15.2 12994 7.2 7.2 7.2 325 46.2 46.2 47.9
2009 3666 9.1 9.1 9.1 2842 25.1 25.1 24.9 712 16.5 16.5 17.0 12902 7.2 7.2 7.2 379 53.8 53.8 52.1
2010 3818 9.4 9.4 9.5 2895 25.6 25.6 25.7 0 0.0 0.0 0.0 13231 7.4 7.4 7.4 0 0.0 0.0 0.0
2011 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 13294 7.4 7.4 7.5 0 0.0 0.0 0.0
2012 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 13685 7.6 7.6 7.9 0 0.0 0.0 0.0
2013 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 14271 8.0 8.0 8.2 0 0.0 0.0 0.0
Stage 
0 5 0.0 0.4 11 0.1 0.1 0 0.0 0.0 7727 4.3 8.8 19 2.7 9.9
I 14416 35.6 36.1 39.0 2986 26.4 28.7 32.4 740 17.1 21.3 25.6 29581 16.5 26.6 33.7 113 16.1 19.6 28.7
II 17234 42.6 43.2 46.6 4333 38.3 42.3 47.8 1553 36.0 42.3 50.8 44115 24.6 39.2 49.7 190 27.0 31.4 45.9
III 5159 12.8 13.3 14.4 1779 15.7 17.5 19.8 664 15.4 19.7 23.6 13091 7.3 13.1 16.6 110 15.6 17.3 25.3
IV 2662 6.6 7.0 918 8.1 11.4 444 10.3 16.8 8200 4.6 12.3 110 15.6 21.8
Unknown 972 2.4 1278 11.3 918 21.3 76525 42.7 162 23.0
Grade                  
G1 6839 16.9 22.1 22.9 1399 12.4 15.0 15.6 370 8.6 10.3 11.1 21261 11.9 16.5 16.8 82 11.6 20.1 23.5
G2 14376 35.5 48.2 48.9 4414 39.0 48.0 48.1 2102 48.7 57.9 57.6 73916 41.2 53.5 54.5 176 25.0 48.3 46.7
G3 8245 20.4 28.5 28.2 3549 31.4 37.0 36.3 1169 27.1 31.7 31.3 42223 23.6 30.0 28.7 135 19.2 31.6 29.8
Unknown 10988 27.2 1943 17.2 678 15.7 41839 23.3 311 44.2
Morphology                  
Ductal 25812 63.8 63.8 65.2 8058 71.3 71.3 71.6 2771 64.2 64.2 65.3 115345 64.4 64.4 66.7 401 57.0 59.6 69.3
Lobular 5276 13.0 13.0 12.9 1643 14.5 14.5 14.3 591 13.7 13.7 13.9 21634 12.1 12.1 12.8 53 7.5 7.7 8.8
Mixed/other 9360 23.1 23.1 21.9 1604 14.2 14.2 14.1 957 22.2 22.2 20.8 42260 23.6 23.6 20.5 189 26.8 32.7 21.9
Unknown 0 0.0 0 0.0 0 0.0 0 0.0 61 8.7
Hormone receptor expression          
ER- and PR- 2798 6.9 14.4 14.1 0 0.0 0.0 0.0 570 13.2 16.6 16.4 6823 3.8 16.1 15.1 115 16.3 28.5 23.8
ER+ and/or PR+ 18576 45.9 85.6 85.9 0 0.0 0.0 0.0 3142 72.7 83.4 83.6 44586 24.9 83.9 84.9 380 54.0 71.5 76.2
Unknown 19074 47.2 11305 100.0 100.0 100.0 607 14.1 127830 71.3 209 29.7
Step 1: Distribution of patients aged 70 years and older by category before imputation; Step 2: Distribution of 
patients aged 70 years and older by category after imputation; Step 3: Distribution of patients aged 70 years and
 older with stage I-III breast cancer by category after imputation. 
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Table 1. Distribution of patient and tumour characteristics by country, before and after imputation (Step 1 and 
2) and after selection of patients with stage I-III breast cancer (Step 3)
Netherlands Belgium Ireland England Greater Poland
Step 1 Step 2 Step 3 Step 1 Step 2 Step 3 Step 1 Step 2 Step 3 Step 1 Step 2 Step 3 Step 1 Step 2 Step 3
N  %  % % N  %  % % N  %  % % N  %  % % N  %  % %
Total N 40,448 11,305 4,319 179,239 704
Year of diagnosis
2000 3745 9.3 9.3 9.2 0 0.0 0.0 0.0 0 0.0 0.0 0.0 11837 6.6 6.6 6.4 0 0.0 0.0 0.0
2001 3688 9.1 9.1 9.1 0 0.0 0.0 0.0 0 0.0 0.0 0.0 12073 6.7 6.7 6.6 0 0.0 0.0 0.0
2002 3555 8.8 8.8 8.7 0 0.0 0.0 0.0 0 0.0 0.0 0.0 11995 6.7 6.7 6.7 0 0.0 0.0 0.0
2003 3553 8.8 8.8 8.7 0 0.0 0.0 0.0 533 12.3 12.3 12.4 12409 6.9 6.9 6.9 0 0.0 0.0 0.0
2004 3656 9.0 9.0 9.0 0 0.0 0.0 0.0 566 13.1 13.1 13.1 12302 6.9 6.9 6.8 0 0.0 0.0 0.0
2005 3609 8.9 8.9 8.9 0 0.0 0.0 0.0 567 13.1 13.1 12.7 12935 7.2 7.2 7.1 0 0.0 0.0 0.0
2006 3590 8.9 8.9 8.9 0 0.0 0.0 0.0 638 14.8 14.8 14.6 12666 7.1 7.1 7.0 0 0.0 0.0 0.0
2007 3771 9.3 9.3 9.5 2763 24.4 24.4 24.7 641 14.8 14.8 15.0 12645 7.1 7.1 7.0 0 0.0 0.0 0.0
2008 3797 9.4 9.4 9.4 2805 24.8 24.8 24.7 662 15.3 15.3 15.2 12994 7.2 7.2 7.2 325 46.2 46.2 47.9
2009 3666 9.1 9.1 9.1 2842 25.1 25.1 24.9 712 16.5 16.5 17.0 12902 7.2 7.2 7.2 379 53.8 53.8 52.1
2010 3818 9.4 9.4 9.5 2895 25.6 25.6 25.7 0 0.0 0.0 0.0 13231 7.4 7.4 7.4 0 0.0 0.0 0.0
2011 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 13294 7.4 7.4 7.5 0 0.0 0.0 0.0
2012 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 13685 7.6 7.6 7.9 0 0.0 0.0 0.0
2013 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0 14271 8.0 8.0 8.2 0 0.0 0.0 0.0
Stage 
0 5 0.0 0.4 11 0.1 0.1 0 0.0 0.0 7727 4.3 8.8 19 2.7 9.9
I 14416 35.6 36.1 39.0 2986 26.4 28.7 32.4 740 17.1 21.3 25.6 29581 16.5 26.6 33.7 113 16.1 19.6 28.7
II 17234 42.6 43.2 46.6 4333 38.3 42.3 47.8 1553 36.0 42.3 50.8 44115 24.6 39.2 49.7 190 27.0 31.4 45.9
III 5159 12.8 13.3 14.4 1779 15.7 17.5 19.8 664 15.4 19.7 23.6 13091 7.3 13.1 16.6 110 15.6 17.3 25.3
IV 2662 6.6 7.0 918 8.1 11.4 444 10.3 16.8 8200 4.6 12.3 110 15.6 21.8
Unknown 972 2.4 1278 11.3 918 21.3 76525 42.7 162 23.0
Grade                  
G1 6839 16.9 22.1 22.9 1399 12.4 15.0 15.6 370 8.6 10.3 11.1 21261 11.9 16.5 16.8 82 11.6 20.1 23.5
G2 14376 35.5 48.2 48.9 4414 39.0 48.0 48.1 2102 48.7 57.9 57.6 73916 41.2 53.5 54.5 176 25.0 48.3 46.7
G3 8245 20.4 28.5 28.2 3549 31.4 37.0 36.3 1169 27.1 31.7 31.3 42223 23.6 30.0 28.7 135 19.2 31.6 29.8
Unknown 10988 27.2 1943 17.2 678 15.7 41839 23.3 311 44.2
Morphology                  
Ductal 25812 63.8 63.8 65.2 8058 71.3 71.3 71.6 2771 64.2 64.2 65.3 115345 64.4 64.4 66.7 401 57.0 59.6 69.3
Lobular 5276 13.0 13.0 12.9 1643 14.5 14.5 14.3 591 13.7 13.7 13.9 21634 12.1 12.1 12.8 53 7.5 7.7 8.8
Mixed/other 9360 23.1 23.1 21.9 1604 14.2 14.2 14.1 957 22.2 22.2 20.8 42260 23.6 23.6 20.5 189 26.8 32.7 21.9
Unknown 0 0.0 0 0.0 0 0.0 0 0.0 61 8.7
Hormone receptor expression          
ER- and PR- 2798 6.9 14.4 14.1 0 0.0 0.0 0.0 570 13.2 16.6 16.4 6823 3.8 16.1 15.1 115 16.3 28.5 23.8
ER+ and/or PR+ 18576 45.9 85.6 85.9 0 0.0 0.0 0.0 3142 72.7 83.4 83.6 44586 24.9 83.9 84.9 380 54.0 71.5 76.2
Unknown 19074 47.2 11305 100.0 100.0 100.0 607 14.1 127830 71.3 209 29.7
Step 1: Distribution of patients aged 70 years and older by category before imputation; Step 2: Distribution of 
patients aged 70 years and older by category after imputation; Step 3: Distribution of patients aged 70 years and
 older with stage I-III breast cancer by category after imputation. 
28 Chapter 2 
survival outcomes 
As shown in Table 3, five-year relative survival for patients with stage I breast cancer was 
high for all countries, indicating that there is little to no excess mortality in this stage of 
disease. For England, relative survival was significantly lower compared to Belgium (93.4% 
95% CI 93.1-93.7, adjusted RER 2.96, P <0.001). Due to low excess mortality in this specific 
group, RERs for some countries could not be estimated (Table 3, Figure 2A). For patients 
with stage II breast cancer, five-year relative survival was lowest in England (79.1%, 95% CI 
78.8-79.4) and highest in Ireland (86.3%, 95% CI 84.9-87.7). Relative survival was signifi-
cantly lower in England when compared to Belgium (adjusted RER 1.45, 95% CI 1.27-1.66, 
Table 3, Figure 2B). For patients with stage III breast cancer, relative survival was lowest 
in England (48.2%) and highest in Belgium (60.1%). England, Ireland and Greater Poland 
showed a significantly worse relative survival compared to Belgium (Table 3, Figure 2C). 
Table 2. Proportional distribution of most extensive breast surgery by stage of disease
No surgery BCS Mastectomy Not specified
% % % %
Stage I
The Netherlands 11.7 50.3 38.0 0.0
Belgium 11.1 65.1 23.8 0.0
Ireland 17.8 54.4 27.8 0.0
England 24.2 48.9 26.9 0.0
Greater Poland 2.5 21.1 52.4 24.0
Stage II 
The Netherlands 18.2 22.3 59.5 0.0
Belgium 16.9 35.8 47.3 0.0
Ireland 21.2 34.8 44.0 0.0
England 28.1 27.5 44.4 .0
Greater Poland 8.9 8.3 66.1 16.7
Stage III
The Netherlands 30.1 8.3 61.5 0.0
Belgium 22.0 14.4 63.6 0.0
Ireland 50.8 10.4 38.8 0.0
England 44.1 9.5 46.3 0.0
Greater Poland 4.6 3.4 81.8 10.2
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Figure 2. Proportion of patients receiving treatment and adjusted relative excess risks (RERs) of death 
by stage of disease
Proportions of patients receiving therapy and adjusted relative excess risks (RER) of death by country 
for patients with stage I (A), stage II (B) or stage III (C) breast cancer. Countries were ranked according 
to the sum of proportions of each given treatment and the country with the highest sum of given tre-
atment was assigned as reference country. Breast surgery: % of patients receiving any type of breast 
surgery; axillary surgery: % of patients receiving axillary surgery if they received any type of breast sur-
gery; radiotherapy: % of patients receiving radiotherapy if they have received breast conserving surgery; 
endocrine therapy: % of patients receiving endocrine therapy if they have received any type of breast 
surgery; chemotherapy: % of patients receiving chemotherapy if they have received any type of breast 
surgery. Error bars represent 95% confidence intervals. RER was adjusted for the following variables: 
age, year of diagnosis, grade and morphology. 
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treatment patterns and survival differences 
As shown in Figure 2A, representing stage I breast cancer, the proportion of patients receiv-
ing adjuvant endocrine therapy was considerably lower in the Netherlands while all other 
treatment modalities were comparable. No corresponding differences in adjusted RERs 
were observed. For stage II breast cancer, no evident pattern between treatment and sur-
vival outcomes between countries was observed. For stage III breast cancer, the proportion 
of patients receiving chemotherapy was substantially lower in the Netherlands compared 
to Belgium, while other treatment modalities did not differ greatly. Relative survival was 
not significantly different between Belgium and the Netherlands (Figure 2C). However, 
the proportion of patients receiving any type of surgery was lower in Ireland and England 
compared to Belgium while other treatment modalities were similar. Concordantly, relative 
survival was significantly lower in England and Ireland, compared to Belgium. 
sensitivity analyses 
The additional sensitivity analysis showed little variation in treatment outcomes between 
patients diagnosed in 2008 or 2009 and the complete cohort within a country (Supplemen-
tary tables 4 to 6). Supplementary Table 7 shows five-year relative survival outcomes for 
all patients diagnosed in 2008 and 2009. The estimated relative survival and the crude and 
adjusted RERs in this cohort were comparable to estimates found in the complete cohort. 
disCussion
To our knowledge, this is the largest and most recent European population-based study 
presenting information on stage, tumour characteristics, treatment and survival outcomes 
in older patients with breast cancer. First, this study showed substantial variation in Europe 
for treatment of older patients with non-metastatic breast cancer diagnosed between 2000 
and 2013. Second, this study reports substantial variation, most pronounced in advanced 
stage breast cancer, in survival among older patients between European countries. Third, 
































































































Figure 3. Proportion of patients receiving breast surgery, primary endocrine therapy or no therapy by 
stage of disease
32 Chapter 2 
reported in the Netherlands was not accompanied by poorer survival outcomes; but for stage 
III breast cancer, poorer survival outcomes were observed in those countries were breast 
surgery was more frequently omitted. In general, this study suggests that how national and 
European guidelines lack evidence for treatment of breast cancer in older patients, resulting 
in poor consensus in the international community on how to optimally treat older patients. 
The major strength of our study is that we have the largest available and most detailed 
population-based dataset in Europe. Although a randomized controlled trial (RCT) remains 
the golden standard for assessment of effectiveness of therapy, real world data has some 
advantages over RCTs, especially for older patients. It provides a broader and more faithful 
presentation of patterns of care and comparative effectiveness than RCTs. It furthermore 
shows a more balanced outcome of benefits and harms of treatment as relative survival 
represents all excess mortality due to breast cancer: both death directly related to breast 
cancer itself and death indirectly related to breast cancer. 
Limitations in this study should be addressed. Most importantly, data provided by the 
CRs was not complete for all cases. We performed multiple imputation for missing patient 
and tumour characteristics. Simulation studies have shown that handling missing data by 
multiple imputation produces more accurate estimates of relative survival rates, especially 
for late-stage and high-grade tumours when compared to complete-case analysis.17,18 Due 
to the high proportion of unknown hormone receptor status in England (71.3%), the 
imputed proportions of hormone receptor status as described in Table 1 might be  more 
uncertain. For Belgium, hormone receptor expression was not available for the cohort at 
time of analysis but an additional analysis for the year of 2008 showed that hormone recep-
tor distribution was comparable to other countries (data available on request). In England, 
data on systemic treatment was not complete but completeness improved over time. Due 
to incompleteness, non-registered treatment could not be interpreted as not given and 
therefore this was marked as unknown in tables and figures. For surgical outcomes in Eng-
land, audits of selected data have shown good completeness but an element of uncertainty 
should be borne in mind. Moreover, in patients with very high age there might have been 
poorer diagnostic work-up leading to higher data incompleteness. Although age itself was 
available for all patients and included as a predictive factor in the multiple imputation, the 
imputed data for the oldest patients may be more uncertain compared to younger patients. 
Another potential weakness is the broad timeline for inclusion of patients and changes in 
diagnostic procedures and treatment in this period that could have affected variation in 
survival outcomes. For this reason we performed a sensitivity analyses, but survival rates in 
the cohort of the years 2008 and 2009 were comparable to complete cohort outcomes. This is 
in line with previous studies, showing no or limited improvement in survival rates for older 
patients with breast cancer over the last decade.19-21 Data on individual factors that could af-
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fect treatment outcomes and survival such as comorbidities, patient preferences and breast 
cancer subtypes as well as anti-Her2Neu therapy were not available or not complete in the 
CRs. In addition, there was great variation in the numbers of patients included between the 
participating countries. This has resulted in less precise estimates for the smallest groups of 
patients included hampering the interpretation of the data. 
The design of this study allowed us to explore possible associations between treatment 
patterns and survival outcomes. Across Europe, large treatment variation exists and these 
variations can be used as a natural experiment as variation in assignment to a specific type 
of treatment was based on country of residence and was therefore not related to the out-
come. This enabled us to draw a comparison between treatment patterns and outcomes in 
an observational setting.8 
A notable finding was the low proportion of patients receiving adjuvant endocrine therapy 
with stage I breast cancer in the Netherlands compared to the other countries (19.6% vs. up 
to 84.6% in Belgium), while other treatments did not differ substantially between countries 
(Figure 2A). In the Netherlands, endocrine therapy is only recommended in hormone 
receptor positive patients with lymph node positive disease or otherwise unfavourable tu-
mour characteristics (high grade or size ≥ 2 cm)22, while in all the other countries adjuvant 
endocrine therapy is prescribed in all patients with hormone receptor positive breast cancer 
(for an overview of guidelines we refer to Supplementary Table 8). This variation in endo-
crine therapy was not linked with variation in survival between countries (Belgium 98.6%, 
Ireland 100.0%, The Netherlands 98.7%), potentially suggesting that adjuvant endocrine 
therapy does not influence breast cancer related mortality in a low risk group (Table 3). A 
previous study comparing Ireland and The Netherlands found similar results.23 In addition, 
a population-based study from Denmark identified a subgroup of older patients with low 
risk breast cancer not treated with adjuvant endocrine therapy that was not at increased 
risk of mortality.24 The pattern described in this study potentially suggests that adjuvant 
endocrine therapy might not contribute to additional survival benefit but further studies are 
necessary to validate these findings. 
In patients with stage III breast cancer, variation in local treatment as well as systemic treat-
ment was apparent. In Belgium, proportions of given local and systemic treatment were 
high compared to other countries. The proportion of patients in whom breast surgery was 
omitted was considerably lower in Belgium (22.0%) compared to Ireland (50.8%) while 
other treatment modalities were similar. Only limited evidence is available for the effective-
ness of primary endocrine therapy. A meta-analysis showed inferior disease control for two 
to three years after diagnosis but no differences in overall survival compared to surgical 
treatment followed by adjuvant endocrine therapy.25 The SIOG guideline recommends that 
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it should only be considered in patients with a life expectancy of less than five years.2 In our 
study, Ireland had a significantly lower survival rate from stage III compared to Belgium 
(53.5% versus 60.1%, adjusted RER 1.27, 95% CI 1.07-1.50, P 0.007). Part of these differ-
ences might be explained by variation in breast surgery. It suggests that in this group of high 
risk patients breast surgery could result in additional breast cancer survival benefit.
This study demonstrates substantial international variation in type of locoregional treat-
ment, while the various guidelines apply largely similar recommendations (Supplementary 
Table 8). Particularly in Poland, patients with early stage breast cancer were less likely to 
receive BCS (Table 2). In those patients with stage II breast cancer who received BCS, we 
found that radiotherapy was considerably lower in Poland than in other countries. For early 
stage breast cancer, omission of radiotherapy after BCS may be justified following publica-
tion of the PRIME II trial showing no overall survival difference and a small increase in 
local recurrences in patients aged 70 years or older with low risk hormone receptor positive 
breast cancer.26 However, no such evidence is available for patients with higher stage disease.
The Netherlands was most conservative in the administration of chemotherapy. For stage III 
breast cancer, only 10.3% of the Dutch patients received chemotherapy, compared to 35.2% 
in Belgium. Other international observational studies have found similar patterns.23,27 The 
conservative prescription of chemotherapy in the Netherlands can partly be explained by 
their national guidelines. It states explicitly that patients aged over 70 years should not 
receive chemotherapy, unless they are considered very fit.22 No other national or European 
guidelines use this explicit age criterion (Supplementary Table 8).28 The SIOG opposes 
guidelines using age as a criterion for any treatment as they state that ‘age alone should not 
dictate any aspect of management of older individuals with breast cancer’.2 Unfortunately, 
evidence for the effectiveness of chemotherapy in older patients is scarce. In the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) polychemotherapy overview patients aged 
70 years or older were significantly underrepresented. Despite this, the EBCTCG did not 
find evidence for differences in the effectiveness of chemotherapy for (fit) older patients.29 
Two clinical trials assessing the effect of chemotherapy versus no chemotherapy in older 
patients with breast cancer were closed prematurely due to poor accrual.30,31 This also dem-
onstrates the difficulty of performing trials in older patients. Although this study showed 
that relative survival was lower in The Netherlands (55.1%) compared to Belgium (60.1%), 
this difference was not significant after adjusting for confounders. Whether chemotherapy 
could be beneficial in a broader selection of older patients and if it should be offered more 
frequently in countries with low proportions of chemotherapy remains debatable. 
In addition to given treatment, other factors could explain variation in both treatment and 
relative survival between countries. These include access to and quality of healthcare, varia-
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tion in general health and comorbidities and variation in breast cancer subtypes between 
countries. For instance, national wealth and total national expenditure on health are related 
to breast cancer guideline adherence and breast cancer survival.27 In Poland, the St. Gallen 
Consensus Conference guidelines were used during 2008 and 2009 but adherence to guide-
lines was affected by suboptimal reimbursement of treatment costs.32 This could explain 
poorer survival outcomes for Greater Poland. The EUROCARE-5 study attributed lower 
survival outcomes in the UK partly to poor access to health care and hence a higher propor-
tion of advanced stage of disease.19 However, when looking further within specific stages, 
variation in survival was still apparent in our study. Furthermore, it has been suggested that 
cancer survival correlates with general health and burden of comorbidities.33 For instance, if 
patients are unfit for surgery, radiotherapy, or chemotherapy due to comorbidities unrelated 
to cancer itself, it can also affect cancer related outcomes. Unfortunately, CRs could not 
provide us with comprehensive or comparable information on comorbidities for individual 
patients. Further information on other factors such as comorbidities and quality of life, 
may be key to gaining a better understanding of treatment processes and patient related 
outcomes. Additional studies should address the relationship between geriatric character-
istics, comorbidities, cancer treatment and quality of life and survival outcomes to bridge 
the knowledge gap for a rapidly growing older population where more evidence-based 
treatment is urgently needed. Moreover, cultural factors across countries both in patient 
preferences and health care professionals could impact decision making in cancer treat-
ment. For instance, we hypothesize that primary endocrine therapy is more common in the 
United Kingdom and Ireland because trials investigating this treatment have mostly been 
performed in these countries and this might have enhanced the enthusiasm to propose this 
type of treatment by health care providers.25 Moreover, patient preferences for treatment 
might vary between younger and older patients and there might be differences in these 
preferences across countries. For the majority of older patients maintaining or increas-
ing quality of life becomes more important than increasing length of life.34 The burden of 
frequent hospital visits associated with radiotherapy and the risk of a second surgery are 
treatment-related aspects that withhold some older patients to undergo breast-conserving 
surgery.35 Although a majority of patients would accept adjuvant chemotherapy, older 
patients are less willing to trade of cognitive or physical capacity for survival benefit.36,37
With this study from the EURECCA breast cancer group, we showed large variation in the 
treatment of older patients with breast cancer between European countries. This implies a 
lack of consensus in the international community on how to optimally treat older patients 
with breast cancer, reflecting the lack of evidence based knowledge and the struggle in clini-
cal practice to treat the very heterogeneous older population. Overall, this study shows that 
for older patients with low risk breast cancer, differences in adjuvant endocrine therapy do 
not appear to impact survival outcomes, potentially suggesting overtreatment of these low 
36 Chapter 2 
risk patients with adjuvant endocrine therapy. On the other hand, variation in the omission 
of breast surgery in older patients with high risk breast cancer appeared to impact survival 
substantially, indicating potential undertreatment in this high risk group. Balancing risk 
of death due to breast cancer and risk of death due to other causes seems essential for 
personalised treatment of older patients with breast cancer. 
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Supplementary Table 2. Proportional distribution of locoregional and systemic treatment modalities 
by stage of disease
Axillary surgery Radiotherapy Endocrine therapy Chemotherapy
Yes % Yes % Unknown % Yes % Unknown % Yes % Unknown %
Stage I 
The Netherlands 89.7 92.4 0.0 19.6 0.0 0.5 0.0
Belgium 94.3 87.7 0.0 84.6 0.0 5.4 0.0
Ireland 84.4 74.7 0.0 79.5 0.0 6.0 0.0
England 89.2 44.6 55.4 47.5 52.5 5.9 94.1
Greater Poland 85.9 75.3 0.0 68.9 0.0 11.4 0.0
Stage II 
The Netherlands 92.8 88.8 0.0 64.5 0.0 2.2 0.0
Belgium 94.3 84.8 0.0 79.5 0.0 16.1 0.0
Ireland 91.6 77.4 0.0 75.3 0.0 19.4 0.0
England 92.8 48.9 51.1 47.9 52.1 14.0 86.0
Greater Poland 87.8 56.5 0.0 65.4 0.0 23.1 0.0
Stage III
The Netherlands 94.2 85.4 0.0 70.7 0.0 10.3 0.0
Belgium 95.3 81.2 0.0 74.0 0.0 35.2 0.0
Ireland 87.9 73.2 0.0 72.6 0.0 31.6 0.0
England 92.5 38.0 62.0 43.8 56.2 28.1 71.9
Greater Poland 94.0 100.0 0.0 62.6 0.0 42.7 0.0
Axillary surgery: % of patients receiving axillary surgery if they received any type of breast surgery; ra-
diotherapy: % of patients receiving radiotherapy if they have received breast conserving surgery; endo-
crine therapy: % of patients receiving endocrine therapy if they have received any type of breast surgery; 
chemotherapy: % of patients receiving chemotherapy if they have received any type of breast surgery.
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Supplementary Table 3. Proportional distribution of patients receiving breast surgery, primary endo-
crine therapy or no therapy by stage of disease
Any type of breast surgery Primary endocrine therapy No treatment Unknown
% % % %
Stage I 
The Netherlands 88.3 9.4 2.3 0.0
Belgium 88.9 8.0 3.1 0.0
Ireland 82.2 15.1 2.7 0.0
England 75.8 15.6 0.0 8.6
Greater Poland 97.5 2.0 0.0 0.4
Stage II 
The Netherlands 81.8 15.6 2.6 0.0
Belgium 83.1 12.6 4.3 0.0
Ireland 78.8 17.9 3.3 0.0
England 71.9 18.3 0.0 9.9
Greater Poland 91.1 6.5 2.0 0.4
Stage III
The Netherlands 69.9 23.6 6.5 0.0
Belgium 78.0 15.1 6.9 0.0
Ireland 49.2 39.2 11.6 0.0
England 55.9 24.9 0.0 19.3
Greater Poland 95.4 1.8 1.8 1.0
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Supplementary Table 4. Proportional distribution of most extensive breast surgery for patients diag-
nosed in 2008 or 2009 by stage of disease
No surgery BCS Mastectomy Not specified
% % % %
Stage I
The Netherlands 13.3 51.9 34.9 0.0
Belgium 11.5 65.1 23.3 0.0
Ireland 24.3 56.8 18.9 0.0
England 24.2 50.3 25.5 0.0
Greater Poland 2.5 21.1 52.4 24.0
Stage II 
The Netherlands 22.4 22.5 55.2 0.0
Belgium 16.5 36.6 46.9 0.0
Ireland 26.3 34.0 39.7 0.0
England 28.9 27.0 44.1 0.0
Greater Poland 8.9 8.3 66.1 16.7
Stage III
The Netherlands 28.1 10.0 62.0 0.0
Belgium 23.1 14.6 62.3 0.0
Ireland 53.4 8.0 38.7 0.0
England 42.0 10.5 47.5 0.0
Greater Poland 4.6 3.4 81.8 10.2
BCS= breast conserving surgery
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Supplementary Table 5. Proportional distribution of locoregional and systemic treatment modalities 
for patients diagnosed in 2008 or 2009 
Axillary surgery Radiotherapy Endocrine therapy Chemotherapy
Yes % Yes % Unknown % Yes % Unknown % Yes % Unknown %
Stage I 
The Netherlands 96.2 93.2 0.0 29.8 0.0 1.1
Belgium 94.4 88.6 0.0 84.5 0.0 5.4 0.0
Ireland 90.5 81.9 0.0 77.5 0.0 6.9 0.0
England 91.6 38.4 61.6 46.1 53.9 6.7 0.0
Greater Poland 85.9 75.3 0.0 68.9 0.0 11.4 93.3
Stage II 0.0
The Netherlands 95.6 89.9 0.0 72.4 0.0 2.8
Belgium 93.7 84.9 0.0 79.6 0.0 17.0 0.0
Ireland 94.2 85.2 0.0 75.4 0.0 23.4 0.0
England 94.4 44.0 56.0 45.6 54.4 15.6 0.0
Greater Poland 87.8 56.5 0.0 65.4 0.0 23.1 84.4
Stage III 0.0
The Netherlands 96.6 89.9 0.0 70.5 0.0 16.0
Belgium 95.4 79.7 0.0 73.1 0.0 37.0 0.0
Ireland 94.6 85.5 0.0 71.0 0.0 37.1 0.0
England 94.3 33.1 66.9 40.1 59.9 29.7 0.0
Greater Poland 94.0 100.0 0.0 62.6 0.0 42.7 70.3
Axillary surgery: % of patients receiving axillary surgery if they received any type of breast surgery; ra-
diotherapy: % of patients receiving radiotherapy if they have received breast conserving surgery; endo-
crine therapy: % of patients receiving endocrine therapy if they have received any type of breast surgery; 
chemotherapy: % of patients receiving chemotherapy if they have received any type of breast surgery.
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Supplementary Table 6. Proportion of patients diagnosed in 2008 and 2009 receiving breast surgery, 
primary endocrine therapy or no therapy by stage of disease
Any type of breast surgery Primary endocrine therapy No treatment Unknown
% % % %
Stage I 
The Netherlands 86.7 11.5 1.8 0.0
Belgium 88.5 8.6 2.9 0.0
Ireland 75.7 20.6 3.7 0.0
England 75.8 15.8 0.0 8.4
Greater Poland 97.5 2.0 0.0 0.4
Stage II 
The Netherlands 77.6 19.5 2.8 0.0
Belgium 83.5 12.4 4.1 0.0
Ireland 73.7 23.7 2.5 0.0
England 71.1 18.5 0.0 10.4
Greater Poland 91.1 6.5 2.0 0.4
Stage III
The Netherlands 71.9 22.4 5.7 0.0
Belgium 76.9 16.4 6.6 0.0
Ireland 46.6 43.3 10.1 0.0
England 58.0 22.4 0.0 19.6
Greater Poland 95.4 1.8 1.8 1.0
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Supplementary Table 7. Five year relative survival for patients diagnosed in 2008 and 2009
RS 95% CI Crude 
RER




Belgium 97.9 96.1-98.9 reference reference
Greater Poland 103.2 103.2-103.3 NA# 0.998 1.71# 0.02-117 0.801
Ireland 100.6 100.6-100.6 0.92# 0.11-7.48 0.938 0.28# 0.001-1600# 0.926
The Netherlands 95.9 94.6-96.8 0.61 0.21-1.81 0.374 1.41 0.35-5.61 0.617
England 94.0 93.2-94.7 0.99 0.41-2.40 0.981 2.42 0.54-10.93 0.229
Stage II
Belgium 85.1 83.8-86.4 reference reference
Ireland 86.8 84.2-89.0 0.70 0.41-1.20 0.193 0.84 0.53-1.33 0.456
The Netherlands 81.4 80.1-82.7 1.08 0.84-1.38 0.559 1.11 0.88-1.40 0.401
Greater Poland 85.3 80.7-88.9 1.19 0.67-2.11 0.548 1.40 0.73-2.66 0.308
England 80.5 79.8-81.1 1.20 0.98-1.47 0.080 1.33 1.10-1.61 0.004
Stage III
Belgium 60.9 58.7-62.9 reference reference
Greater Poland 58.5 52.7-63.8 1.37 0.93-2.02 0.113 1.59 1.38-1.79 0.015
The Netherlands 57.1 54.9-59.2 1.11 0.85-1.45 0.442 1.12 0.87-1.44 0.355
Ireland 54.7 50.7-58.6 1.35 1.00-1.83 0.053 1.36 1.02-1.82 0.038
England 50.6 49.3-51.8 1.50 1.26-1.78 <0.001 1.50 1.27-1.76 <0.001
Countries were ranked according to the sum of proportions of each given treatment and the country 
with the highest sum of given treatment was assigned as reference country. n/N: numbers of events/
numbers at risk, RS: five-year relative survival, 95% CI: 95% Confidence Interval, crude RER: univariate 
relative excess risk, adjusted RER: multivariable relative excess risk, adjusted for the following confoun-
ders: age (continuous), year of diagnosis, grade, morphology. NA: not addressed. # Due to low excess 
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ABstRACt 
Background: After five years of median follow-up, the Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) trial observed no difference in disease free survival between ex-
emestane monotherapy and a sequential scheme of tamoxifen followed by exemestane in 
postmenopausal patients with early-stage, hormone receptor positive (HR+) breast cancer. 
As recurrence risk in HR+ breast cancer remains linear beyond five years after diagnosis, 
long-term follow-up outcomes of this trial were analysed. 
Methods: The TEAM trial, a multicenter phase III open-label randomised controlled 
trial, included postmenopausal patients with early stage HR+ positive breast cancer from 
nine countries between 2001 and 2006. Patients were randomly allocated in a 1:1 ratio by 
a computer-generated random permuted block method to either five years of open-label 
exemestane monotherapy (25 mg daily) or a sequential scheme of tamoxifen (20 mg daily) 
followed by exemestane for a total duration of five years. Randomisation was performed 
centrally in each country. Long term follow-up data for disease recurrence and survival 
was collected in six participating countries and analyzed by intention-to-treat. The primary 
endpoint was disease free survival (DFS) at ten years of follow-up. The trial is registered 
with ClinicalTrials.gov, NCT00279448, NCT00032136; NTR 267; Ethics Commission Trial 
27/2001.
Findings: 6120 patients were included in the current intention-to-treat analysis. Median 
follow-up was 9·8 years (interquartile range 8·0-10·3). During follow-up, 921 (30%) of 
3075 patients in the exemestane arm and 929 (31%) of 3045 patients in the sequential arm 
experienced a DFS event. DFS at ten years was 67% (95% CI 65-69) for the exemestane arm 
and 67% (95% CI 65-69) for the sequential arm (hazard ratio (HR) 0·96, 95% CI 0·88-1·05, 
p=0·39). 
Interpretation: The long-term findings of the TEAM trial confirm that both exemestane 
alone and sequential therapy with upfront tamoxifen are equally effective as adjuvant en-
docrine therapy in postmenopausal HR+ early breast cancer patients. These results validate 
the opportunity to individualize adjuvant endocrine strategy accordingly, based on patient 
preferences, comorbidities and tolerability. 
Funding: Unrestricted grant Pfizer, Dutch Cancer Foundation (UL 2010-4674). 
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ReseARCh in Context 
evidence before this study
We performed a search in PubMed MEDLINE (OVID-version), Embase (OVID-
version), and Cochrane, limited to articles published before March 1st 2017. For the 
search, we combined the terms ‘long-term follow-up’, ‘aromatase inhibitors’, ‘tamoxifen’, 
‘sequential therapy’, ‘postmenopausal women’, and ‘hormone receptor positive breast 
cancer’, also using various synonyms and related terms. This resulted in 104 papers, of 
which five were relevant results from randomised clinical trials. The majority of these 
trials studied long-term follow-up of other adjuvant endocrine therapy regimes, such as 
five years of tamoxifen versus anastrozole in the ATAC trial, or tamoxifen monotherapy 
versus sequential therapy in the IES trial. Furthermore, our search strategy identified 
a recent meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative 
Group (EBCTCG), comparing all major regimes including an aromatase inhibitor (AI) 
with each other, a sequential scheme or with tamoxifen alone, for the longest follow-up 
available. In this meta-analysis, the comparison between AI monotherapy and tamoxi-
fen followed by AI was limited to seven years of follow-up; hence, none of the included 
trials had ten-years data available.
Added value of this study
This study is the first trial to report on ten-year follow-up of randomizing patients 
between five years of AI monotherapy or sequential therapy with upfront tamoxifen 
followed by an AI. After ten years, no significant differences in either DFS or OS be-
tween both schedules were observed. However, we did observe a small difference in 
disease recurrence, in favour of patients treated with exemestane monotherapy (20% 
versus 22% with sequential scheme).
implications of all the available evidence
For postmenopausal patients with early-stage, HR+ breast cancer five years of tamoxi-
fen monotherapy, AI monotherapy, or sequential treatment with upfront tamoxifen 
are valid investigated treatment schedules to prevent relapse after surgery. Earlier, the 
EBCTCG meta-analysis showed that both the sequential strategy and AI monotherapy 
are superior to tamoxifen monotherapy after ten years of follow-up. The current analy-
sis of the TEAM trial shows that at ten years of follow-up, both the sequential scheme 
with upfront tamoxifen and AI monotherapy are equal with regard to DFS and OS. 
Therefore, both strategies are equally effective treatment options for postmenopausal 
patients with HR+ early breast cancer.
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intRoduCtion
For more than three decades, tamoxifen has been the hallmark for adjuvant treatment in 
women with hormone receptor positive (HR+) breast cancer, leading to a proportional risk 
reduction in recurrence of breast cancer and death by 40% and 26% respectively.1 Over the 
last ten years, aromatase inhibitors (AI), given either for five years or for two to three years 
after two to three years of tamoxifen, have shown superior efficacy over tamoxifen alone, 
further reducing the proportional risk of breast cancer recurrence by approximately 30% 
over five years of follow-up.2 
HR+ patients who remain disease free after five years of adjuvant endocrine treatment, still 
face a substantial risk of recurrence (11% and 20% ten and fifteen years after diagnosis, 
respectively3,4), indicating the importance of long-term follow-up for trials comparing 
adjuvant endocrine treatment strategies. 
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase III trial compared five 
years of exemestane with a sequential scheme of 2·5 years of tamoxifen followed by 2·5 years 
of exemestane. After five years of median follow-up, no significant difference for disease free 
survival (DFS), overall survival (OS) and relapse free survival (RFS) was observed between 
the two treatment strategies.5 The current analysis of the TEAM trial is the first study to 
present ten-year outcomes of the efficacy of five years of AI (exemestane) versus sequential 
therapy (tamoxifen followed by exemestane). 
Methods
study design and participants 
The TEAM trial is a phase III open-label randomised controlled trial that enrolled postmeno-
pausal women with histologically confirmed breast adenocarcinoma and locally assessed 
estrogen- (ER) and/or progesterone-receptor-positive (PgR) disease who had completed 
local treatment with curative intent between 2001 and 2006.5 There were no age-related 
restrictions for inclusion. Other eligibility criteria were an ECOG performance status of 0 or 
1, adequate hematological parameters (PLT > 100x109/L, WBC > 3x 109/L), renal (creatinine 
<1.5 ULN) and liver function (ASAT or ALAT <2.5 ULN). Exclusion criteria included: 
earlier adjuvant endocrine therapy or neo-adjuvant chemotherapy, uncontrolled cardiac 
disease, other malignancies or other serious illnesses interfering with subject compliance, 
adequate informed consent or study participation. 
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Randomisation and masking
Patients were randomly assigned in a 1:1 ratio centrally in each country by use of a 
computer-generated random permuted block method with stratification per country. Treat-
ment allocation was not masked to participants, those prescribing the medication, those 
assessing outcomes and analysing the data. Patients were enrolled by the local clinicians in 
the participating hospitals. 
Procedures
Endocrine treatment was started within ten weeks after completion of surgery and end of 
chemotherapy if indicated, and was administered orally daily for five years in both treat-
ment arms. Patients were initially assigned either to exemestane (25 mg once a day) for a 
duration of five years or tamoxifen (20 mg once a day, orally) for a duration of five years. 
After the publication of the IES trial,6 the the protocol was amended. Patients assigned to 
tamoxifen were switched after 2·5 to three years to exemestane therapy for a total duration 
of five years of treatment. Dose reductions were not allowed. Patient visits were required 
every 3 months during the first year, and every 6 months during the remaining active treat-
ment period. Study endpoints and adverse events were recorded during each visit during 
active treatment. performed mammography was performed yearly, laboratory tests and 
other radiological evaluations were performed as determined by local guidelines. 
The original study was conducted in 566 hospitals in nine countries. For the current pre-planned 
long term follow-up analysis, we only included patients who were enrolled in countries where 
follow-up was collected for at least two additional years after the five years of endocrine therapy 
in the context of the study. For this reason, patients from Japan (n=184), France (n=1,230), and 
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Figure 1: trial profile
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different countries and sent as a batch per country to Leiden, and thereafter merged into one 
database. Information on cause of death was gathered on the case report form and thereafter 
categorized into ten pre-specified groups. Classification of cause of death was verified by the 
TEAM central datacenter. Late side effects after five years of endocrine therapy in this current 
analysis were not recorded. Database cutoff was set at February 19, 2016. 
outcomes
The primary endpoint was disease free survival (DFS), defined as the time from randomisa-
tion to disease recurrence or death from any cause. Disease recurrence was defined as dis-
ease recurrence (locoregional or distant) or a new primary breast cancer. Ductal carcinoma 
in situ was not considered as recurrent disease. Secondary outcomes were overall survival 
(OS) defined as time from randomization to time of death due to any cause, recurrence free 
interval (RFI) defined as time from randomisation to recurrence or time of death due to 
breast cancer if no recurrence was reported before death and distant recurrence free interval 
(DRFI) defined as time from randomisation to distant recurrence or time of death due to 
breast cancer if no recurrence was reported before death. Patients with distant metastases at 
time of death were categorized as death due to breast cancer. 
statistical analysis 
All patients who were randomly assigned to treatment, except those who withdrew consent 
before start of treatment, were included in the intent-to-treat population. All analyses were 
performed in the intent-to-treat population. A power calculation was performed before study 
initation for analyses after five years of follow-up, and has been described extensively previ-
ously.5 All tests were two-sided and a p-value of less than or equal to 0·05 was considered 
statistically significant. Kaplan-Meier estimates of DFS and OS were calculated for each treat-
ment group. DFS and OS were compared between treatment groups using log-rank tests and 
stratified by country and additional stratification factors within countries (nodal status (posi-
tive versus negative), PgR status (positive versus negative), adjuvant chemotherapy (yes versus 
no)). All hazard ratios (HRs) were calculated with a Cox regression analysis using the same 
stratification factors as the log-rank tests. Cumulative incidence of recurrence and subdistribu-
tion hazard ratios (sHRs) for RFI and DRFI were calculated using the Fine and Gray model for 
competing risks, taking other causes of death into account as competing events.7 Proportional 
differences were tested using Pearson’s χ2 test. All time-to-event curves were truncated after ten 
years of follow-up, while HRs and sHRs include all events until database cutoff. 
Additional analyses
Predefined subgroup analyses were performed for DFS. Interaction between treatment and 
prognostic factors was tested for effect modification using the Cox proportional hazard 
model. A post-hoc analysis was performed to study the relation between treatment and breast 
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cancer specific mortality (BCSM) and other cause mortality (OCM). Cumulative incidence 
of recurrence and sHRs were calculated using the Fine and Gray model for competing risks. 
An additional five year conditional survival analysis for DFS using the Cox proportional 
hazard model was performed as a post-hoc analysis to compare treatment groups for late 
disease recurrences, and subgroup analyses were performed to test interaction between 
treatment and prognostic factors for late recurrences. Furthermore, to estimate the influ-
ence of HER2 positive patients included in this study population, analyses were repeated 
post-hoc after exclusion of the HER2 positive patients. Kaplan Meier estimates were calcu-
lated for ten year DFS for each treatment arm in the remaining population. 
For this long-term follow up analysis, patients from countries that did not collect long-term 
follow-up data were excluded. To assess whether findings from this study could be general-
ized to the original population various additional post-hoc analyses were performed. First, 
baseline clinicopathological factors between the in- and excluded patients were compared. 
Second, DFS at five years after randomisation was compared between the in-and excluded 
patients. Third, treatment effect between the in- and excluded patients at five years was 
tested for interaction. Last, a sensitivity analysis was performed to compare treatment arms 
for DFS with complete follow up time for the original TEAM population. Patients from 
countries that did not collect outcomes after five years were censored. 
Statistical analyses were performed using R 3.3.0 version using the survival, prodlim and 
cmprsk packages.
The study was conducted in compliance with the guidelines of the Declaration of Helsinki, 
International Conference on Harmonization and Good Clinical Practice. Appropriate ap-
provals from the ethical committee were obtained. All patients provided written informed 
consent. This study is registered in France with ClinicalTrials.gov, NCT00279448; the Neth-
erlands and Belgium with Netherlands Trial Register, NTR 267; the UK and Ireland with 
ClinicalTrials.gov, NCT00032136; and Germany with Ethics Commission Trial, 27/2001. 
Role of the funding source 
The TEAM trial was initially funded by an unrestricted grant from Pfizer. Collection of long 
term follow-up was funded by the Dutch Cancer Foundation (UL 2010-4674). Funding 
sources had no role in the study design, data collection, analysis, interpretation of the data, 
writing of the manuscript, or the decision to publish. Study investigators listed as authors 
were involved in data interpretation writing the report and the decision to submit. The 
corresponding author had full access to all of the data and the final responsibility to submit 
for publication. All authors had access to the raw data.
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Results
In the original TEAM trial, 9766 patients were included in the intention-to-treat population 
between January 16th 2001 and January 31st 2006.5 Overall, 6120 (63%) patients from six 
countries were included in the current intention-to-treat population and analyzed for the 
primary and secondary outcomes (Figure 1). Median follow-up was 9·8 years (IQR 8·0-10·3) 
and median age at diagnosis was 63·8 years (IQR 57·8-70·8). Baseline characteristics were 
similar between both treatment arms (Table 1). 





N % N %
Age (years)          
< 50 102 3.3 109 3.5
50-59 948 31.1 926 30.1
60-69 1193 39.2 1180 38.4
≥ 70 802 26.3 860 28.0
Histological grade          
G1 (well) 301 9.9 315 10.2
G2 (moderate) 1569 51.5 1599 52.0
G3-G4 (poor) 930 30.5 905 29.4
Unknown 245 8.0 256 8.3
Tumour (T) stage          
T0,Tis 1 0.0 1 0.0
T1 1500 49.3 1526 49.6
T2 1321 43.4 1363 44.3
T3, T4 216 7.1 175 5.7
Tx, unknown 7 0.2 10 0.3
Nodal (N) stage          
N0 1295 42.5 1308 42.5
N1 1538 50.5 1562 50.8
N2-3 201 6.6 195 6.3
Unknown 11 0.4 10 0.3
Metastasis (M) stage          
M0 (no distant metastasis) 3041 99.9 3069 99.8
M1 (distant metastasis) 2 0.1 5 0.2
Not assessed 2 0.1 1 0.0
Estrogen-receptor status          
Positive 2970 97.5 3014 98.0
Negative 75 2.5 58 1.9
Unknown 0 0.0 3 0.1
Progesterone-receptor status          
Positive 2163 71.0 2215 72.0
Negative 535 17.6 535 17.4
Unknown 347 11.4 325 10.6
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During the ten year study period, 921 (30%) of 3075 patients in the exemestane group and 929 
(31%) of 3045 patients in the sequential group experienced a DFS event (Table 2). The Kaplan-
Meier-estimated ten year DFS percentage was 67% (95% CI 65-69) for the exemestane arm 
and 67% (95% CI 65-69) for the sequential arm (HR 0·96, 95% CI 0·88-1·05, p=0·39, Figure 
2A). Treatment effect was consistent between all subgroups and no significant interaction was 
observed between treatment and clinicopathological factors (Figure 3). Overall, hazard ratios 
were similar to those of the previous report after five years of median follow-up.5 





N % N %
Most extensive surgery          
Mastectomy 1464 48.1 1409 45.8
Wide local excision 1577 51.8 1663 54.1
No resection 0 0.0 1 0.0
Unknown 4 0.1 2 0.1
Time from surgery to initiation of hormone treatment (months)      
< 3 1882 62.5 1886 61.8
3 to 6 628 20.8 694 22.7
≥ 6 502 16.7 472 15.5
Unknown 33 1.1 23 0.7
Adjuvant radiotherapy          
Yes 2053 67.4 2114 68.7
No 984 32.3 950 30.9
Unknown 8 0.3 11 0.4
Adjuvant chemotherapy          
Yes 1112 36.5 1141 37.1
No 1933 63.5 1934 62.9
Unknown 0 0 0 0
Country          
Netherlands 1379 45.3 1374 44.7
Germany 723 23.7 748 24.3
United Kingdom and Ireland 639 21.0 636 20.7
Greece 100 3.3 107 3.5
  Belgium 204 6.7   210 6.8
Table 2. Disease-free survival events*




N % N %
Total 929 30.5 921 30.0
Locoregional recurrence only** 71 2.3 52 1.7
Distant metastases 502 16.5 470 15.3
New primary breast cancer*** 50 1.6 45 1.5
Intercurrent deaths 306 10.0 354 11.5
* only first events for DFS were recorded **Includes ipsilateral breast cancer. ***Without distant me-
tastasis.
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During follow-up, 733 (24%) of 3075 patients in the exemestane arm died and 727 (24%) of 
3045 patients in the sequential arm (Table 3). Overall survival after ten years was 74% (95% 
CI 72-75)in the exemestane group and 73% (95% CI 72-75) in the sequential group (HR 
0·98, 95% CI 0·89-1·09, p=0·74, Figure 2B). BC recurrence occurred in 567 (18%) of 3075 
patients in the exemestane arm and 623 (20%) of 3045 patients in the sequential arm during 
follow-up. Cumulative incidence for BC recurrences after ten years of follow up was slightly 
lower in the exemestane group (20%, 95% CI 19-22) than in the sequential group (22%, 95% 
CI 20-24) (sHR for RFI 0·88, 95% CI 0·79-0·99, p=0·03, Figure 4A). Distant recurrences oc-
curred in 468 (15%) of 3075 patients in the exemestane arm and 497 (16%) of 3045 patients 
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3045 (0) 2789 (45) 2545 (90) 2180 (280) 1656 (622) 852 (1312)
3075 (0) 2881 (27) 2635 (51) 2225 (269) 1736 (605) 878 (1317)
HR 0.96 (95% CI 0.88-1.05)






















3045 (0) 2920 (47) 2709 (94) 2328 (301) 1785 (673) 931 (1426)
3075 (0) 2972 (28) 2782 (54) 2369 (283) 1857 (643) 969 (1415)
HR 0.98 (95% CI 0.89-1.09)
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Favours exemestane Favours tamoxifen followed 
by exemestane 
339/1526 (22%)
Figure 3: Subgroup analysis of disease free survival 
Numbers are number of events by numbers at risk at time of randomization (n/N(%)). The gray line 
represents a hazard ratio of 1.00, the black line is the overall hazard ratio of 0.96 
Ten year follow-up of the TEAM trial 63
in the sequential arm. No difference in cumulative incidence for distant recurrence was 
observed for exemestane alone versus sequential therapy (16% (95% CI 15-18) versus 18% 
(95% CI 16-19) respectively, sHR for DRFI 0·91, 95% CI 0·80-1·03, p=0·15, Figure 4B). 
Table 3. Causes of death




N % N %
Death due to breast cancer* 419 13.8 377 12.3
Death due to other causes 308 10.1 356 11.6
Second malignant disease 72 2.4 85 2.8
Endometrial cancer 2 0.1 1 0.0
Cardiac related 45 1.5 61 2.0
Thromboembolism 5 0.2 11 0.4
Pulmonary related 18 0.6 20 0.7
Cerebral related 16 0.5 23 0.7
Vascular related 2 0.1 4 0.1
Other 91 3.0 95 3.1
Unknown reason 57 1.9 57 1.9
*Death due to breast cancer was defined as death due to breast cancer as recorded or if distant metasta-
sis were present at time of death 
Additional analyses 
In the exemestane arm, 377 (12%) of 3075 patients died due to breast cancer and in the 
sequential arm 419 (14%) of 3045 patients died due to breast cancer (Table 3). Cumula-
tive incidence for BCSM after ten years of follow-up was 13·5% (95% CI 12·3-14·9) in the 
exemestane arm and 15·4% (95% CI 13·0-16·9) in the sequential arm (sHR 0·88, 95% CI 
0·77-1·01, p=0·07, Figure 5). Death due to other causes than BC occurred in 356 (12%) of 
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sHR 0.91 (95% CI 0.80-1.03)
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sHR 0.88 (95% CI 0.79-0.99)
Figure 4: Cumulative incidence of recurrences (A) and distant recurrences (B)
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3075 patients in the exemestane arm and 308 (10%) of 3045 patients in the sequential arm 
(Table 3). Cumulative incidence for OCM was 12·8% (95% CI 11·5-14·2) in the exemestane 
arm and 11·3% (95% CI 10·0-12·6) in the sequential arm (sHR 1·14, 95% CI 1·00-1·31, 
p=0·08, Figure 5). No significant differences for cause of death were observed between the 
treatment arms. The number and types of new primary non-breast cancers are shown in 
Table 4. Endometrial cancer occurred more frequently in the sequential arm than in the 
exemestane arm (23 (0·8%) of 3045 patientsversus 7 (0·2%) of 3075 patients, respectively). 
Other second, non-breast cancers were not different between both treatment arms (Table 4). 
Five years after randomization, 2470 (80%) of 3075 patients in the exemestane arm and 
2385 (78%) of 3045 patients in the sequential arm were alive and disease free. 431 (17%) of 
2470 patients in the exemestane arm and 423 (18%) of 2385 patients in the sequential arm 
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Figure 5: Stacked cumulative incidence of breast cancer specific mortality (BCSM) and other cause 
mortality (OCM) by treatment arm 
Cumulative incidence function for cause of death stacked on top of each other by the two treatment 
arms. Sum of the two functions represents all-cause mortality.
Table 4. Non-breast cancers
Tamoxifen followed by 
exemestane (n=3045) Exemestane (n=3075)
N % N %
Non-breast cancers 
Colorectal 40 1.3 52 1.7
Lung 32 1.1 37 1.2
Endometrial 23 0.8 7 0.2
Other 132 4.3 140 4.6
One patient in the sequential arm developed two colorectal tumours; five patients in the sequential arm 
and six patients in the exemestane arm developed more than one non-breast cancer tumour. 
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CI 78-82) in the exemestane arm and 81% (95% 79-82) in the sequential arm (HR 0·98, 95% 
CI 0·86-1·13, p=0·82). This effect was consistent among all subgroups and no significant 
interaction was observed between treatment and clinicopathological factors (webappendix, 
page 1).
For the repeated analysis excluding the HER2 positive patients, 560 HER2 positive patients 
(9 %) were excluded from the original trial population. In the remaining HER2 negative or 
HER2 unknown population, 812 (29%) of 2819 patients assigned to the exemestane arm 
and 814 (30%) of 2741 patients assigned to the sequential arm experienced a DFS event. 
DFS at ten years was 68% (95% CI 66-70) for patients in the exemestane arm and 67% (95% 
CI 66-69) for patients in the sequential arm. This was not significantly different compared 
to the results of the total study population.
Patients from countries that did not collect long-term follow-up had more favourable 
tumour characteristics at baseline (webappendix, page 2). DFS at five years for patients 
included in the long-term follow-up analysis was lower than that of excluded patients (DFS 
84%, 95% CI 83-84 and DFS 90%, 95% CI 89-91, respectively). Treatment effect for DFS at 
five years was comparable between patients included in the long-term follow-up analysis 
and patients that were excluded (HR 0·96 (95% CI 0·88-1·06) and HR 1·01 (95% CI 0·84-
1·22), respectively, p-value for interaction = 0·66). Treatment effect for the original TEAM 
population was comparable to the results of the long-term follow-up study (HR 0·97, 95% 
CI 0·90-1·06). 
disCussion
To our knowledge, this is the first trial reporting ten year outcomes of five years of AI 
monotherapy compared to five years sequential therapy with upfront tamoxifen, showing 
that after ten years of median follow-up both exemestane monotherapy and the sequential 
scheme are equally effective treatment strategies for postmenopausal patients with HR+ 
early breast cancer. No significant differences between the treatment arms were observed 
for DFS and OS, although a small benefit was observed for exemestane monotherapy with 
regard to cumulative incidence of recurrences. An additional analysis looking into cause of 
death suggests a lower breast cancer specific mortality but a higher other cause mortality for 
exemestane monotherapy compared to sequential therapy. 
The results from this ten year analysis of the TEAM trial are consistent with the long-term 
analysis of the BIG 1-98 trial. After a median follow-up of 8·0 years, this study reported 
no differences between letrozole and sequential therapy (tamoxifen followed by letrozole) 
for DFS (HR 1·07, 0·92-1·25) and OS (HR 1·10, 0·90-1·33).8 The TEAM results reported 
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in this study represent a much larger patient cohort and after a longer follow-up period, 
thereby strengthening the results reported from the BIG 1-98 trial. Furthermore, our results 
are in line with findings from the EBCTCG meta-analysis, including all trials investigating 
the value of AI versus tamoxifen regimens in postmenopausal HR+ breast cancer patients. 
They observed a very small benefit regarding recurrences rates of AI monotherapy over the 
sequential scheme with upfront tamoxifen after a median follow-up period of seven years 
(recurrence rate 14·5% versus 13·8%), but observed no benefit with respect to OS in this 
same time period.2 In view of the current ten year results of the TEAM trial and data from 
the BIG 1-98 trial and EBCTCG meta-analysis, both the sequential scheme with upfront 
tamoxifen and AI monotherapy are equally effective strategies.
When considering cause of death, results of the current analyses suggest that there might 
be a small benefit of exemestane therapy on breast cancer-specific mortality, although the 
percentage of distant metastasis was not significantly different (Figure 4B). Interestingly, 
this beneficial effect of exemestane on breast cancer-specific mortality seems to be coun-
terbalanced by an increase in non-breast cancer related mortality leading to similar overall 
survival rates. In the TEAM trial report after five years of median follow-up, significantly 
more cardiovascular adverse events were observed in the patients receiving exemestane 
alone.5 After ten years of follow-up, death due to cardiac cause or vascular cause was higher 
in the exemestane arm (n=65) than in the sequential arm (n=47). In addition, more patients 
died due to a thromboembolic cause in the exemestane arm (n=11) than in the sequential 
arm (n=5) (Table 3). Unfortunately, this trial was not designed to show a significant differ-
ence in cause of death. A recently published meta-analysis showed a significantly higher risk 
for cardiovascular events for patients treated with AI monotherapy compared to upfront 
tamoxifen followed by an AI (RR 1·16, 95% CI 1·03-1·31). It has been suggested that the 
occurrence of more cardiovascular events in patients receiving an AI compared to patients 
receiving tamoxifen is most likely explained by the protective effect of tamoxifen on car-
diovascular outcomes.9,10 The increased risk of death with an AI has also been observed in 
the ABCSG-12 trial, investigating zoledronic acid versus no zoledronic acid with adjuvant 
tamoxifen or anastrozol (in combination with LHRH analogues) in premenopausal BC 
patients. Anastrozol and tamoxifen (in combination with LHRH analogues) were equally 
effective for disease free survival after eight years of follow-up but a significantly worse 
overall survival for anastrozol was observed.11 Overall, these findings suggest that although 
AI might be more favorable for breast cancer related outcomes, it lacks the cardioprotective 
effect of tamoxifen, which might be preferred for patients with a relatively low risk breast 
cancer and high risk cardiovascular profile. Further long-term research is necessary to 
confirm these observations and to better define subgroups with high risk for cardiovascular 
diseases that might benefit from upfront tamoxifen.
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An important remaining question is whether it is possible to select some subgroups for 
which there is a more clear benefit for either upfront tamoxifen or AI use. In the BIG 1-98 
trial, patients with a poor prognosis (using ER and PgR status, HER2 status, Ki-67 index 
and clinical prognostic factors) appeared to have more benefit regarding DFS from letro-
zole monotherapy compared to any other treatment strategy.12 A meta-analysis, compar-
ing tamoxifen and AI monotherapy (either for five or two to three years), suggested that 
HER2-negative tumors would benefit more from AI monotherapy.13 However, this study 
evaluated only the period in which the active treatment was different between both arms. 
Our analysis, covering 10 years of follow-up and comparing the sequential scheme with 
AI monotherapy in a large cohort, failed to identify any clinicopathological subgroup that 
would benefit more from either the sequential treatment or AI monotherapy. Therefore, 
the identification of a subgroup for which there is a more clear benefit of either therapy 
remains challenging. In the context of the TEAM pathology study, we plan to combine 
clinicopathological factors with biomarkers. This will hopefully identify biomarkers that 
will allow for better stratification. 
With no evident improvement in disease related outcomes and overall survival nor a clear 
benefit for a specific subgroup for either AI monotherapy or sequential therapy, the choice 
of therapy might depend on safety and tolerability not only during but also after completion 
of treatment. The TEAM five-year analysis showed that the use of tamoxifen is associated 
with an increase in gynaecological- and thromboembolic side effects, whereas exemestane 
was more often associated with musculoskeletal disorders like arthralgia, osteoporosis and 
subsequent fractures.5 In the current analyses, after ten years of median follow-up and 
five years after treatment completion, more endometrial cancers were still observed in the 
sequential than in the exemestane arm, although absolute numbers were low (23 versus 
7, Table 4). Further analysis showed that median time to diagnosis of endometrial cancer 
was 7·0 years after randomization in this study for patients who received the sequential 
therapy. This suggests a long-term carry-over effect of tamoxifen use. Reassuringly, deaths 
due to endometrial cancer did not occur more frequently in one of the groups (Table 3). 
Unfortunately, no other long-term adverse events on the abovementioned items were col-
lected in the context of the TEAM study. In the ATAC trial, fractures were more common 
during treatment in the anastrozole arm compared to the tamoxifen arm, but were similar 
after treatment completion at ten years of follow-up, suggesting no carry-over effect after 
treatment completion.14 Although some evidence from side studies of the TEAM trial and 
the BIG 1-98 trial suggest poorer cognitive functioning in patients receiving tamoxifen 
compared to patients using an AI,15,16 it remains unclear whether tamoxifen also affects 
long term cognitive functioning. Quality of life did not appear to be different between AIs 
and tamoxifen in several trials.17-19 However, no quality of life data from these trials are 
available after completion of therapy. It would be worthwhile to develop a cardiovascular 
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risk and potentially other risk profiles, enabling to select the appropriate therapy regimen 
for a particular patient.
Another relevant unanswered question is the optimal length of adjuvant endocrine therapy, 
which is currently being studied in several trials.20 Of note, 435 (16%) of the 2,753 Dutch 
patients in this analysis continued with letrozole beyond five years in the context of the 
prospective phase-III Investigation on the Duration of Extended Adjuvant Letrozole treat-
ment (IDEAL) trial (randomization between 2·5 or five years of extended therapy with 
letrozole).21 TEAM trial patients that continued in the IDEAL trial were equally distributed 
among both treatment arms of the TEAM trial and were equally randomised for either 2·5 
or five years of extended therapy in the IDEAL trial. Differences between the two treatment 
arms in the TEAM trial are therefore not likely explained by the extended therapy. However, 
extended therapy could have affected the ten year results at a similar rate for both arms 
and possibly have led to an underestimation of recurrence rates. Given the equivalence of 
sequential therapy (tamoxifen followed by AI) compared with AI therapy for the first five 
years of adjuvant endocrine therapy, it will be highly interesting whether upfront tamoxifen 
or AI monotherapy during five years has a differential benefit in patients who will receive 
extended endocrine therapy.
During the inclusion period of the TEAM trial (study closure January 31, 2006), adjuvant 
trastuzumab was not yet administered as the first reports on the efficacy of adjuvant trastu-
zumab therapy only became available mid-2005.22,23 In the current patient cohort, only a 
minority of patients had HER2 positive breast cancer (n=560, 9%). Our subgroup analysis 
did not show any difference in treatment effect between patients with HER2-negative, 
HER2-positive or unknown HER2 status, and no significant interaction between subgroups 
was observed (Figure 3). Further, repeated analyses excluding the HER2 positive patients 
were consistent with the findings in the total cohort. Given these results, the findings of the 
total study cohort may be considered reliable estimates of outcome for HER2 negative/HR+ 
patients. 
Some countries that did not collect long-term follow-up (such as the United States and 
Japan) included relatively more low-risk patients in the TEAM trial (wepappendix, page 2). 
As a result, these patients had a significantly higher DFS at five years after randomization 
compared to patients included in the current long-term follow-up analysis. However, as 
subgroup analysis in this study showed that prognostic factors did not influence treatment 
effect (Figure 2), it is not expected to affect the findings of the current analyses. More-
over, no significant interaction for treatment was found between patients included in this 
long-term follow-up analysis and excluded patients . Therefore, we expect that results for 
treatment comparison in the current study cohort are representative for the original TEAM 
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population. Furthermore, a sensitivity analysis that included both the included patients and 
excluded patients (with five years of follow-up) yielded consistent results. Despite the de-
creased number of patients included in the current analyses, the power to detect differences 
between treatment arms for the primary endpoint was sufficient as the number of events 
due to longer follow-up time increased compared to the five year evaluation of this study 
(current analysis: n=1850, Table 2; previous report: n=1428,5 respectively).
There are some other limitations that we are aware of. Firstly, we did not collect long-term 
adverse events for the current analyses. Secondly, as mentioned previously, extended 
adjuvant therapy either inside or outside a study protocol could have possibly led to an 
underestimation of disease recurrence. Finally, we collected data on cause of death and 
although cause of death classification is more reliable in clinical trial settings, it could have 
been subject to misclassification. 
In conclusion, both the sequential scheme with upfront tamoxifen and exemestane mono-
therapy for five years are equally effective adjuvant treatment options for postmenopausal, 
hormone-receptor-positive breast cancer patients, with comparable survival rates after ten 
years of median follow-up. This allows the possibility for shared decision making between 
the clinician and patient, balancing individual patient characteristics and preferences, 
side effect profiles, and tolerability. Future studies will hopefully show which subgroup, if 
any, benefits more from either strategy, and whether extension of any of these strategies is 
worthwhile. 
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Supplementary Table 1. Subgroup analysis of disease free survival for patients who remained disease 
free at five years after randomization
n N HR (95% CI)
Histological grade
G1 (well) 96 525 1.14 (0.76-1.71)
  G2 (moderate) 415 2594 0.98 (0.81-1.19) 
  G3-G4 (poor) 278 1398 0.90 (0.72-1.15)
  Gx/unknown 65 383 0.99 (0.72-1.92)
Tumour size
T ≤2cm 347 2537 1.09 (0.88-1.34)
T >2cm 504 2273 0.93 (0.81-1.27)
Nodal status
negative 304 2167 1.01 (0.81-1.27)
  positive 548 2676 0.96 (0.81-1.14)
Progesterone receptor status 
positive 611 3564 0.97 (0.83-1.14)
negative 153 764 1.17 (0.85-1.61)
not performed 90 527 0.81 (0.53-1.24)
HER2
positive 87 408 1.01 (0.67-1.55)
negative 617 3087 0.96 (0.82-1.12)
not performed 150 1360 1.09 (0.79-1.50)
Most extensive surgery
mastectomy 479 2128 0.91 (0.76-1.09)
wide local excision 375 2724 1.12 (0.91-1.37)
Radiotherapy
yes 542 3377 1.06 (0.90-1.26)
no 311 1467 0.87 (0.70-1.10)
Chemotherapy
yes 261 1797 1.10 (0.86-1.40)
  no 593 3058 0.93 (0.80-1.10)
Age (years)
<50 19 166 0.91 (0.37-2.25)
50-59 200 1560 0.88 (0.67-1.17)
60-69 278 1942 0.88 (0.67-1.17)
≥70 357 1187 1.12 (0.69-1.11)
Overall estimate 854 4855 0.98 (0.86-1.13)
n: number of events, N: numbers at risk at time of randomization, hazard ratio (HR) and corresponding 
95% confidence intervals (95% CI) for sequential therapy (reference) and exemestane monotherapy.
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Supplementary Table 2. Baseline characteristics of patients in the original TEAM population, patients 
included for the current analysis and patients excluded for the current analysis
Original TEAM 
population
Included for ten 
year analysis
Excluded for ten 
year analysis 
(n=9766) (n=6120) (n=3646)
N % N % N % P value* 
Age (years)          
< 50 331 3.4 211 3.4 120 3.3 0.44
50-59 3017 30.9 1874 30.6 1143 31.3
60-69 3731 38.2 2373 38.8 1358 37.2
≥ 70 2687 27.5 1662 27.2 1025 28.1
Histological grade
G1 (well) 1677 17.2 616 10.1 1061 29.1 <0.001
G2 (moderate) 4797 49.1 3168 51.8 1629 44.7
G3-G4 (poor) 2438 25.0 1835 30.0 603 16.5
Unknown 854 8.7 501 8.2 353 9.7
Tumour (T) stage
T0,Tis 6 0.1 2 0.0 4 0.1 <0.001
T1 5690 58.3 3026 49.4 2664 73.1
T2 3592 36.8 2684 43.9 908 24.9
T3, T4 457 4.7 391 6.4 66 1.8
Tx, unknown 21 0.2 17 0.3 4 0.1
Nodal (N) stage
N0 5112 52.3 2603 42.5 2509 68.8 <0.001
N1 4110 42.1 3100 50.7 1010 27.7
N2-3 478 4.9 396 6.5 82 2.2
Unknown 66 0.7 21 0.3 45 1.2
Metastasis (M) stage 
M0 (no distant metastasis) 9725 99.6 6110 99.8 3615 99.1 <0.001
M1 (distant metastasis) 8 0.1 7 0.1 1 0.0
Not assessed 33 0.3 3 0.0 30 0.8
Estrogen-receptor status
Positive 9586 98.2 5984 97.8 3602 98.8 0.001
Negative 176 1.8 133 2.2 43 1.2
Unknown 4 0.0 3 0.0 1 0.0
Progesterone-receptor status 
Positive 7300 74.7 4378 71.5 2922 80.1 <0.001
Negative 1725 17.7 1070 17.5 655 18.0
Unknown 741 7.6 672 11.0 69 1.9
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Supplementary Table 2. Baseline characteristics of patients in the original TEAM population, patients 
included for the current analysis and patients excluded for the current analysis (continued)
Original TEAM 
population
Included for ten 
year analysis
Excluded for ten 
year analysis 
(n=9766) (n=6120) (n=3646)
N % N % N % P value* 
Most extensive surgery
Mastectomy 4333 44.4 2873 46.9 1460 40.0 <0.001
Wide local excision 5423 55.5 3240 52.9 2183 59.9
No resection 3 0.0 1 0.0 2 0.1
Unknown 7 0.1 6 0.1 1 0.0
Time from surgery to initiation of hormone treatment (months)
< 3 5100 52.2 3768 61.6 1332 36.5 <0.001
3 to 6 2661 27.2 1322 21.6 1339 36.7
≥ 6 1912 19.6 974 15.9 938 25.7
Unknown 93 1.0 56 0.9 37 1.0
Adjuvant radiotherapy
Yes 6697 68.6 4167 68.1 2530 69.4 <0.001
No 2976 30.5 1934 31.6 1042 28.6
Unknown 93 1.0 19 0.3 74 2.0
Adjuvant chemotherapy
Yes 3514 36.0 2253 36.8 1261 34.6 <0.001
No 6252 64.0 3867 63.2 2385 65.4
Unknown 0 0 0
* P value corresponds to proportional distribution of patients included in the current analysis versus 
patient excluded in the current analysis
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ABstRACt
Background: Previous retrospective studies have shown that older cancer survivors are 
affected in physical functioning after treatment. Prospective data of physical functioning 
in older patients with breast cancer are lacking. The aim of this study was to assess change 
in physical functioning in different age groups of patients with hormone-receptor positive 
breast cancer who were enrolled in the in the Tamoxifen Exemestane Adjuvant Multina-
tional (TEAM) phase III trial.
Patient and methods: Two physical parameters were assessed. Physical functioning was 
assessed from the EORTC QLQ-C30 questionnaire one (T1) and two years (T2) after diag-
nosis. Physical activity was measured in Metabolic Equivalent of Task (MET) hours/week 
at T1 and T2. Physical activity before diagnosis (T0) was assessed retrospectively at the T1 
questionnaire. Patients were divided in three age groups; age < 60, 60-70 and 70 years and 
older. Decline in physical functioning was assessed using linear regression analysis. Differ-
ences in mean values of physical activity levels were calculated using repeated measures one 
way ANOVA.  
Results: A total of 431 patients were included for analysis. In all age groups, physical activity 
levels at T1 and T2 were significantly lower than prediagnostic physical activity levels (T0) 
(P<0,001 for all age groups). Age above 70 years was independently associated with decline 
in physical functioning between T1 and T2 (beta -4.62, 95% CI -8.73 – - 0.51, P=0.028). 
Conclusion: In contrary to younger patients, patients aged over 70 years treated with breast 
surgery and adjuvant hormonal therapy did not improve between years one and two after 
diagnosis to the same extent as younger patients.
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intRoduCtion 
Breast cancer is the most common diagnosed cancer among women and the second  leading 
cause of cancer-related mortality in women in the United States[1]. Due to increasing life 
expectancy, breast cancer is becoming a disease of older adults. Of the estimated 232.670 
new cases of breast cancer in 2014 in the United States, 41.4% of these patients was 65 years 
or older.1,2,3 
Older patients comprise a very heterogeneous group, with the majority having at least one 
co-morbidity.4 Multiple comorbidity can result in poorer functional status, quality of life 
and health outcomes.5 Furthermore, older patients with breast cancer are at increased risk 
for adverse events and toxicities of breast cancer treatment.6 Consequently, older patients 
may be more vulnerable to decline of physical functioning during and after cancer treat-
ment.   
A recent meta-analysis has shown that physical activity has clinically important effects on 
physical function, psychological outcomes and quality of life.7 Functional limitations after 
breast cancer treatment are associated with higher all-cause mortality. Possibly, physical ac-
tivity could modify these functional limitations.8 In addition, a systematic review has shown 
that physical activity is associated with an improved overall survival. However, it remains 
unclear if this is a causal relation or an association that is explained by other factors.9 In 
older adults, maintaining physical function could make the difference between independent 
and assisted living. Therefore it is important to maintain the level of pre-diagnostic physical 
activity during and after breast cancer treatment in older patients. 
Previous studies have shown that older cancer survivors are often affected in physical func-
tioning, while younger patients are mostly affected in psychological functioning.10 However, 
these studies were mostly retrospective in design and did not assess pre-diagnostic physical 
functioning. In addition, most of these studies had no information regarding co-morbidities 
and treatment regimens, which may influence physical activity. The Tamoxifen Exemestane 
Adjuvant Multinational (TEAM) phase III randomized controlled trial was originally 
designed to compare two endocrine therapies for early hormone-receptor-positive breast 
cancer. Long term exemestane alone was compared to tamoxifen followed by exemestane. 
In contrast to other trials, the TEAM trial had no upper age limit. Therefore a relatively high 
number of older patients were included in the trial. The TEAM-lifestyle side study provides 
extensive information on physical functioning before, one and two years after randomiza-
tion. Due to its trial design, co-morbidities and treatment strategies were well documented. 
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The aim of this study was to assess change in physical functioning in different age groups 
after surgical treatment among patients with hormone-receptor-positive early stage breast 
cancer.
MAteRiAls And Methods 
The TEAM trial is a phase III open label, international randomized trial comparing 5 years 
of exemestane with 2.5-3 years tamoxifen followed by 2.5-3 years of exemestane in hormone 
receptor positive, early breast cancer patients. Details of the study design and population 
have been published previously.11 The TEAM lifestyle (TEAM-L) study is a side study from 
the TEAM trial. The population and study design of the TEAM-L study have been exten-
sively described in detail elsewhere.12 Only patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 or 1 were included in this trial. There was no upper 
age limit.
In short, lifestyle and quality of life questionnaires were sent to Dutch participants of the 
TEAM trial to prospectively investigate lifestyle habits. One year after randomization par-
ticipants received a questionnaire on current (T1) and pre-diagnostic (T0) physical activity 
levels and on current (T1) quality of life indicators.  Two years after randomization a similar 
questionnaire was sent out (T2). 
data collection 
Patient, tumour and treatment characteristics were collected. Patients were included if 
physical functioning derived from the EORTC questionnaire was available at T1 and T2. A 
previous study within the TEAM-L study did not observe differences in clinical character-
istics between the population of the TEAM trial and the subgroup of TEAM-L respondents 
at T2.12 Patients were divided into three age groups: age younger than 60, 60 to 70 years and 
70 years and older. 
Physical functioning was measured using two different questionnaires. First, self-reported 
physical functioning was assessed in the validated European Organisation for Research and 
Treatment of Cancer quality of life questionnaire (EORTC QLQ –C30, version 3.0) at T1 
and T2. The EORTC QLQ-C30 contained five items which were calculated into one physical 
functioning score as described previously.13 
Additionally, physical activity was quantified by using the validated European Prospective 
Investigation into Cancer (EPIC) physical activity questionnaire.14 In this questionnaire, 
patients were asked to report the amount of time they spent per week during summer and 
winter in recreational and household activities. Metabolic equivalent values were calculated 
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from the mean hours reported to estimate the intensity of recreational and household activ-
ity per week (Metabolic Equivalent of Task (MET) hours/week).15
statistical Analysis 
Statistical analysis was performed in SPSS version 20 and Stata 12.0. The TEAM lifestyle 
study was designed to assess change in functioning and quality of life in subgroups of pa-
tients. We used two-sided testing and P values of 0.05 or smaller were considered statistical 
significant. If a value of a specific characteristic of an individual patient was missing it was 
assigned to the “unknown” category of that characteristic. The proportion of missing values 
for each characteristic is shown in table 1 (unknown categories). For regression analysis, 
unknown categories in the characteristics were included as a separate category in the 
analysis (table 2).  Baseline characteristics among different age groups were compared using 
chi square tests. Mean physical functioning scores derived from the EORTC questionnaire 
and mean MET-hours/week in three age categories were calculated. Mean differences in 
physical functioning and physical activity between age groups were compared using one 
way ANOVA. Mean differences at the different time points within age groups were calcu-
lated by paired sample t-test and repeated measures one way ANOVA. Change in physical 
functioning was calculated by subtracting the calculated score for physical functioning from 
the EORTC questionnaire at T2 by the calculated score at T1. Univariate and multivariable 
regression were used to estimate the change in physical functioning for several variables. In 
the multivariable regression analysis we used an adjusted model, correcting for all known 
variables (age, number of comorbidities, BMI, ECOG performance score, T-stage, N-stage, 




Overall, 431 patients were included (figure 1). At baseline, Body-Mass Index (BMI) was 
higher in the older patients (P=0.006). Patients in the oldest age group were more likely 
to present with stage T2 breast cancer (P=0.010). In older patients a mastectomy was per-
formed more frequently in comparison to their younger counterparts (P=0.004). Addition-
ally, older patients received radiotherapy and chemotherapy less often (P=0.003, P<0.001 
respectively). Older patients were more frequently assigned to the exemestane treatment 
arm (P=0.008, table 1). 
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Table 1. Patient characteristics 
 
 
    Age < 60 
(n=167)
  Age 60-70 
(n=164)






    n (%) n (%) n (%)   P-value*
Patient characteristics                  
Number of comorbidities
    0 64 (38.3)   49 (29.9)   31 (31.0)   0.213
    1 to 2 77 (46.1)   74 (45.1)   46 (46.0)    
    ≥ 3 26 (15.6)   41 (25.0)   23 (23.0)    
BMI at T1
    < 25 75 (44.9)   49 (29.9)   33 (33.0)   0.027
    25-30 57 (34.1)   81 (49.4)   41 (41.0)    
    ≥ 30 31 (18.6)   31 (18.9)   20 (20.0)    
    Unknown 4 (2.4)   3 (1.8)   6 (6.0)    
ECOG performance status
    0 137 (82.0)   129 (78.7)   76 (76.0)   0.755 
    1 20 (12.0)   26 (15.9)   17 (17.0)    
    Unknown 10 (6.0)   9 (5.5)   7 (7.0)    
N=2754 patients in 76 TEAM 
centers randomized
N=742 patients invited in 
TEAM-L sidestudy
N=440 responders to TEAM-L 
T2 questionnaire 
N=431 included for analysis
N=2012 patients not
invited due to: 
- Centre not willing to participate
- Randomization not within side 
study frame
N=9 missing data on physical 
functioning on T2 
Figure 1. Flow chart of the inclusion of patients in the TEAM-L study. 
T2, 2 year after the diagnosis; TEAM, Tamoxifen Exemestane Adjuvant Multicenter; TEAM-L, Tamoxifen 
Exemestane Adjuvant Multicenter Lifestyle.
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Table 1. Patient characteristics  (continued)






Age ≥ 70 
(n=100)
 
n (%) n (%) n (%)   P-value*
Tumour characteristics                  
T-stage
    In situ / T1 77 (46.1)   94 (57.3)   33 (33.0)   0.010
    T2 79 (47.3)   60 (36.6)   60 (60.0)    
    T3 / T4 9 (5.4)   9 (5.5)   7 (7.0)    
    Unknown 2 (1.2)   1 (0.6)   0 (0.0)    
N-stage
    N0 42 (25.1)   40 (24.4)   33 (33.0)   0.216
    N+ 123 (73.7)   124 (75.6)   67 (67.0)    
    Unknown 2 (1.2)   0 (0.0)   0 (0.0)    
Grade
    I 27 (16.2)   29 (17.7)   18 (18.0)   0.883
    II 69 (41.3)   74 (45.1)   43 (43.0)    
    III 56 (33.5)   51 (31.1)   34 (34.0)    
    Unknown 15 (9.0)   10 (6.1)    5 (5.0)    
Treatment                    
Most extensive surgery
    None 1 (0.6)   1 (0.6)   0 (0.0)   0.004
    BCS 84 (50.3)   94 (57.3)   32 (32.0)    
    Mastectomy 81 (48.5)   69 (42.1)   68 (68.0)    
    Unknown 1 (0.6)   1 (0.6)   0 (0.0)    
Most extensive axillary surgery
    SNLB 37 (22.2)   35 (21.3)   28 (28.0)   0.704
    ALND 128 (76.6)   127 (77.4)   70 (70.0)    
    Unknown 2 (1.2)   2 (1.2)   2 (2.0)    
Radiotherapy
    No radiotherapy 48 (28.7)   44 (26.8)   48 (48.0)   0.003
    Radiotherapy 118 (70.7)   116 (70.7)   51 (51.0)    
    Unknown 1 (0.6)   4 (2.4)   1 (1.0)    
Chemotherapy
    No chemotherapy 44 (26.3)   124 (75.6)   100 (100.0)   <0.001
    Chemotherapy 123 (73.7)   40 (24.4)   0 (0.0)    
Endocrine therapy
    Exemestane 83 (49.7)   71 (43.3)   63 (63.0)   0.008
    Tamoxifen 84 (50.3)   93 (56.7)   37 (37.0)    
* P-values represent statistical significance of proportional differences among the three age groups
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Physical functioning 
Physical functioning, expressed as a mean score within a range of 0-100, is only reported 
between T1 and T2, no baseline results were available. As shown in figure 2, physical 
functioning in the oldest age group was significantly lower compared to the younger age 
groups at T1 and T2 (p<0.001 for T1 and T2). Patients aged 70 years and older showed a 
decrease in physical functioning of -2.59 points (SE 1.46) between T2 and T1 while patients 
aged 60 years or younger  showed an increase in physical functioning of 1.86 points (SE 
0.95), P=0.008. In addition, age above 70 years was an independent predictor for decline 
in physical functioning in multivariable regression analysis compared to the youngest age 
group (beta -4.62, 95% CI -8.73 – - 0.51, P=0.028, table 2). 
Additional variables were tested for predictive value (table 2).  ECOG performance score 
of 1 was predictive for decrease in physical functioning in multivariable regression analysis 
(beta -3.65, 95% CI  -7.13 – -0.16, P=0.040). Chemotherapy was a significant predictor for 
increased physical functioning in univariate analysis (beta 3.11, 95% CI 0.68-5.55, P=0.012) 
. In adjusted analysis however, this effect was no longer significant (beta 0.40 95% CI -2.96-
3.77, P=0.813). A trend was found for decrease in physical functioning among patients who 
were assigned to the tamoxifen-exemestane treatment arm, even though younger patients 
were more likely to receive this combination  (beta -2.08, 95% CI -4.46-0.28, P=0.084). After 
adjusted regression analysis this effect increased (beta -2.44, 95% CI -4.98-0.02, P=0.052). 
The number of comorbidities was not predictive for physical functioning. No other tumour 























Figure 2: Mean physical functioning in different age groups
T1: one year after diagnosis; T2: two years after diagnosis. Mean physical functioning scores were calcu-
lated from the  EORTC QLQ-C30 questionnaire.
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Table 2. Change in physical parameters between one and two years after diagnosis
 
 
      univariate  
 
 adjusted*    
      Bèta 95% CI p-value Bèta 95% CI P-value
Physical functioning                
Patient characteristics                
Age-group
    < 60   Ref       Ref      
    60-70   -2.19 (-4.88-0.50) 0.110   -1.32 (-4.55-1.91) 0.422
    ≥ 70   - 4.46 (-7.55--1.36) 0.005   -4.62 (-8.73--0.51) 0.028
Number of comorbidities
    0   Ref       Ref    
    1 to 2   0.14 (-2.57-2.85) 0.918   0.29 (-2.49-3.06) 0.839
    ≥ 3   -0.25 (-3.57-3.07) 0.883   0.34 (-3.14-3.82) 0.848
BMI at T1
    <25   Ref       Ref    
    25-30   -0.25 (-2.96-2.45) 0.854   0.12 (-2.68-2.93) 0.932
    ≥ 30   -0.84 (-4.22-2.53) 0.623   -0.28 (-3.76-3.21) 0.876
    Unknown   0.52 (-6.62-7.66) 0.886   2.82 (-4.44-10.09) 0.446
ECOG performance status 
    0   Ref       Ref    
    1   -3.10 (-6.48--0.27) 0.072   -3.65 (-7.13--0.16) 0.040
    Unknown   -2.14 (-7.15-2.87) 0.402   -1.81 (-6.96-3.34) 0.490
Tumour characteristics                  
T-stage
    In situ / T1 Ref     Ref    
    T2   1.80 (-0.64-4.26) 0.149   2.35 (-0.30-5.00) 0.082
    T3 / T4   3.79 (-1.43-9.01) 0.154   3.68 (-1.97-9.33) 0.201
    Unknown   10.01 (-4.30-24.33) 0.170   15.43 (-7.10-37.97) 0.179
N-stage
    N0   Ref     Ref    
    N+   -0.45 (-3.15-2.24) 0.742   -1.83 (5.75-2.09) 0.358
    Unknown   -3.68 (-21.31-13.96) 0.682   -6.91 (-29.08-15.26) 0.540
Grade
    I   Ref       Ref    
    II   0.18 (-3.21-3.56) 0.918   -0.76 (-4.27-2.75) 0.671
    III   2.09 (-1.46-5.63) 0.248   1.19 (-2.64-5.02) 0.541
    Unknown   2.43 (-2.91-7.77) 0.372   0.99 (-4.63-6.62) 0.729
Treatment                  
Most extensive surgery**
    BCS   Ref       Ref    
    Mastectomy 0.80 (-1.59-3.19) 0.511   -1.82 (-5.75-2.09) 0.520
    Unknown   -2.90 (-20.46-14.64) 0.745   -2.26 (-24.61-20.10) 0.843
Most extensive axillary surgery 
    SNLB   Ref       Ref    
    ALND   1.07 (-1.75-3.90) 0.455   1.91 (-2.15-5.97) 0.356
    Unknown   -1.71 (-12.10-8.67) 0.746   -3.18 (-14.41-8.06) 0.843
Radiotherapy
    No radiotherapy Ref       Ref    
    Radiotherapy 0.82 (-1.72-3.38) 0.523   1.26 (-2.36-4.87) 0.496
    Unknown   -2.82 (-13.12-7.47) 0.591   -0.26 (-11.78-11.27) 0.965
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Physical activity 
Mean values for physical activity measured in MET hours/week at T0, T1 and T2 are shown 
in figure 3. Complementary to the previous physical functioning score, mean physical activ-
ity was significantly lower in the oldest age group in comparison to the younger age groups 
at all time points (p<0.001 at all time points). Patients in all age groups showed a strong 
decline in physical activity two years after diagnosis (T2) compared to physical activity 
levels prior to diagnosis (T0) (P=0.002 for age group < 60 years, P=0.003 for age group 60-
70, P=0.002 for age group ≥ 70). Change in physical activity over time was not significantly 
different between age groups. 
Table 2. Change in physical parameters between one and two years after diagnosis (continued)
  univariate  
 
 adjusted*    
  Bèta 95% CI p-value Bèta 95% CI P-value
Chemotherapy
    No chemotherapy Ref   Ref    
    Chemotherapy 3.11 (0.68-5.55) 0.012   0.40 (-2.96-3.77) 0.813
Endocrine therapy
    Exemestane   Ref     Ref    
    Tamoxifen   -2.08 (-4.46-0.28) 0.084   -2.44 (-4.89-0.02) 0.052
Physical activity                  
Age-group
    < 60 Ref     -
    60-70 -1.03 (-3.89-1.82) 0.534 -
    ≥ 70   -1.04 (-4.32-2.24) 0.438   -    
Physical functioning score calculated from the EORTC-QLQ C30 questionnaire and change in physical 
activity calculated in MET/hours per week from the EPIC questionnaire
* adjusted for age, number of comorbidities, BMI at T1, ECOG, T stage, N stage, grade, surgery, axillary 
surgery, radiotherapy, chemotherapy and endocrine therapy

















Figure 3: Mean physical activity in different age groups
T0: at time of diagnosis; T1: one year after diagnosis; T2: two years after diagnosis.  Mean physical activity 
was calculated from the  EPIC physical activity questionnaire.
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Age above 70 years was not predictive for change in physical activity between T2 and T1 
in univariate regression analysis compared to the youngest age group (bèta -1.04, 95% CI 
-4.32-2.24, P=0.438, table 2). In addition, no other patient, tumour or treatment character-
istics were predictive for change in physical activity. 
disCussion
This study has shown that patients aged over 70 years treated with adjuvant hormonal 
therapy after breast cancer surgery showed significantly stronger decline in physical func-
tioning between one and two years after diagnosis compared to their younger counterparts. 
Furthermore, we observed a decrease in physical activity level two years after diagnosis 
compared to prediagnostic physical activity among postmenopausal patients with breast 
cancer.  
Our findings are in line with previous studies that examined physical activity among  pa-
tients with breast cancer and reported a strong decline in physical activity immediately after 
diagnosis.16-19 Only one study has examined physical recovery after surgery. The authors 
retrospectively assessed physical activity measured in leisure MET hours/week before 
diagnosis, during treatment and one year after diagnosis in a population based cohort 
study among primary breast cancer patients aged 50-75 years. After an initial decrease in 
physical activity during treatment, physical activity increased towards prediagnostic value 
one year after surgery and age was associated with decrease in physical activity one year 
after surgery.17 Although exact time points between the studies differ, there is a similar 
pattern of initial decrease followed by subsequent increase of physical activity among all 
patients with breast cancer. In addition, the CALGB 49907, a randomized controlled trial 
and the CALGB 369901, a prospective cohort study, assessed physical functioning among 
older women treated with chemotherapy. In both studies, physical functioning improved in 
the first twelve months. However, in line with our findings, patients experienced decline in 
physical functioning from one to two years after diagnosis.20,21 Figure 2 and figure 3 show a 
similar pattern for physical functioning and physical activity across the age groups between 
one and two years after, suggesting that there is a relation between the two parameters. A 
possible explanation for the observed decline in physical functioning in the oldest patients 
may be that functional decline in the older patient with breast cancer could be part of 
biological aging. This study had no control group of non-cancer subjects with similar age 
distribution. Therefore we were unable to distinguish the impact of cancer and treatment 
on physical functioning from age related deterioration. Two previous studies compared 
physical functioning in patients with cancer and a control group without cancer. Arndt 
et al. compared physical functioning from the EORTC QLQ C-30 questionnaire of breast 
cancer patients one year after diagnosis with a control population. They found a difference 
88 Chapter 4 
in younger breast cancer patients, but not in older patients (70-80 years).22 Unfortunately, 
they did not report levels of physical functioning before diagnosis. Kroenke et al. compared 
physical functioning in the Nurses’ Health Study before and after diagnosis. Functional 
decline among older women without breast cancer was half of that of older women with 
breast cancer.23 They used a relatively young population, with a reported upper age limit of 
72 years. In this breast cancer population, 68% used hormonal therapy and 20% used che-
motherapy. Overall, functional decline in older patients with breast cancer is closely related 
to age. However, cancer and cancer therapy probably have impact on physical functioning 
as is shown in the study by Kroenke and might accelerate decline in physical functioning. 
Previous studies described a significant reduction in physical functioning during and after 
chemotherapy among patients with breast cancer.24-26 In our study, there was an imbalance 
in the proportion of patients receiving adjuvant chemotherapy between the age groups as 74 
% of the youngest patients received chemotherapy and none of the older patients received 
chemotherapy. This might impact the level of physical functioning as measured one year 
after diagnosis and  change in functioning from one to two years after diagnosis. However, 
in the multivariable model where chemotherapy was included as a covariate, older age re-
mained an independent prognostic factor for physical decline. Furthermore, older patients 
were less frequently assigned to the tamoxifen treatment arm. This could be the result of 
randomization but we cannot rule out that there is selective loss to follow up among the 
older patients in the tamoxifen arm. 
BMI was not predictive for change in physical functioning after surgery. This is an interest-
ing finding, as BMI is associated with poor physical activity in patients with breast cancer 
[18]. However, we did observe a lower mean physical activity level among patients with 
obesity although this level did not change significantly over time. Additionally, to our 
surprise, the number of comorbidities did not influence change in physical functioning. In 
contradiction to results in previous studies, patients with a higher number of comorbidities 
did not report lower mean levels of physical functioning.5,24 Probably this is due to selection 
of patients in our study: only patients with a good ECOG performance score were included. 
This selection resulted in lower numbers of comorbidities in the patient population com-
pared to the general population.27 As expected, increased ECOG performance status was 
predictive for decline in physical functioning independent of other patient characteristics. 
The performance status may therefore be a useful clinical tool to detect patients at risk for 
physical decline after breast cancer diagnosis. However, a previous study has shown that the 
comprehensive geriatric assessment is a better predictor for physical functioning than the 
ECOG performance score in older patients.28 In addition, the geriatric assessment is able to 
identify areas of vulnerability that would not be identified by routine history and physical 
examination.29 As it is able to distinguish frail older patients from fit older patients, it is 
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likely to be a better predictor than just chronological age for decline in physical function-
ing as well. Currently, the International Society for Geriatric Oncology (SIOG) advice to 
perform a geriatric assessment in all older patients with cancer.30 
Although not statistically significant, there was a trend for decreased physical function-
ing among patients allocated to the tamoxifen-exemestane treatment arm. This could not 
be explained by adverse events: the TEAM trial found significantly more musculoskeletal 
adverse events as they occurred more frequently in the exemestane treatment arm. No 
other adverse events associated with physical limitations were more frequently seen in the 
tamoxifen group.11 The major strength of this study is the prospective design. We were able 
to prospectively collect reliable and well-registered data that made our study less subject to 
recall bias. Physical functioning was measured with two different validated questionnaires 
to increase the reliability of our findings.  To our knowledge, this is the first study on physi-
cal functioning in older patients with breast cancer with a follow up of two years. We hereby 
provide further insight into recovery of physical functioning in the course of time. Further-
more, our study had no upper age limit, providing us with an unique opportunity to study 
older patients and examine the effect of age on physical activity and physical functioning. 
However, this study was subject to several limitations as well. Most importantly, the TEAM 
trial only included patients with a low ECOG performance score. This led to inclusion of 
relatively fit older adults. Also, older patients included in the TEAM  study had a high socio-
economic status and a low comorbidity burden in comparison with the age matched general 
population.31 Due to this selection, the effect of age on decline in physical functioning could 
be underestimated when findings are extrapolated to the general population. Furthermore, 
although post-diagnostic physical functioning and physical activity were examined prospec-
tively, levels of physical activity before diagnosis were assessed retrospectively. Although 
the EPIC questionnaire is validated for prospective follow up, it is not validated to assess 
physical activity retrospectively and it could therefore be subject to recall bias. However, it 
is not likely that the effect of recall bias differed between age groups.  In addition, no data on 
physical functioning before diagnosis was available and therefore it is not possible to assess 
change from diagnosis to one year after diagnosis. Physical parameters could be affected 
by recurrence of disease. In this study, the number of patients who experienced a recur-
rence was low (n=9) and divided equally among all age groups. At last, we performed an 
additional analysis which showed that actual hours of activity corresponded well to physical 
activity calculated in MET hours. 
It is important to prevent worsening of physical functioning in the older patients as it could 
interfere with independent living. This stresses the need for further research into the effect 
of intervention programs to prevent loss of functioning during hormonal treatment among 
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older patients with breast cancer. A multitude of randomized controlled trials on the effect 
of exercise on quality of life in patients with cancer have been performed in the last decade. 
A recent meta-analysis evaluated exercise intervention among post treatment cancer sur-
vivors. In the breast cancer subgroup analysis they did found an improvement in overall 
health related quality of life at varying time points (12 weeks, 6 months). No sustainable 
effect of exercise on physical functioning was observed.32 Unfortunately, this meta-analysis 
did not perform age-specific subgroup analyses. Most of the included trials focused on 
exercise interventions in younger patients and may not be suitable for older patients. Morey 
et al. conducted a randomized controlled trial among older long term cancer survivors (> 
65 years) examining the effect of a home based tailored programme promoting exercise and 
healthy diet. At twelve months follow up, they found an increase of physical functioning 
and overall quality of life in the intervention group compared to the control group.33 This 
suggests that tailored exercise programmes for older patients with breast cancer might be 
effective.      
With regard to the expanding aging population, the increasing number of older patients 
with breast cancer and the continuously improving breast cancer treatments, more research 
is required to evaluate and improve long term physical functioning in older patients with 
breast cancer. Unfortunately, older adults are generally underrepresented in clinical trials.34 
Participating older patients are relatively healthy compared to the general population. Con-
sequently, trial results cannot be extrapolated to the general older breast cancer population.31 
Furthermore, few studies investigate functional status and quality of life. These endpoints 
might be particularly relevant for older patients with breast cancer.35,36 Prospective studies 
that measure physical functioning before and after treatment are needed to evaluate change 
in physical functioning in relation to treatment.
Conclusion 
In contrary to younger patients, patients aged over 70 years treated with breast surgery and 
adjuvant hormonal therapy did not improve in physical functioning between one and two 
years after diagnosis to the same extent as younger patients. With respect to our aging breast 
cancer population, more research is needed to clarify the interaction of physical function-
ing, breast cancer and the ageing process.
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ABstRACt
Aim of study: Due to increasing life expectancy, patients with breast cancer remain at risk 
of dying due to breast cancer over a long time. This study aims to assess the impact of age on 
breast cancer mortality and other cause mortality ten years after diagnosis. 
Methods: Postmenopausal patients with hormone-receptor positive breast cancer were 
included in the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial between 
2001 and 2006. Age at diagnosis was categorized as <65 years (n=3369), 65 to 74 years 
(n=1896) and ≥75 years (n=854). Breast cancer mortality was assessed using competing risk 
analysis by considering other cause mortality as a competing event. 
Results: After a median follow-up of 9.8 years (interquartile range 8.0-10.3), cumulative 
incidence of breast cancer mortality increased with increasing age (age <65 years 11.7% 
(95% CI 10.2-13.2), 65-74 years 12.7% (11.2-14.2), ≥ 75 years 15.6% (13.1-18.0). Univariate 
subdistribution Hazard Ratio (sHR) increased with increasing age (age 65-74 years sHR 
1.08, 95% confidence interval (CI) 0.92-1.27, ≥75 years sHR 1.30, 95% CI 1.06-1.58, P= 
0.013). Multivariable sHR adjusted for tumour and treatment characteristics increased with 
age but did not reach significance (age 65-74 years sHR 1.11, 95% CI 0.94-1.31; ≥75 years 
sHR 1.18, 95% CI 0.94-1.48, P= 0.055). 
Conclusion: Ten years after diagnosis, older age at diagnosis is associated with increasing 
breast cancer mortality in univariate analysis but it did not reach significance in multi-
variable analysis. Increasing breast cancer mortality is not outweighed by a substantially 
increasing other cause mortality with increasing age. This underlines the need to improve 
the balance between undertreatment and overtreatment in older patients with breast cancer. 
Impact of age on breast cancer mortality and competing causes of death 99
intRoduCtion 
Age is the strongest predictor for the development of breast cancer.1 Due to aging of the 
population, the number of older patients diagnosed with breast cancer is rapidly growing. 
With increasing life expectancy, older patients remain at risk of dying of breast cancer over a 
longer time period. At the same time, the risk of dying from other causes than breast cancer 
increases substantially with advancing age.2 Survival estimates that take these competing 
causes of death into account are essential for individual decision making to balance between 
benefits and toxicities of cancer therapy.3 
As older patients are poorly represented in clinical trials,4 the relation between age at diag-
nosis and breast cancer mortality was mainly investigated in observational studies, report-
ing a higher breast cancer mortality with increasing age.5-9 Due to lack of information on 
cause of death, most studies use relative survival as a measurement of breast cancer-related 
survival. The Tamoxifen and Exemestane Adjuvant Multicenter (TEAM) trial included a 
large number of older postmenopausal patients, and contains reliable information on cause 
of death. A previous analysis after five years of follow-up observed higher breast cancer 
mortality with increasing age, despite a higher proportion of other cause mortality with 
increasing age.9 
As patients above 75 years currently have an anticipated life expectancy of 12 years and 
breast cancer can recur until 20 years after initial diagnosis,10 it is relevant to investigate how 
breast cancer mortality and other cause mortality compete over a longer time period after 
breast cancer. Therefore, the aim of this study was to assess the relation between age at diag-
nosis and breast cancer mortality and other cause mortality ten years after diagnosis among 
postmenopausal patients with hormone receptor-positive early breast cancer included in 
the TEAM trial. 
PAtients And Methods
The TEAM study is a randomized controlled trial including postmenopausal patients with 
non-metastatic estrogen and/or progesterone positive breast cancer. Details of the trial have 
been extensively described in previous publications.11,12 In short, patients were included 
between 2001 and 2006 and randomized to receive exemestane for five years, or tamoxifen 
followed by exemestane for a total duration of five years. If patients had an Eastern Coopera-
tive Oncology Group (ECOG) performance status higher than two, a previous malignancy 
with a disease-free interval of fewer than five years or significant cardiac or other diseases 
interfering with study participation they were ineligible. Cause of death was indicated on 
a case report form and categorized into 10 pre-specified groups (Table 2). Classification of 
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cause of death was verified centrally by the TEAM datacenter. The database was locked on 
February 19, 2016 for the study endpoints after ten years of follow-up.
For the current analysis, only patients from countries that completed ten years of follow-up 
were included (The Netherlands, Belgium, Luxembourg, United Kingdom, Ireland, Greece 
and Germany). After ten years of follow-up there was no difference in the primary endpoint 
between the two treatment arms.11 
The trial was registered in international trial databases (ClinicalTrials.gov NCT00279448, 
NCT00032136, and NCT00036270; the Netherlands Trial Registry NTR267; Ethics 
Commission Trial 27/2001; and the University hospital Medical Information Network 
C000000057). Approvals from ethical committees and written informed consent from all 
patients were obtained.12
outcomes
For age at diagnosis patients were categorized into three categories (<65 years (reference 
group), 65-74 years and ≥75 years) according to the guidelines of the International So-
ciety of Geriatric Oncology (SIOG).13 Breast cancer mortality was defined as time from 
randomization to death due to breast cancer. Deaths that occurred after distant recurrence 
were defined as death due to breast cancer with other cause mortality as a competing event. 
Other cause mortality was defined as all other causes of death than breast cancer, and in the 
analyses breast cancer mortality was considered as competing event. Distant recurrence was 
classified according to the Tumour-Node-Metastasis classification (6th edition).14 If patients 
died due to breast cancer, the presence of distant recurrence was assumed and other cause 
mortality was considered as competing event. 
statistical Analyses 
Pearson χ2 test was used to compare proportional differences between age groups. Cumula-
tive incidences of breast cancer mortality, other cause mortality and distant recurrence were 
calculated using the Cumulative Incidence Competing Risk Methods.15,16 The Fine and Gray 
model was used to calculate the effect of prognostic factors for the cause-specific incidences 
of death or distant recurrence taking into account the effect of competing causes of death.16 
The effect of prognostic factors is expressed as subdistribution hazard ratio’s (sHR).15,16 
P- values for trend over increasing age were reported. The multivariable model included 
clinically relevant covariates (histological grade, tumour size, lymph node status, proges-
terone receptor status, Her2 receptor status, most extensive breast surgery, radiotherapy, 
chemotherapy, type of endocrine therapy and country of residence). Multiple imputation 
by chained equation was performed to account for missing values, assuming that data were 
missing at random.17 Analyses were based on pooled results of five imputed data sets using 
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Rubin’s rules. All statistical tests were two-sided. P-values of less than 0.05 were considered 
statistically significant. All analyses were performed in R version 3.3.0 using the survival, 
cmprsk and mice packages. 
Additional analyses
An additional analysis was performed to assess the impact of age at diagnosis on breast 
cancer mortality in those patients who were diagnosed with a distant recurrence during 
follow-up. Furthermore, two sensitivity analyses were performed to test the validity of the 
study endpoints (Supplementary Material).  
Results
Overall, 6119 postmenopausal patients were included. 3369 patients (55%) were aged 
<65 years, 1896 were 65-74 years (31%), and 854 patients (14%) were aged ≥75 years at 
diagnosis. Median follow-up was 9.8 years (interquartile range 8.0-10.3). Table 1 shows the 
baseline characteristics by age group. Patients aged ≥75 years were more likely to present 
with larger tumours, no difference was observed in nodal status or differentiation grade. The 
proportion of patients undergoing a mastectomy increased significantly with increasing age, 
whereas administration of radiotherapy and adjuvant chemotherapy decreased significantly 
with increasing age. 
Table 1. Patient, tumour and treatment characteristics by age at diagnosis
< 65 years 65-74 years ≥ 75 years
n=3369 n=1896 n=854
n %  %* n % %*   n % %* P 
Histological grade 
G1, well 330 9.8 10.6 200 10.5 11.5 86 10.1 11.6 0.527
G2, modeate 1721 51.1 55.5 1011 53.3 56.9 436 51.1 56.2
G3, G4, poor 1034 30.7 33.8 553 29.2 31.6 248 29.0 32.2
Unknown 284 8.4 132 7.0 84 9.8
T size
T1 1797 53.3 53.5 954 50.3 50.4 275 32.2 32.2 <0.001
T2 1353 40.2 40.4 830 43.8 43.9 501 58.7 58.7
T3, T4 208 6.2 6.2 107 5.6 5.7 78 9.1 9.1
Unknown 11 0.3 5 0.3 0
N status
N0 1437 42.7 42.8 818 43.1 43.4 348 40.7 41.1 0.842
N1 1703 50.5 50.7 954 50.3 50.4 442 51.8 52.0
N2/N3 221 6.6 6.6 117 6.2 6.2 58 6.8 6.9
Unknown 8 0.2 7 0.4 6 0.7
Progesterone receptor
Positive 2431 72.2 72.2 1330 70.1 70.1 616 72.1 72.1 0.275
Negative 938 27.8 27.8 1330 29.9 29.9 238 27.9 27.9
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During follow-up, 551 of 3369 (16%) patients aged <65 years at diagnosis, 467 of 1896 (25%) 
patients aged 65 to 75 years and 443 of 854 (52%) patients aged ≥75 years at diagnosis died. 
Breast cancer was the leading cause of death among all age groups, but proportionally de-
creased with increasing age at diagnosis (Table 2). Ten-year cumulative incidence of breast 
cancer mortality increased from 11.7%  in patients aged <65 years, to 12.7%  in patients aged 
65-74 years and 15.6% in patients aged ≥75 years (Table 3, Figure 1). In univariate analysis, 
increasing age was associated with a higher breast cancer mortality (age group 65-74 years 
sHR 1.08, 95% CI 0.92-1.27; age group ≥75 years sHR 1.30, 95% CI 1.06-1.58, P= 0.013, 
Table 3). In multivariable analysis, breast cancer mortality increased with advancing age 
although it did not reach statistical significance (age group 65-74 years sHR 1.11, 95% CI 
0.94-1.31; age group ≥75 years sHR 1.18, 95% CI 0.94-1.48, P= 0.055, Table 3). 
Table 1. Patient, tumour and treatment characteristics by age at diagnosis (continued)
< 65 years 65-74 years ≥ 75 years
n=3369 n=1896 n=854
n %  %* n % %*   n % %* P 
Her2 receptor
Positive 328 9.7 13.9 166 8.8 12.4 66 7.7 10.4 0.069
Negative 2000 59.4 86.1 1212 63.9 87.6 612 71.7 89.6
  Unknown 1041 30.9 518 27.3 176 20.6
Most extensive surgery
Mastectomy 1395 41.4 41.5 898 47.4 47.4 580 67.9 68.0 <0.001
Wide local excision 1970 58.5 58.5 997 52.6 52.6 273 32.0 32.0
Unknown 4 0.1 1 0.1 1 0.1
Radiotherapy 
Yes 2499 74.2 74.4 1247 65.8 66.0 420 49.2 49.3 <0.001
No 861 25.6 25.6 642 33.9 34.0 431 50.5 50.7
Unknown 9 0.3 7 0.4 3 0.4
Radiotherapy if wide local excision 0.001
Yes 1873 95.1 - 922 92.5 - 244 89.4 -
No 94 4.8 - 73 7.3 - 28 10.3 -
Unknown 3 0.2 2 0.2 1 0.4
Chemotherapy
Yes 1855 55.1 55.1 376 19.8 19.8 21 2.5 2.5 <0.001
No 1514 44.9 44.9 1520 80.2 80.2 833 97.5 97.5
Endocrine therapy
Tamoxifen followed by exemestane 1689 50.1 50.1 943 49.7 49.7 413 48.4 48.4 0.651
Exemestane 1680 49.9 49.9 953 50.3 50.3 441 51.6 51.6
Country
Germany 871 25.9 25.9 454 23.9 23.9 146 17.1 17.1 <0.001
Greece 110 3.3 3.3 71 3.7 3.7 26 3.0 3.0
Netherlands and Belgium 1692 50.2 50.2 958 50.5 50.5 516 60.4 60.4
United Kingdom and Ireland 696 20.7 20.7 413 21.8 21.8 166 19.4 19.4
*proportional distribution after multiple imputation 
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Table 2. Cause of death by age at diagnosis
< 65 years 65-74 years ≥ 75 years
All deaths n=551 % n=467 % n=443 %
Breast cancer 412 74.8 250 53.5 134 30.2
Second primary tumour 66 12.0 58 12.4 33 7.4
Endometrial cancer 1 0.2 2 0.4 0 0
Cardiac disorder 13 2.4 37 7.9 56 12.6
Thromboembolism 3 0.5 2 0.4 11 2.5
Pulmonary disorder 5 0.9 18 3.9 15 3.4
Cerebral disorder 4 0.7 14 3.0 21 4.7
Vascular disorder 1 0.2 2 0.4 3 0.7
Other 21 3.8 50 10.7 111 25.1
Unknown 21 3.8 34 7.3 59 13.3
Percentages represent the proportion of all deaths by age group. 
Ten-year cumulative incidence of other cause mortality increased with older age at diagnosis 
(patients aged <65 years 3.7%; 65-74 years 10.6%; ≥75 years 33.4%, Figure 1). Both models 
showed a strong association between age and other cause mortality (Table 3). 
< 65 65-74 ≥ 75




















Breast cancer mortality Other cause mortality
Figure 1. Cumulative incidence of mortality by cause of death per age group 
Stacked cumulative incidence of breast cancer mortality (red) and other cause mortality (blue) by age 
group from time since diagnosis. 
104 Chapter 5 
Cumulative incidence of distant recurrence increased between five and ten years in all age 
groups. In both models, age was not associated with a higher risk of distant recurrence after 
ten years (age group 65-74 years multivariable sHR 1.05, 95% CI 0.90-1.23, age group ≥75 
years 0.97, 95% CI 0.79-1.20, P= 0.462, Table 3). 
Additional analyses 
Older patients that developed a distant recurrence during follow-up were at higher risk of 
dying due to breast cancer compared to younger patients (patients aged 65-74 years multi-
variable sHR 1.30, 95% CI 1.09-1.56; patients aged ≥75 years sHR 2.18, 95% CI 1.70-2.78, 
P<0.001). 
When not assuming breast cancer as the cause of death after diagnosis of distant recur-
rence, 39 deaths originally classified as death due to breast cancer were now considered as 
death due to other causes (Supplementary Table 1). A similar trend for the effect of age at 
diagnosis and breast cancer mortality in univariate analysis was observed while there was 
no clear trend between increasing age and breast cancer mortality in multivariate analysis 
(Supplementary Table 2). Outcomes of further sensitivity analyses are described in the 
Supplementary Material.  
Table 3. Survival outcomes by age at diagnosis
Cumulative incidence (%)  
(95% CI)
Univariate 
sHR# (95% CI) P value##  
Multivariable 
sHR# (95% CI) P value##
Five years after 
diagnosis
Ten years after 
diagnosis 
Breast cancer mortality
< 65 6.4 (5.6-7.2) 11.7 (10.2-13.2) Reference 0.013 Reference 0.055
65-74 6.6 (5.5-7.7) 12.7 (11.2-14.2) 1.08 (0.92-1.27) 1.11 (0.94-1.31)
≥ 75 8.9 (7.0-10.8) 15.6 (13.1-18.0) 1.30 (1.06-1.58) 1.18 (0.94-1.48)
Other cause mortality
< 65 1.2 (0.7-1.5) 3.7 (3.1-4.3) Reference <0.001 Reference <0.001
65-74 4.9 (3.9-5.9) 10.6 (9.2-12.0) 2.88 (2.33-3.56) 2.44 (1.95-3.06)
≥ 75 14.6 (12.3-17.0) 33.4 (30.2-36.5) 10.53 (8.63-12.86) 7.97 (6.31-10.06)
Distant recurrence 
< 65 10.2 (9.2-11.3) 17.8 (16.4-19.2) Reference 0.462 Reference 0.995
65-74 10.0 (8.6-11.3) 18.8 (16.9-20.8) 1.02 (0.89-1.17) 1.05 (0.90-1.23)
≥ 75 12.3 (10.1-14.5) 18.8 (16.0-21.5) 1.07 (0.89-1.29) 0.97 (0.79-1.20)
# Calculated for complete follow-up time. ## P for trend.
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disCussion
After ten years of follow-up, increasing age at diagnosis is associated with higher breast 
cancer mortality and this is not outweighed by a substantially higher other cause mortality. 
After adjusting for breast cancer and treatment characteristics, a similar trend was observed 
although this did not reach significance. Moreover, distant recurrences occurred at a similar 
rate between younger and older patients, despite substantially higher other cause mortal-
ity among the oldest patient group. In those patients that developed distant recurrence, 
increasing age was associated with increasing breast cancer mortality subsequently. These 
findings indicate the need to develop prediction tools that include both breast cancer and 
other cause mortality to balance harms and benefits of treatment. 
A previous report of the TEAM trial after five years of follow-up described a significant 
association between increasing age and breast cancer mortality, independent of tumour and 
treatment characteristics9.  In our study cohort, we observed a corresponding trend after 
adjusting for similar confounders but it did not reach significance. There are some possible 
explanations for the different outcomes in both analyses. The population in the current ten-
year cohort was different from the original population: in the current cohort patients had 
larger tumours and were more often lymph node-positive and a poorer disease-free survival 
than in the original TEAM population.11 Furthermore, the authors applied a Cox model 
for the main analyses while in this study, a competing risk regression model was applied. 
After the publication of the study in 2012, this study group has gained more experience and 
knowledge in the application and interpretation of the competing risk model.3 With this 
current knowledge it was decided that the competing risk model was more appropriate than 
the Cox model to predict outcomes between age groups. Moreover, in the current study 
multiple imputation analysis was performed to account for missing values. 
In a population with a high probability of competing events it is important to take compet-
ing events into account when estimating the risk of breast cancer mortality, as it could 
otherwise overestimate the risk of breast cancer mortality.3 Unfortunately, previous studies 
describing the relation between age at diagnosis and cause of death among patients diag-
nosed with breast cancer used various statistical techniques. In the ATAC trial, a positive 
association between increasing age and risk of breast cancer recurrence and death without 
recurrence was reported using the Cox model.18 However, this effect of age at diagnosis 
might be overestimated because competing events were not considered.3 In trials from the 
NCIC Clinical Trials Group, the effect of age at diagnosis on breast cancer mortality and 
competing causes of death was studied using various competing risk models.19-21 Age was 
predictive for breast cancer mortality after 3.9 and 4.1 years of follow-up,19,20 but not after 
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7.9 years of follow-up.21 These findings suggest that there is need for consensus on appropri-
ate statistical models to assess the impact of age on breast cancer mortality. 
It is interesting to elaborate why older patients were at higher risk of breast cancer mortality. 
In this study we report similar rates of distant recurrence among all age groups despite 
substantially higher risk of other cause mortality. Older patients had a substantially higher 
risk to die due to breast cancer than younger patients after diagnosis of distant recurrence. 
This may explain the trend for higher breast cancer mortality observed in this study. Un-
fortunately, there is no further information of distant recurrence available and it remains 
unclear if our results are explained by tumour biology or given treatment. In view of our 
data, we hypothesize that older patients may receive less intensive treatment of distant 
recurrences leading to higher breast cancer mortality. Further research hereon is highly 
warranted.  Moreover, in the multivariable analysis, the trend between age and breast cancer 
mortality did not reach significance, indicating that there is a role for variation in tumour 
or treatment characteristics at baseline. In our study older patients were more likely to pres-
ent with larger tumours than younger patients (Table 1). Previous studies have reported 
that tumour size is directly associated with poorer breast cancer outcomes22 and that older 
patients are more likely to present with larger tumours.23 Although this might suggest there 
is a direct relationship between tumour size, age and breast cancer mortality, another study 
has described a different relationship between age, tumour size and lymph node involve-
ment among older patients; after the age of 70, patients with smaller tumours appeared to 
have a higher risk of lymph node involvement than patients with larger tumours, suggesting 
a poorer prognosis for older patients with smaller tumours.24 
Furthermore, older patients were less likely to receive chemotherapy despite having larger 
tumours (Table 1) and this could have influenced the outcomes as well. Previous studies 
have shown that chemotherapy in older patients is as effective as in younger patients, 
though risk of toxicity is higher.13,25 Due to the very low number of older patients receiving 
chemotherapy, it was impossible to perform further analyses exploring the effect variation 
of chemotherapy on breast cancer mortality and therefore no firm conclusions regarding 
overtreatment or undertreatment can be derived from this data.  
Obviously, other cause mortality is strongly related to age.26 To provide a full overview of 
the prognosis of an individual patient it is of vital importance to investigate factors that 
are prognostic for other cause mortality along with prognostic factors for breast cancer 
mortality. In patients with breast cancer, it has been reported that comorbidities are strongly 
related to other cause mortality.18,27 Unfortunately, in the TEAM study information on co-
morbidities was only collected for a small subgroup of patients and therefore comorbidities 
were not included in this analysis. Geriatric indicators and comorbidities could be used to 
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predict the risk of toxicities to provide a profound estimation of breast cancer mortality, 
other cause mortality and benefits and harms of treatment.28 
Some additional limitations should be mentioned. First, misclassification of cause of death 
could have occurred and this could possibly influence cause-specific survival outcomes.29 
A sensitivity analysis was performed applying a less stringent classification of breast cancer 
mortality. Consistent with our main results, a similar trend for increasing breast cancer 
mortality with increasing age was observed. In multivariable analysis, no trend between 
increasing age at diagnosis and breast cancer mortality was observed. This might be ex-
plained due to a loss of power as there were fewer breast cancer mortality events. Moreover, 
unknown cause of death was more frequently reported among older patients and this 
could have influenced our findings. Finally, a previous study has shown that older patients 
included in the TEAM study were relatively healthy compared to the general population, 
which may limit the external validity of the present findings.30  
In conclusion, this study shows that breast cancer mortality continues to increase after ten 
years of follow-up among postmenopausal patients diagnosed with hormone receptor-
positive breast cancer regardless of the increasing other cause mortality. In older patients, 
breast cancer mortality remained higher compared to younger patients and this was not 
outweighed by substantially higher other cause mortality. A similar trend was observed in 
multivariable analysis, although this did not reach significance. Moreover, older patients 
were at a substantially higher risk of dying due to breast cancer after diagnosis of distant 
recurrence. These findings emphasize the impact of breast cancer on mortality among older 
patients and underline the need for prediction tools that include both breast cancer and 
other cause mortality in order to accurately balance harms and benefits of treatment.
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Supplementary Table 1. Cause of death using less stringent definition 
< 65 years 65-74 years ≥ 75 years
n=551 % n=467 % n=443 %
Breast cancer 400 72.6 238 51.0 119 26.9
Second primary tumor 69 12.5 60 12.8 35 7.9
Endometrial cancer 1 0.2 2 0.4 1 0
Cardiac disorder 13 2.4 40 8.6 60 13.5
Thromboembolism 4 0.7 2 0.4 11 2.5
Pulmonary disorder 6 1.1 18 3.9 18 4.1
Cerebral disorder 5 0.9 16 3.4 22 5.0
Vascular disorder 1 0.2 3 0.6 3 0.7
Other 31 5.1 54 11.6 115 26.0
Unknown 21 3.8 34 7.3 59 13.3
Cause of death definition: If a patient died after occurrence of distant 
metastases, cause of death was not assumed to be breast cancer related unless cause of death was un-
known.
Supplementary Table 2. Survival outcomes by age at diagnosis using different endpoint definitions
Univariate sHR# 
(95% CI) P value##  
Multivariable sHR# 
(95% CI) P value##
Breast cancer mortality
< 65 Reference 0.131 Reference 0.387
65-74 1.06 (0.90-1.24) 1.11 (0.93-1.33)
≥ 75 1.17 (0.95-1.44) 1.08 (0.85-1.38)
Other cause mortality
< 65 Reference <0.001 Reference <0.001
65-74 2.81 (2.29-3.46) 2.51 (2.02-3.12)
≥ 75 10.29 (8.49-12.48) 8.33 (6.64-10.45)
Distant recurrence 
< 65 Reference 0.832 Reference 0.530
65-74 1.00 (0.87-1.15) 1.02 (0.87-1.20)
≥ 75 1.03 (0.85-1.24) 0.91 (0.73-1.14)
Cause of death definition: If a patient died after occurrence of distant metastases, cause of death was not 
assumed to be breast cancer related unless cause of death was unknown. Distant recurrence definition: 
if a patient died due to breast cancer, distant recurrence was not automatically assumed 
# Calculated for complete follow-up time. ## P for trend.
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ABstRACt 
Background: Increasing life expectancy leads to increasing numbers of older patients diag-
nosed with breast cancer. The aim of this study was to determine the long-term impact of 
comorbidities and age at time of breast cancer diagnosis on breast cancer mortality when 
taking into account competing causes of death.
Patients and Methods: Cohort analysis of Dutch and Belgian patients with hormone 
receptor-positive breast cancer included in the Tamoxifen and Exemestane Adjuvant Mul-
tinational (TEAM) trial between January 2001 and January 2006. Patients were categorized 
by number of comorbidities (no comorbidities, 1-2 comorbidities and >2 comorbidities) 
and age (<70 years and ≥70 years). Main outcome was breast cancer mortality considering 
other cause mortality as competing event.
Results: Use of chemotherapy was lower in older patients (1%, irrespective of the number of 
comorbidities) compared to younger patients (50%, 44% and 38% for patients with no, 1-2 
or >2 comorbidities, P<0.001). Cumulative incidence of breast cancer mortality was higher 
among patients ≥70 without comorbidities (22.2%, 95% CI 17.5-26.9) compared to patients 
<70 without comorbidities (15.6%, 13.6-17.7, reference group), multivariable subdistribu-
tion Hazard Ratio (sHR) 1.49 (1.12-1.97, P=0.005) after a median follow-up of 10 years. 
Breast cancer mortality in other subgroups was not higher compared to the reference group. 
Conclusion: Older patients without comorbidities have a higher risk of dying due to breast 
cancer than younger patients, even when taking into account higher competing mortality, 
while use of chemotherapy in this group was low. These findings underline the need to take 
into account comorbidities, age and competing mortality in the prognosis of breast cancer 
for accurate decision making. 
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intRoduCtion
Increasing life expectancy and decreasing birth rates are important factors contributing to 
rapid ageing of the population.1 As increasing age is an important predictive factor for the 
development of breast cancer, it is expected that the number of older patients diagnosed with 
breast cancer will increase concomitantly.2 In older patients, breast cancer occurs against 
a background of other diseases.3 On the other hand, studies have shown that increasing 
longevity may be accompanied by an extended period of good health, resulting in a relevant 
population of older patients with breast cancer and minimal comorbidity.4 This diversity in 
health status in older patients is challenging for clinicians when balancing the benefits and 
toxicities of breast cancer treatment. 
To provide optimal decision making in older patients it is important to consider breast can-
cer prognosis as well as the chance of dying due to other causes than breast cancer for the 
forthcoming years. Accurate estimation of breast cancer mortality risk in this group should 
take into account other cause mortality by applying competing risk analysis.5 Increasing 
age and comorbidity are independently associated with reduced life expectancy,6,7  and this 
influences the risk of other cause mortality in patients diagnosed with breast cancer. While 
several studies have shown that increasing age at diagnosis is associated with worse breast 
cancer outcomes,8,9 this association for comorbidities remains a matter of debate.6 
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial compared two types of 
adjuvant endocrine therapy (exemestane monotherapy versus tamoxifen followed by ex-
emestane) in postmenopausal patients with hormone receptor-positive early breast cancer, 
and recently our group reported no difference in outcomes between both treatment groups 
after ten years of follow-up.10,1. Data on comorbidities at time of diagnosis and long-term 
follow-up were collected in enrolled TEAM patients in two countries (The Netherlands, and 
Belgium). In this analysis, we studied the impact of comorbidities and age at diagnosis on 
breast cancer mortality and other cause mortality after ten years of follow-up, taking into 
account competing causes of death. 
PAtients And Methods
The TEAM study is a randomized controlled trial of which the details have previously been 
described.10,11 In summary, postmenopausal, early hormone receptor-positive breast cancer 
patients who had completed local treatment with curative intent were included between 
January 2001 and January 2006, and randomized to receive exemestane (25 mg, once daily) 
for five years, or  sequential treatment of tamoxifen (20 mg, once daily) followed by ex-
emestane for a duration of five years. Patients with a previous malignancy five years before 
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breast cancer diagnosis, significant cardiac or other diseases that interfered with study par-
ticipation, or an Eastern Cooperative Oncology Group (ECOG) performance status >2 were 
considered ineligible. Information on the type of surgery, radiotherapy and chemotherapy 
was collected at the case report form (CRF) at time of inclusion. During follow-up informa-
tion was registered on disease recurrence and cause of death. The database was locked on 
February 19th, 2016. Patients were censored at date of last follow-up or at database lock for 
event-free patients. After ten years of follow-up no difference was observed for the primary 
endpoint (disease-free survival) between the two treatment arms10 and thereafter the cohort 
has been used for observational research to explore determinants and outcomes of breast 
cancer. 
For this analysis, all Dutch and Belgian patients were selected from the central TEAM 
database, as these countries collected information on comorbidities at inclusion and on 
long-term follow-up. Selected patients were categorized into two age categories for age at 
diagnosis (<70 years and ≥70 years) according to the International Organization for Ge-
riatric Oncology (SIOG) recommendations.12 Information on comorbidities at diagnosis 
was extracted from medical charts and registered on the CRF in free text areas. For further 
analysis, comorbidities were classified according to the ICD-10 classification of diseases.13 
The number of comorbidities was categorized into three categories (no comorbidities, 1-2 
comorbidities, >2 comorbidities). Cause of death was indicated on the CRF and later veri-
fied and categorized into ten prespecified groups defined in the protocol (Supplementary 
Table 1) by the central TEAM datacentre. 
Endpoints in the current study were breast cancer mortality and other cause mortality. 
Breast cancer mortality was defined as time from randomization to death due to breast 
cancer, considering other cause mortality as a competing event. As defined in the protocol, 
death that occurred after distant recurrence was defined as caused by breast cancer. Other 
cause mortality was defined as all other causes of death than death due to breast cancer 
whereby breast cancer mortality was considered as a competing event.
The study was performed in compliance with the guidelines of the Declaration of Helsinki, 
International Conference on Harmonization, and Good Clinical Practice. Approvals from 
the respective ethical committees were obtained. All patients provided written informed 
consent. The TEAM trial was registered in the Netherlands and Belgium (the Netherlands 
Trial Registry NTR267; Ethics Commission Trial 27/2001). 
statistical analyses 
Pearson χ2 test was used to compare proportional differences of tumor and treatment char-
acteristics between subgroups. Cumulative incidences of breast cancer-related mortality 
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and other cause mortality were calculated using the Cumulative Incidence Competing Risk 
Methods (CICRM),14,15 which assumes that patients who experienced a competing event 
remain in the risk set calculation for the event of interest and, as a consequence, estimates 
actual probabilities of reaching different endpoints.5 The Fine and Gray model was used to 
calculate the effect of risk factors for the cause-specific incidences of death, thereby taking 
into account the effect of competing causes of death.15 The effect of risk factors is expressed 
in terms of subdistribution hazard ratio’s (sHR).14,15 The multivariable model included the 
covariates that were included in the PREDICT+ prognostication tool (tumor size (in mil-
limeters), histological grade, lymph-node stage according to the Tumour-Node-Metastasis 
classification, estrogen (ER) receptor status, Human epidermal growth receptor (Her2) sta-
tus).16 Missing values were addressed by multiple imputation by chained equation (MICE) 
using five imputed data assuming that distribution of missing data is at random (MAR).17 
Results were based on pooled results of the imputed data using the Rubin’s rules. All statisti-
cal analyses were performed in R statistics version 3.3.3 using the survival, cmprsk and mice 
packages.18 Results were considered statistically significant when two-sided P-value was less 
than 0.05.
Additional analysis 
Sensitivity analysis was performed to test the robustness of the “breast cancer mortality” 
endpoint definition as described in the TEAM protocol. For this additional analysis, breast 
cancer mortality was defined as death due to breast cancer following the information as 
registered on the CRF (and not assuming that deaths that occurred after distant recurrence 
were defined as breast cancer related deaths). 
Results 
Overall, 3159 Dutch and Belgian patients were included in the TEAM trial of which 2203 
(69.7%) patients were aged <70 years and 956 (30.3%) were aged ≥70 years at diagnosis. Me-
dian follow up in was 10.2 years (IQR 9.9-10.8). Table 1 shows the baseline characteristics 
overall and by age group. Median age at diagnosis was 60 years (IQR 56-64) and 75 years 
(IQR 72-79) in de the younger and older cohort respectively. Tumor size was significantly 
higher in patients aged ≥70 years at time of diagnosis. Older patients were more likely to 
have a higher number of comorbidities at diagnosis (Table 1). For both younger and older 
patients, hypertension, arthrosis and diabetes were the most prevalent types of comorbidi-
ties, although the proportions of patients having these comorbidities were higher in older 
patients (Table 2). 
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Figure 1 and Supplementary Table 2 show treatment characteristics by age group and 
number of comorbidities. Breast-conserving surgery was performed less frequently in case 
of >2 comorbidities among patients diagnosed <70 years (51%, 52% and 43% in patients 
without, with 1-2, and more than 2 comorbidities, respectively). Patients aged ≥70 years 
at diagnosis were less likely to undergo breast-conserving surgery compared to younger 
patients but this did not vary across the different comorbidity groups (34%, 31% and 32%, 
respectively). Virtually all patients received radiotherapy after breast-conserving surgery. In 
patients aged <70 years at diagnosis, the administration of chemotherapy decreased with an 
increasing number of comorbidities (50%, 44% and 38% in patients without, with 1-2, and 
more than two comorbidities, respectively), while nearly none of the older patients received 
chemotherapy, irrespective comorbidity status (1%, <1% and 1%, respectively).
Table 1. Patient and tumor characteristics by age group and for all patients 
< 70 years (N=2203) ≥ 70 years (N=956) All patients (N=3159)
N % N % P N %
Age at diagnosis, median (IQR) 60 (56-64) 75 (72-79) 64 (58-71)
Tumor size in mm, median 
(IQR)
21 (15-30) 25 (18-32) <0.001 22 (16-30)
Unknown 11 <1 - - 11 <1
Histological grade 0.137
I 310 14 147 15 457 15
II 939 43 425 45 1364 43
III 837 38 314 33 1151 36
Unknown 117 5 70 7 187 6
Nodal stage 0.363
N0 632 29 327 34 959 30
N1 1404 64 562 59 1966 62
N2/N3 165 8 65 7 230 7
Unknown 2 <1 2 <1 4 <1
Estrogen-receptor status <0.001
Negative 57 3 11 1 68 2
Positive 2145 97 945 99 3090 98
Unknown 1 <1 - -
Her2-receptor status 0.062
Negative 1600 73 740 77 2340 74
Positive 231 11 87 9 318 10
Unknown 372 17 129 14 501 16
Number of comorbidities <0.001
0 1196 54 314 33 1510 48
1-2 864 39 494 52 1358 43
≥ 2 143 7 148 16 291 9
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Figure 2 shows the cumulative incidences of breast cancer mortality and other cause mor-
tality stratified by age group and number of comorbidities. Cumulative incidence of breast 
cancer mortality ten years after diagnosis in patients aged <70 years without comorbidities 
was 15.6% (95% CI 13.6-17.7, reference group, Table 3). Compared to this reference group, 
the cumulative incidence of breast cancer mortality in patients aged ≥70 years without co-
morbidities was significantly higher (22.2%, 95% CI 17.5-26.9; sHR 1.45 95% CI 1.09-1.91, 
P= 0.009) which remained significant after adjusting for confounders (sHR 1.49 95% CI, 
1.12-1.97, P=0.005, Table 3). For patients with 1-2 comorbidities, the cumulative incidence 
of breast cancer mortality over the ten years period was not higher than that in the refer-
ence group, applying for both age cohorts. Further, compared to the reference group, the 
cumulative incidence of breast cancer mortality appeared to be higher in patients with >2 
comorbidities in both age groups, being 21.3% (95% CI 14.4-28.3) in patients <70 years 
Table 2. Ten most prevalent comorbidities by age group
Age < 70 years (N=2203) Age ≥ 70 years (N=956)
N (%) N (%)
Hypertension 460 (21) Hypertension 325 (34)
Arthrosis 178 (8) Arthrosis 146 (15)
Diabetes Mellitus 135 (6) Diabetes Mellitus 123 (13)
Hypothyroidism 109 (5) Myocardial infarction 77 (8)
Hypercholesterolemia 106 (5) COPD# 58 (6)
COPD# 90 (4) Hypercholesterolemia 57 (6)
Myocardial infarction 61 (3) Hypothyroidism 52 (5)
Gastric ulcer 45 (2) Cardiac arrhythmias 39 (4)
Mood disorder 40 (2) Transient cerebral 
ischemic attack 
39 (4)
Osteoporosis 36 (2) Cardiac valve disorders 32 (3)
Rheumatism 34 (2) Osteoporosis 30 (3)











































Figure 1 Types of treatment by age group and number of comorbidities 
Type of breast surgery: mastectomy (filled bar) and breast conserving surgery (dotted bar); radiotherapy 
represents the proportion of patients receiving radiotherapy after breast conserving surgery. 
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and 21.3% (95% CI 14.3-28.2) in patients aged ≥70 years, respectively, but this was not 
statistically significant (Table 3). 
Figure 2 Cumulative incidence of breast cancer mortality and other cause mortality by age group and 
number of comorbidities 
Stacked cumulative incidence of breast cancer mortality (red) and other cause mortality (blue) by age 
group and number of comorbidities from time since diagnosis in years.
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The cumulative incidence of other cause mortality ten years after diagnosis was higher with 
increasing numbers of comorbidities and with older age at diagnosis (Figure 2, Table 3).
Additional analysis 
Applying a different definition for breast cancer mortality (see methods), 30 patients previ-
ously categorized as having died due to breast cancer were now assumed to have died due to 
other causes. Univariate and multivariable regression analyses yielded comparable results 
for breast cancer mortality (Supplementary Table 3). 
disCussion
In this subanalysis of Dutch and Belgian TEAM patients, we observed a higher risk of dy-
ing due to breast cancer ten years after diagnosis in older patients without comorbidities 
when compared to younger patients without comorbidities which was independent of 
tumor characteristics. In the other subgroups, breast cancer mortality was not significantly 
different. Other cause mortality increased significantly with age as well as the number of 
comorbidities but this higher other cause mortality did not lead to lower breast cancer 
mortality. Moreover, administration of adjuvant chemotherapy was more driven by age than 
by comorbidities. 
Table 3. Breast cancer mortality and other cause mortality by age group and number of comorbidities
Cumulative incidence 
ten years after diagnosis 







< 70 years; no comorbidities 15.6 (13.6-17.7) Reference Reference
< 70 years ; 1-2 comorbidities 13.4 (11.1-15.8) 0.92 (0.73-1.15) 0.450 0.89 (0.69-1.08) 0.203
< 70 years; > 2 comorbidities 21.3 (14.4-28.3) 1.41 (0.96-2.07) 0.080 1.24 (0.83-1.85) 0.301
≥ 70 years; no comorbidities 22.2 (17.5-26.9) 1.45 (1.09-1.91) 0.009 1.49 (1.12-1.97) 0.005
≥ 70 years; 1-2 comorbidities 14.8 (11.6-18.1) 0.91 (0.69-1.19) 0.490 0.93 (0.71-1.23) 0.615
≥ 70 years; > 2 comorbidities 21.3 (14.3-28.2) 1.31 (0.89-1.94) 0.180 1.22 (0.82-1.80) 0.325
Other cause mortality 
< 70 years; no comorbidities 4.6 (3.4-5.9) Reference Reference
< 70 years ; 1-2 comorbidities 7.4 (5.6-9.2) 1.62 (1.14-2.30) 0.007 1.63 (1.15-2.31) 0.006
< 70 years; > 2 comorbidities 12.5 (6.9-18.2) 3.11 (1.88-5.15) <0.001 3.11 (1.87-5.16) <0.001
≥ 70 years; no comorbidities 23.3 (18.4-28.2) 5.78 (4.12-8.12) <0.001 5.76 (4.10-8.09) <0.001
≥ 70 years; 1-2 comorbidities 33.0 (28.7-37.2) 8.47 (6.31-11.38) <0.001 8.38 (6.23-11.26) <0.001
≥ 70 years; > 2 comorbidities 41.5 (33.1-49.9) 12.14 (8.61-17.11) <0.001 12.05 (8.52-17.04) <0.001
a Covariates included in the model: tumor size, histological grade, lymph-node, ER-receptor status, 
Her2-receptor status).
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To our knowledge, long-term follow-up analysis of mortality outcomes in postmenopausal 
breast cancer patients stratified for both age at diagnosis and comorbidities has not been 
performed before. Several studies reported an increased risk of breast cancer mortality 
with increasing age.8,9,19 In observational studies an increased risk of breast cancer death 
or breast cancer recurrence was observed in patients with one or more comorbidities (not 
stratified for age at diagnosis).7,19-22 On the other hand, the ATAC trial described no impact 
of comorbidities on breast cancer recurrence.23 In addition, in most comparable studies 
the Cox Proportional hazards model was applied,7,19,20,22,23 whereby patients who died due 
to other causes were censored and were assumed to have the same risk of breast cancer 
mortality as non-censored patients. Results described in studies using this methodology 
are therefore likely to be overestimated.5 In the study performed by Berglund et al21 and in 
our study, competing risk analyses were performed enabling to take into account competing 
causes of death, which in our opinion is a more optimal method of analysis. In view of the 
conflicting findings and the importance of the question for clinical practice it is warranted 
to reach consensus on appropriate statistical models to assess the impact of comorbidities 
and age on breast cancer mortality.
Several factors may explain why older patients without comorbidity, in contrast to patients 
with comorbidity, had a higher risk of breast cancer mortality than younger patients with-
out comorbidity. Older patients without comorbidity had a lower other cause mortality 
than older patients with one or more comorbidities (Figure 2, Table 3) and therefore were 
surviving for a longer time period in which they remained at risk for disease recurrence and 
breast cancer death. Also, although older patients presented with larger tumors, adjuvant 
chemotherapy was rarely administered (approximately 1%), compared to 50% of younger 
patients without comorbidity (Table 1, Supplementary Table 2, Figure 1), which possibly 
explained an increased risk of disease recurrence. This indicates potential undertreatment 
of fit older patients and underlines the importance of optimal treatment. 
Other factors could also have contributed to higher breast cancer mortality in the healthy 
older patient group. Previous studies have shown that older patients experience more 
adverse events during and after adjuvant chemotherapy or radiotherapy.12 However, 
as adjuvant chemotherapy was administered in only 1% of older patients overtreatment 
is not likely to have contributed to the observed higher breast cancer mortality. Lack of 
compliance of endocrine therapy in the TEAM trial has been reported to be higher among 
older than among younger patients.24  However, this was independent of the number of 
comorbidities and does not explain the higher breast cancer mortality in older patients 
without comorbidities in our study cohort. 
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Endocrine therapy might lead to an increased risk of other cause mortality especially among 
older patients. The BIG 1-98 trial investigating either letrozole or tamoxifen as adjuvant 
endocrine therapy, reported higher rates of lethal adverse events, all being of cardiovascular 
origin and more cerebrovascular accidents among patients aged >75 years versus younger 
patients 25 In the current study cohort, cardiovascular disease was the second cause of death 
after breast cancer among older patients but it is difficult to estimate to what extent endo-
crine therapy might have attributed to this risk. 
Virtually none of the older patients in this study cohort received adjuvant chemotherapy, 
irrespective of the presence and the number of comorbidities and despite larger tumors at 
diagnosis, which was in line with national guidelines. Due to the very low proportion of 
older patients receiving chemotherapy in our study, further analysis on the potential effect 
of chemotherapy on breast cancer mortality was not possible. Also, as the number of older 
patients included in trials investigating chemotherapy strategies is limited due to either 
eligibility criteria (excluding older patients) or poor accrual in studies for specifically older 
patients,26 current guidelines do not contain clear recommendations for chemotherapy in 
older patients. In a NSABP trial including fit older patients (aged >65 years, good perfor-
mance score, no major organ dysfunction) standard intravenous chemotherapy (either cy-
clophosphamide, methotrexate, and fluorouracil (CMF) or cyclophosphamide/doxorubicin 
(AC)) was compared with oral capecitabine. Better outcomes for disease recurrence and 
overall survival were observed in the standard chemotherapy group at the cost of moderate 
to severe toxic effects.27 In both therapy arms, however, a substantial percentage of patients 
experienced toxicity, needed dose reduction or stopped therapy prematurely. Weekly pa-
clitaxel in older patients is feasible but the efficacy in hormone-receptor positive breast 
cancer is not clear.28,29 Potentially the chemotherapy toxicity tool in older cancer patients 
as was developed by Hurria and colleagues,30n might be helpful in decision making and 
recommending adjuvant chemotherapy. 
In line with other studies, comorbidities were strongly related to other cause mortal-
ity.6,7,19-23,31-34 Our data, however, also indicate  that age appears to be a driving factor of other 
cause mortality (Figure 2, Table 3); patients≥70 years without comorbidities had higher 
other cause mortality compared to patients <70 years with >2 comorbidities. Therefore, 
in our opinion it is important to include both age and number of comorbidities in the risk 
assessment of other cause mortality and also in the toxicity prediction tool. 
To adequately address the clinical benefit of adjuvant systemic therapy in elderly patients 
with breast cancer, the following aspects should be considered. First, life expectancy should 
be evaluated to estimate the risk of other cause mortality using age, comorbidities and other 
geriatric indicators for prediction.35 Second, tumor stage and molecular characteristics 
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including genetic profiling should be considered to estimate breast cancer prognosis. Third, 
estimation of risk of toxicity or complications of treatment using available tools must be 
taken into account.30 
Some limitations of this study should be mentioned. First, classification of cause of death 
could be subject to misclassification. To address this, we performed a sensitivity analysis us-
ing a less stringent definition of breast cancer mortality to estimate the effect of comorbidity 
and age hereon, but this did not change our findings (Supplementary Table 3). Second, we 
were not able to code the severity of comorbidities as this was not collected on the CRF. 
Third, participation in the TEAM trial was restricted by the in- and exclusion criteria (see 
methods). Especially older patients participating in this trial were relatively healthy com-
pared to the general population and this could hamper the interpretation of our findings.36
Overall, this study provides further insight into the role of age at diagnosis and comor-
bidities on the long-term risk of breast cancer mortality and other cause mortality in 
postmenopausal patients with early breast cancer, which especially for the older patient 
cohorts is very relevant. Despite the number of comorbidities or older age, both contrib-
uting to increasing other cause mortality, we did not observe a decrease in breast cancer 
mortality after a follow-up time of ten years. Furthermore, we found that older patients 
without comorbidities were at increased risk of dying due to breast cancer, despite a higher 
other cause mortality. In the light of the changing demographics, this group will expand 
in future years and there is an urgent need to pursue optimal treatment for healthy older 
patients. Also, this study underlines the clinical challenge with respect to decision making, 
balancing between undertreatment and overtreatment of older patients, and indicates that 
assessment of risk for both breast cancer mortality and other cause mortality is indispens-
able for treatment decision making in older patients. Ideally, future prognostic tools for 
breast cancer prognosis should incorporate these items as well as risk of toxicity of adjuvant 
chemotherapy to adequately predict outcomes to optimize personalized treatment for older 
patients with early breast cancer.
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Supplementary Table 2. Proportional distribution of type of treatment by age group and number of 
comorbidities 
Age < 70 years ≥ 70 years
Number of comorbidities 0 1-2 >2 0 1-2 >2
N (%) N (%) N (%) N (%) N (%) N (%) P
Type of breast surgery <0.001
Mastectomy 585 (49) 418 (48) 207 (66) 207 (66) 343 (69) 100 (68)
Breast conserving surgery 611 (51) 446 (52) 61 (43) 107 (34) 151 (31) 48 (32)
Radiotherapy 0.130
Yes 606 (99) 443 (100) 61 (100) 106 (99) 147 (97) 48 (100)
No 4 (<1) 2 (<1) 0 (0) 1 (<1) 4 (3) 9 (0)
Chemotherapy <0.001
Yes 598 (50) 381 (44) 53 (38) 3 (<1) 7 (1) 2 (1)
No 598 (50) 483 (56) 89 (62) 311 (99) 487 (99) 146 (99)
Supplementary Table 3. Breast cancer mortality by age group and number of comorbidities using the 
definition for breast cancer death as outlined in the sensitivity analysis 
Univariate sHR (95% CI) P Multivariable sHR (95% CI) P
< 70 years; no comorbidities Reference Reference
< 70 years ; 1-2 comorbidities 0.88 (0.70-1.11) 0.300 0.83 (0.66-1.05) 0.116
< 70 years; > 2 comorbidities 1.17 (0.77-1.78) 0.450 1.02 (0.66-1.57) 0.935
≥ 70 years; no comorbidities 1.29 (0.96-1.72) 0.091 1.31 (0.98-1.76) 0.068
≥ 70 years; 1-2 comorbidities 0.84 (0.63-1.12) 0.230 0.86 (0.65-1.15) 0.305
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ABstRACt
Background: Growing old goes with an increased risk of disease and a loss of functioning on 
several bodily and mental domains and some argue that maintaining health and functioning 
is essential for a successful old age. Paradoxically, studies have shown that overall wellbeing 
follows a curvilinear pattern with the lowest point at middle age but increases thereafter up 
to very old age.
Objective: To shed further light on this paradox, we reviewed the existing literature on 
how scholars define successful ageing and how they weigh the contribution of health and 
functioning to define success. 
Methods: We performed a novel, hypothesis-free and quantitative analysis of citation 
networks exploring the literature on successful ageing that exists in the Web of Science 
Core Collection Database using the CitNetExplorer software. Outcomes were visualized 
using timeline based citation patterns. The clusters and sub-clusters of citation networks 
identified were starting points for in depth qualitative analysis.
Results: Within the literature from 1902 through 2015, two distinct citation networks were 
identified. The first cluster had 1,146 publications and 3,946 citation links. It focused on 
successful ageing from the perspective of older persons themselves. Analysis of the various 
sub-clusters emphasized the importance of coping strategies, psycho-social engagement, 
and cultural differences. The second cluster had 609 publications and 1,682 citation links 
and viewed successful ageing based on the objective measurements as determined by re-
searchers. Subsequent sub-clustering analysis pointed to different domains of functioning 
and various ways of assessment.  
Conclusion: In the current literature two mutual exclusive concepts of successful ageing 
are circulating that depend on whether the individual himself or an outsider judges the 
situation. These different points of view help to explain the disability paradox as successful 
ageing lies in the eyes of the beholder.
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intRoduCtion
How can people age successfully? Worldwide, many people prioritize good health as an 
important goal in their lives1 and some consider health and functioning in old age as a 
prerequisite when striving for successful ageing.2 Growing old, however, presents us with a 
plethora of debilitating consequences, among which there are disabilities, cognitive decline, 
and loss of social relationships.3 When we assume health to be the driving force for success-
ful ageing while at the same time ageing is associated with an increased risk for diseases 
and loss of functioning, we would expect that ageing is associated with a gradual decline 
in wellbeing. In contrast to this expectation, previous research has shown that in many 
countries around the world, overall wellbeing follows a curvilinear pattern that reaches its 
nadir at middle age but increases thereafter up to very old age.4,5 
Why then are there so many people experiencing high levels of wellbeing despite the fact 
that their bodies fail? This remarkable observation has been previously described in the 
setting of rehabilitation. The ‘disability paradox’ indicates that people with severe physi-
cal disabilities rate their own wellbeing rather positively. This experience of wellbeing is 
unexpected for outsiders, but becomes understandable as people are able to adapt to their 
disabilities.6 When extrapolating the disability paradox to people growing older, maintain-
ing good physical health might not be the only necessary prerequisite when striving to be 
successful in old age. 
To shed further light on this paradox we delved into the literature on the scholarly defini-
tion of successful ageing and the contribution of health to success in old age. To this end 
we conducted an innovative and combined quantitative and qualitative assessment of the 
literature on successful ageing. 
Methods
Considering the extensive literature on successful ageing, and to get a better understanding 
of how the concept has evolved, we decided to analyse citation networks using CitNet-
Explorer software. This software programme enables us to perform a hypothesis-free and 
exploratory quantitative analysis, and a visualization of the citation links of the relevant 
scientific literature.7
A search on Web of Science Core Collection Database was performed on all literature with 
”Successful Aging” or “Successful Ageing” in the title only, at the 28th July 2015.  Both terms 
were used because they are spelled differently in the Unites States and the United Kingdom. 
The search resulted in 1,233 articles. The full record contents of these primary articles, as 
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well as the secondary articles that have been cited were used as input for the CitNetExplorer 
tool.
Clustering analysis in the citation network was performed to identify clusters of publica-
tions that are strongly connected to each other in terms of citation publications,8 forming 
an intellectual network. A cluster can be interpreted to represent a confined intellectual 
topic in the scientific literature. For all clustering analyses, the default resolution  parameter 
(1.00) from the CitNetExplorer programme was used. The resolution parameter determines 
the level of detail at which clusters are identified. The higher the value of the parameter, 
the larger the number of clusters that will be obtained.7 The minimum cluster size set to 10 
publications and small clusters with number of publications below the minimum cluster 
size to be merged as much as possible with other clusters. Clusters were visually identified 
in the citation network by using colours. 
The biggest clusters were then further explored for more detailed citation networks using 
the ‘drill down’ feature of the CitNexExplorer software programme. The various sub-clusters 
were characterized with identifying the pioneering publication, the publication with highest 
citation score, and the most recent publication. Relevant clusters and sub-clusters were then 
scrutinized for in depth qualitative review of the literature and reported in a tabular format. 
Results
Quantitative Analysis
After downloading full record contents of the 1,233 publications that were identified by 
our primary search on ‘successful aging’ or ‘successful ageing’ from the Web of Science 
Core Collection database, the CitNetExplorer program identified 2,638 secondary, citation 
linked publications. We thus obtained and analysed a citation network consisting of 3,871 
publications with 10,804 citation links, within the time window 1902 through 2015. 
Clustering analysis resulted into ten main clusters of publications and due to the minimum 
size requirement, 603 publications do not belong to a cluster.  Table 1 provides citation 
network information for all 10 main clusters, with the clusters ordered according to cluster 
size, descending from the largest to the smallest cluster. As seen in Table 1, the first three 
clusters contain the majority of publications and citation links. The first cluster is the biggest 
in size with 1,146 publications, 3,946 citation links and 77 publications with a citation score 
of ≥ 10. The second and the third cluster consist of 609 publications and 1,682 citation 
links, respectively 541 publications and 1,234 citation links. The other remaining seven 
clusters were smaller, representing less than 10% of all publications and less than 6% of 
the total number of citations links per cluster. It appears that the number of the 100 most 
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frequently cited publications are within the first and the second cluster with substantially 
higher numbers (57 and 33 respectively) than in the third cluster (6). The seven clusters only 
contributed with four out of the 100 most cited papers.
Figure 1 shows a timeline-based network visualization of citation links including the 100 
most cited publications. In this visualization, each circle represents a publication that is 
labelled by the last name of the first author, while curved lines represent citation links. The 
vertical axis represents a timeline and describes the year in which the article was published, 
with more recent publications being located below older publications. If two linked publica-
tions appeared in the same year, then the citing publication is always located somewhere 
below the corresponding cited publication. The location of publications on the horizontal 
axis is determined by the closeness of publications in the citation networks. In other words, 
the closer the circles are positioned to each other, the closer the publications are related to 
each other. 
As is seen in Figure 1, the blue (first) and the green (second) network represent the majority 
of publications in a network with many citation links that are closely related to each other. 
The purple (third) network is positioned at a far distance from the two main networks 
without any citation links to the main network. Based on these findings and the low number 
of publications represented in the 100 most cited publications, the third and other smaller 
clusters were not analysed further. The first two clusters, which will be analysed further, are 
rooted in two classical publications, from here on referred to as the Havighurst-cluster and 
the Katz-cluster.
Table 1. Citation Network Information for All Main Clusters











100 Most Cited 
Publication 
1 Blue 1,146 3,946 2 (0-106) 77 57
2 Green 609 1,682 2 (0-181) 35 33
3 Purple 541 1,234 2 (0-42) 10 6
4 Orange 359 702 2 (0-11) 2 0
5 Yellow 257 452 2 (0-11) 3 0
6 Brown 193 371 2 (0-20) 4 2
7 Pink 60 73 2 (0-7) 0 0
8 Light Blue 47 63 2 (0-13) 1 1
9 Lime 46 71 2 (1-33) 2 1
10 Red 10 16 2 (0-2) 0 0
*Citation scores obtained from CitNetExplorer results
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Qualitative Analysis
A more detailed description of the Havighurst-cluster and the Katz-cluster is presented in 
Table 2. Th e Havighurst-cluster consists of publications discussing the topic of successful 
ageing from the older person’s point of view. Th ese publications advocate the urgency of 
taking into account older people’s perspectives as they indicate which aspects of life are 
important and to what extent these aspects determine older people’s experience of success. 
In contrast, publications included in the Katz-cluster tend to discuss the topic of successful 
ageing purely from the perspective of researchers or clinicians. In general, this cluster exam-
ines quantitatively physical functioning assessments and predictors, using such analyses as a 
categorization of successful ageing. Timewise, the two main groups have started publishing 
articles on this topic in the same period. However, in the fi rst 30 years these two clusters do 
not interact with each other and only started to cite each other from 1987 onwards. Over 
time, the two clusters seemed to be moving closer to each other on the horizontal axis, sug-
gesting that they started to acknowledge the importance of each other perspectives. From 
Figure 1 it seems as if there were no new publications aft er 2011, but this visualised network 
refl ects only the 100 most frequently cited publications out of the extensive literature. Con-
sequently, papers that have been published more recently but not yet have been extensively 
cited are not included. 
In the Havighurst-cluster, the pioneering publication was published in 1953, a book by Havi-
ghurst et al titled ‘Older People’.9 Th is book describes the lives of older people in a small town in 
the United States and the challenges they faced when growing older. At that time, descriptions 
Figure 1. Bibliometric Networks Visualizing the 100 Most Cited Publications on “Successful Ageing”











































































































































































































































































































































































































































































































































































































of old age problems were based on younger people’s perception of older people. The authors 
then decided to see the problems through the eyes of older people themselves, making this 
book the first highly cited publication looking at successful ageing outside the medical domain. 
The most frequently cited article in this cluster, Depp et al, was published in 2006.10 This is 
a review of studies focusing on older individuals who met the criteria of successful ageing. 
The authors acknowledged that successful ageing has been defined, operationalized, measured, 
and predicted in several ways. They pointed out that there is a separation between these op-
erationalized definitions, developmental processes throughout the life span, and definitions of 
successful ageing according to older adults themselves. They highlighted the need to expand 
the primarily physical definitions to a wider definition that encompasses bio-psycho-social 
factors. They proposed that the ideal definition should be acceptable to everyone involved 
including researchers, clinicians, and older people themselves. The most recent article that was 
highly cited came from Pruchno et al in 2010,11 which noted that although objective criteria 
are important components of successful ageing, they do not tell the whole story. They argued 
that success is a function of value judgments as well as objective criteria, thus highlighting the 
importance of adaptive processes that adults undergo when they grow older.
The pioneering publication of the Katz-cluster was published in 1963 and written by Katz 
et al.12 In this paper, they introduced the Index of Activities of Daily Living (Instrumental 
ADL), a systematic approach to measure physical performance in a population of older 
or chronically ill persons. It was introduced to be used as an objective guide to study the 
ageing process and the course of disease. In the original article it was not proposed as an 
instrument to distinguish between ‘usual’ and ‘successful’ aging within an older population, 
but in later studies on successful ageing it was very frequently used to make this distinction. 
The most frequently cited publication in this cluster is the paper written by Rowe and Kahn 
in 198713 , introducing the concept of successful ageing for biomedical research purposes. 
In their paper, they argued that there is substantial heterogeneity among older persons and 
added an additional category to the traditionally used ‘normal aged’ and ‘diseased aged’ 
categories. They argued that within the category of normal ageing, a distinction can be 
made between ‘usual’ ageing and ‘successful’ ageing and that successful ageing can be dif-
ferentiated from usual ageing by the impact of extrinsic factors. Rowe and Kahn made the 
assumption that there was a causal relationship between extrinsic factors and the process 
of ageing. While in the normal ageing group extrinsic factors may contribute or accelerate 
the ageing process, in the successful ageing group, extrinsic factors have a neutral or even 
protective role in this process. Within this cluster the most recent highly cited article was 
by Britton et al14 and it was based on the model of Rowe and Kahn. It tried to identify early 
life and midlife risk factors influencing successful ageing. They classified successful ageing 
as the absence of significant disease and the ability to maintain good physical and mental 
functioning as validated by objective measurements. 
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the havighurst-subclusters
There were 1,146 publications and 3,946 citation links in the Havighurst-cluster and further 
analysis resulted into 11 sub-clusters (see Supplementary Table 1). The five biggest sub-
clusters are summarized in Table 3 and visualized in Supplementary Figure 1. All other six 
sub-clusters were substantially smaller, each representing less than 70 publications and less 
than 100 of the citation links studied and were therefore not analysed further. 
The first sub-cluster mainly revolves around successful ageing as viewed by the older people 
themselves. Studies by Strawbridge et al,15 Montross et al,16 and Phelan et al17 found the dis-
crepancy between the successful ageing definition as operationalized by researchers and suc-
cessful aging according to perception of older people.  They noted that many older people with 
chronic diseases and functional limitations rated themselves as highly successful although 
they may not meet the operationalized definition of successful aging. Phelan et al17  argued 
that the model of successful aging needs to be multidimensional; taking into account all 
aspects of health including physical, functional, psychological, and social domains. Bowling 
et al18 proposed to place successful ageing on a continuum of achievement rather than strict 
dichotomous cut-offs for categorization of success and failure because the current definition 
is unrealistic for most people. In another paper, Bowling et al also highlighted the urgency 
of including elements that matter to older people19, although Knight et al noted that not all 
aspects are seen as equally important by all participants20. The most recent publication in this 
sub-cluster, Cosco et al21 emphasized on the lack of consistency in the definition of successful 
ageing as the underlying weakness for research focusing on this domain.
The second sub-cluster focused on the nature of development and maintenance in ageing 
with the focus on successful adaptation throughout the life course, as described by Schulz et 
al22. Studies23  viewed successful ageing as achieving life goals in spite of losses as a result of 
the dynamic between three processes: selection, optimisation, and compensation as devel-
oped by Baltes and Baltes.24 Ryff et al25 criticized studies which emphasized on the negative 
side of ageing, neglecting the possibility of continued growth and development as people 
grow older. Further, Lupien et al26 showed that well–being and positive views of ageing are 
protective against the damaging effects of age. 
The third sub-cluster focused more on the application of psychosocial models as strategies 
for life management. The most popular model is the selection-optimisation-compensation 
model as applied by Abraham et al27 and Freund et al,28 while other additional models are 
also acknowledged,29 for example proactive coping,30 socio-emotional selectivity,31 assimila-
tive and accommodative coping,32 and primary and secondary control model.33 Although 
varied, in general these models have something in common; they emphasize the adaptation 
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The fourth sub-cluster criticized the primarily physical-oriented term of successful ageing. 
Holstein et al34 and Minkler et al35 warned that this may encourage ageism and discrimina-
tion, further stigmatizing and marginalizing older people who may not meet the narrowly 
defined term of successful ageing. Therefore, Dillaway et al36 noted that researchers and 
clinicians should be more careful when adopting successful ageing terminology without 
understanding the potential socio-political consequences. They called for a new, expanded 
conceptualization of successful ageing which is more multidimensional and incorporate 
lay people’s perspectives which has been shown to predict quality of life more powerfully 
compared to the more simpler models.37 
The fifth sub-cluster focused on the cross-national perspective of successful ageing. In this 
sub-cluster, the subjective perspective is not apparent as it revolves around healthy ageing 
based on objective measurements, taking into account the different cultural backgrounds 
in different countries. For example Hank et al38 observed the cross-national variation in 
successful ageing among European countries using objective measurements. However, the 
highest cited publication in this sub-cluster, Pruchno et al,11 analysed people who aged 
successfully according to both subjective and objective criteria, none, and one or the other 
criteria by applying mathematical model from directly measured variables . They argued for 
a multidimensional model of successful ageing comprising both objective and subjective 
indicators.
the Katz-subclusters
There were 609 publications and 1682 citation links in the Katz-cluster and sub-clustering 
analysis resulted into 10 sub-clusters (see Supplementary Table 2). Highlights of literature 
in the three biggest sub-clusters are summarized in Table 4 and visualized in Supplementary 
Figure 2. All other seven sub-clusters were substantially smaller, each representing less than 
60 publications and less than 100 citation links studied and were therefore not analysed 
further.
In contrast to findings from sub-clustering of the Havighurst-cluster, there is no obvious 
pattern recognizable in the qualitative analysis across the sub-clusters of the Katz-cluster. 
This could best be explained by the fact that the overwhelming majority of the cited papers 
apply a similar framework for their studies, which was mainly based on the MacArtur study. 
The MacArthur studies aimed to identify risk factors that were associated with successful 
ageing and could offer potential for effective intervention to promote successful ageing on 
both the individual and the population level. In order to identify these predictors, Berkman 
et al39 first developed a model to identify older persons which could be considered to have 
aged successfully. Predetermined objective criteria of physical and cognitive functioning 
were used to define high, medium, and low functioning subgroups within a cohort popula-
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tion of community dwelling older persons aged 70-79. They hypothesized that high levels of 
cognitive and physical functioning were necessary for independence and quality of life, and 
a high level of functioning was therefore used as a proxy for successful ageing. For follow 
up studies, successful ageing was described as maintenance of high level of functioning over 
time according to objective measurements. To measure the level of cognitive and physical 
functioning, validated instruments were used. The sub-clusters reflect the different ap-
proaches to operationalize this objective definition of successful ageing, reflected in highly 
cited papers describing different instruments such as the Wechsler Intelligence Scale40 and 
the Boston Naming test41 for cognitive functioning and the original paper by Katz et al,12 
introducing the IADL for physical functioning.
Using the definition of successful ageing as established by the MacArthur study, several 
other studies replicated this objective approach in observational cohort studies.42-45 Most 
studies in the Katz-cluster focused on finding demographic, behavioural, psycho-social, 
and biological predictors which were associated with better performance or maintenance 
of high level functioning. Each study has their own set of risk factors covering one or more 
Table 4. Highlights of Literature Visualized in the Sub-clustering Results of the Katz-cluster







Pioneers Katz et al (1963)12
Studies of Illness in the Aged
The Index of ADL: A 
Standardized Measure of 
Biological and Subjective 
Function
Wechsler et al (1981)40
Wechsler Adult Intelligence 
Scale - Revised
Holmes et al (1967)53




Berkman et al (1993)39
High, Usual, and Impaired 
Functioning in Community-
Dwelling Older Men and 
Women – Findings from 
the Macarthur Foundation 
Research Network on Successful 
Aging
Wechsler et al (1981)40
Wechsler Adult Intelligence 
Scale - Revised
Rowe et al (1987)13
Human Aging – Usual and 
Successful
Most Recent Andrews et al (2002)42
Successful Aging in the 
Australian Longitudinal 
Study of Aging: Applying the 
Macarthur Model Cross-
Nationally
Wong et al (1989)43
Personal Meaning and 
Successful Aging
Rowe et al (1997)54
Successful Aging
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predictors, with some overlapping others. Although in this cluster, successful ageing is 
defined as combination of physical and cognitive functioning, most studies chose to focus 
on either one or the other. The authors of these studies either categorized people as success-
fully aged based on physical or cognitive cut-offs, or used changes in physical or cognitive 
performance as a proxy for successful ageing.
disCussion
Exploratory analysis of citation patterns in the scientific literature on successful ageing 
resulted into a dichotomy between the two main networks of publications; the Havighurst-
cluster and the Katz-cluster. Starting from two seminal contributions, the two main groups 
started to publish highly cited manuscripts but it took 30 years before the two clusters 
started to acknowledge each other. In addition, the citation analysis showed the two clus-
ters moving closer to each other, interrelating each other’s publications. In the later years, 
citation patterns showed that the majority of frequently cited publications come from the 
Havighurst-cluster.
Qualitative assessment of the citation networks further confirmed the distinct character-
istics of the two clusters. The Havighurst-cluster focused on successful ageing from the 
perspective of older persons themselves, while the Katz-cluster stayed within the objective 
measurements determined by researchers. Intention-wise, the Havighurst-cluster advocated 
the view of older persons, warning the harm of medical categorization of success and failure 
in stigmatizing and marginalizing older persons and encouraging ageism. On the other 
hand, the Katz-cluster focused on identifying risk factors for prevention. Across the lifes-
pan, the Havighurst-cluster highlighted the importance of process of adaptation of goals in 
the face of losses while in the Katz-cluster, to be successful older persons have to maintain 
their functioning within the cut-offs that were predetermined by researchers. Overall, the 
principle difference is the discrepancy between the thoughts of older people about success-
ful ageing themselves and the successful ageing concepts as applied by researchers from an 
outsider perspective.
Why is there such a discrepancy between the two clusters representing perspectives of older 
people and researchers respectively? As an explanation, we introduce a conceptual frame-
work to explain successful ageing by adopting the anthropologists’ approach. In 1954, the 
American linguist Pike introduced the concepts of ‘etic’ and ‘emic’ to describe the meaning 
of words the interpretation of an event from a different point of view.46 Briefly, the ‘etic’ per-
spective is used to describe a phenomenon as viewed and interpreted by someone outside 
the experience and emphasizes what the observer considers to be important. In contrast, 
the ‘emic’ perspective describes a phenomenon from an internal point of view based on the 
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individual’s observation, explanatory framework, norms, values and interpretations. These 
perspectives originated from the linguistic discipline and are now extensively used within 
anthropology, but one can imagine that these could also be applied within the two main 
clusters identified in the citation networks. In the Katz-cluster, studies apply their definition 
of successful ageing as an external perspective on the older population; therefore this can be 
viewed as an ‘etic’ classification. On the other hand, the studies in the Havighurst-cluster try 
to define successful ageing from an older people’s perspective. These studies represent the 
‘emic’ approach, emphasizing the need of accounting how older persons themselves view 
and experience health when aiming for a successful old age. However, in some studies, the 
Havighurst-cluster operationalized emic perspectives using an etic approach by applying 
mathematical models or scoring systems. On the whole, these different perspectives enable 
us to explain the disability paradox as a result of two opposing views on observed and 
experienced success in old age.
The purpose of this manuscript is to reflect on the definition of ‘successful ageing’ as used by 
a great variety of scholars, including those who come from the humanities. As the definition 
of successful ageing is not a numerical endpoint, such as an absolute or a relative risk, our 
investigation does not lend itself for a traditional precision-weighted analysis. Instead of a 
classic meta-analysis, we used automated bibliographic networks of papers, and the number 
of citations to determine the relevance of the scientific contribution. Effectively, this method 
provides us with a quality-weighted analysis of the narrative data on successful ageing.  It 
allows to summarize the abundant literature on the topic using a hypothesis free approach. 
With this method we overcome a subjective interpretation of the material, as the importance 
of the contribution is determined by the number of citations and thus by the field itself.
The strength of this study lies in the novel methodological approach to guide us on review-
ing the extensive literature on successful ageing. We delved into this literature using the 
CitNetExplorer tool to analyse citation patterns, allowing us to perform hypothesis-free, 
exploratory analysis thus minimizing bias. Further, we did not have any inclusion or exclu-
sion criteria and included all studies from the search term ’successful ageing’ in all years 
documented in the Web of Science Database. Using CitNetExplorer we were able to obtain 
timeline based visualization of citation networks to guide our qualitative assessment. The 
tool also allowed us to assess an extensive literature over a very long time window. The novel 
method is also accompanied with some limitations.  It prevented us from analyzing the 
citation patterns of the most recent publications because papers need to be published long 
enough to be frequently cited and included in the network. In addition, CitNetExplorer can 
only import articles and its references from the Web of Science Database. For this reason, we 
were not able to perform a search in a different database. Therefore, we could have missed 
relevant publications that were not included in the Web of Science Database. Furthermore, 
A citation network analysis on the definition of successful ageing 147
the software programme does not provide the opportunity to include or exclude a reference 
manually.  Therefore, some articles identified by the CitNetExplorer tool did not have suc-
cessful ageing as their main topic. Mostly, these were papers that were frequently used as a 
reference to describe a measurement instrument (such as the Wechsler Intelligence Scale or 
the Katz Activities of Daily Living). Although these references seem not directly related to 
the topic, they are helpful in defining the concept of successful ageing over time.
In conclusion, the novel methodological approach that we used to explore the extensive lit-
erature led to a clear divide in the field of successful ageing. Two distinct concepts emerged, 
describing successful ageing from opposing perspectives which could be described accord-
ing to other academic disciplines as ‘etic’ and ‘emic’. The etic approach focused on objective 
measures defined by researchers to describe success. The emic approach focused on suc-
cessful ageing from the perspective of older persons themselves. This explains the paradox 
between observed and experienced success in old age as successful ageing as wellbeing is 
determined by people themselves. 
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Supplementary Table 1. Citation Network Information for Havighurst-cluster




Number of Citations* 
Median (Range)
Number of Publications with 
≥ 10 Citations*
All 1,146 3,946 2 (0-106) 77
1 310 1,062 4 (0-106) 40
2 191 404 3 (0-35) 12
3 155 319 2 (0-17) 4
4 152 300 2 (0-28) 9
5 97 152 2 (0-21) 3
6 61 93 2 (0-10) 1
7 46 54 2 (0-22) 1
8 37 56 2 (0-45) 1
9 36 48 2 (0-38) 3
10 35 57 2 (0-10) 1
11 26 28 0 (0-104) 2
*Citation scores obtained from CitNetExplorer results
Supplementary Table 2. Citation Network Information for Katz-cluster




Number of Citations* 
Median (Range)
Number of Publications with 
≥ 10 Citations*
All 609 1,682 2 (0-181) 35
1 162 493 3 (0-81) 19
2 72 115 2 (0-12) 1
3 63 120 2 (0181) 2
4 60 80 2 (0-48) 1
5 58 99 2 (0-36) 5
6 56 79 2 (0-11) 1
7 41 71 2 (0-27) 2
8 41 80 2 (0-12) 1
9 40 55 3 (0-36) 3
10 16 15 2 (0-7) 0
*Citation scores obtained from CitNetExplorer results
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Supplementary Figure 1. Bibliometric Networks Visualizing of 100 Most Cited Publications from Sub-
clustering of the Havighurst-cluster
Supplementary Figure 2. Bibliometric Networks Visualizing of 100 Most Cited Publications from Sub-
clustering of the Katz-cluster
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Reporting absolute risks in survival analysis for main endpoints and subgroups have 
been recommended by the STROBE and CONSORT guidelines but too often this recom-
mendation is neglected. Clinical studies often use the Cox proportional hazard regression 
model to estimate effect sizes and to adjust for confounders. This may explain why there is 
a predominance for reporting relative risks in clinical studies. In this article, we present the 
Aalen additive hazards model, a less well known but easy to apply additive survival model to 
calculate absolute risks. This model directly estimates absolute risk differences and provides 
the opportunity to include covariates in the model, to address confounding factors and test 
for interaction, similar to the Cox proportional hazards model. As an example, we use data 
from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) study to report on the 
effect of age on breast cancer related mortality in absolute risks using the Aalen additive 
hazards model and relative risks using the Cox proportional hazards model. We discuss 
the interpretation of both risk estimates and demonstrate that the effect of age on breast 
cancer mortality among subgroups changes depending on the relative or absolute model. 
We conclude that the additive hazards model is more representative for clinical practice and 
provides a better interpretation of the impact of age on breast cancer mortality for clinicians 
and patients.  
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intRoduCtion
Most clinical papers report on effect sizes of exposures and treatments as relative risks, 
reinforcing the strength of the (causal) relation.1,2 However, for an individual the interpreta-
tion of a relative risk is ambiguous, as the absolute risk is not taken into account.3 Earlier we 
reported that among women who suffer from breast cancer, those 75 years or older were at 
a 1.63-fold higher risk to die from cancer compared to women younger than 65 years.4 The 
question that immediately that is immediately raised is; ‘1.63 times what?’. The key question 
for an older patient is whether she should be worried about this increased likelihood to 
die from breast cancer, and for the treating physician it is essential to ascertain whether 
additional treatment would be effective to reduce the risk with resultant significant clinical 
benefit. 
When reporting the impact of a clinical intervention, the Number Needed to Treat (NNT) 
and Number Needed to Harm (NNH) are commonly used composite estimates that integrate 
information on both the absolute risk and the relative change of that risk. Observational 
studies report on the natural history of the disease and not primarily on outcomes of an 
intervention. For this reason it is counter-intuitive to report on the impact of risk factors as 
the number needed to treat, or to harm. The ‘STrengthening the Reporting of OBservational 
studies in Epidemiology’ (STROBE) consensus report recommends reporting outcomes as 
both relative and absolute measures of effect.5 It is sobering that despite these sound meth-
odological arguments effect sizes in observational studies are almost exclusively reported as 
relative risks serving the etiologic interpretations of the findings but not the clinical impact 
on individuals.1 
Observational studies often rely on survival analyses and use Cox proportional hazard re-
gression to correct for confounding factors.6 This preferred choice of methods may explain 
why there is a predominance for reporting relative risks in observational studies. There is 
however no methodological barrier for applying alternative models that regress additional 
hazards and allow for entering additional covariates to adjust for confounding. Here, we 
present the Aalen additive hazards model, a less well known but easy to apply additive sur-
vival model to calculate absolute risks. Similar to the Cox proportional hazards model, this 
model directly estimates absolute risk differences and provides the opportunity to include 
covariates in the model, address confounding factors and test for interaction.7 We present 
an example from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) study report-
ing on the effect of age on breast cancer mortality in absolute risks next to standard relative 
risks to enable a better understanding of the clinical impact. Furthermore, we provide a 




The TEAM study was designed as a randomized controlled trial including postmenopausal 
patients with estrogen receptor and/or progesterone positive breast cancer. Patients were 
included between January 2001 and January 2006 and randomized to receive exemestane 
for five years, or a sequential treatment regimen of tamoxifen followed by exemestane for 
a total of five years. Further details of this study are extensively described elsewhere.8 After 
five years of follow up there were no differences in any of the primary end points between 
the two treatment arms,8 and thereafter the total cohort is used for observational research 
into exploring determinants for, and outcomes of breast cancer. 
For the present analysis, patients were categorized in three categories of age at diagnosis (< 
65 years, 65-74 years and ≥ 75 years).9 First, the effect of age on mortality from breast cancer 
was examined in the complete cohort of patients. Second, the effect of age was examined in 
subgroups of patients with specific prognostic markers of breast cancer mortality, i.e. tumor 
size and lymph node status.10 Tumor size was divided into two categories: < 2 cm and ≥ 2 cm 
whereas lymph node status was defined as negative (no regional lymph node metastasis) or 
positive (one or more positive regional lymph nodes). The follow-up was defined as the time 
from inclusion in the study to death from breast cancer, death from other causes or time of 
censoring at the end of follow-up. Cause of death was indicated on a case report form and 
categorized into ten pre-specified groups and verified by the central datacenter. If a patient 
was diagnosed with metastatic breast cancer prior to or at time of death, cause of death was 
categorized as death from breast cancer.  
survival models 
Time to event models estimate the probability of experiencing an event in the next unit of 
time. The so-called hazard at time t can be modelled either on a relative (multiplicative) or 
an absolute (additive) scale. For the present analyses, we applied the most commonly used 
multiplicative (Cox) and additive survival model (Aalen).7 Both models include a baseline 
hazard, which follows a non-parametric time-dependent function. The Cox proportional 
hazards model than estimates on - a multiplicative scale - the increase of the hazard in the 
group of interest when compared to the hazard in the reference group. This is referred to as 
the hazard ratio (HR) and estimates a proportional measure of the strength of the relation. 
In the Aalen model, the additional hazard in the group of interest is modelled as a linear 
function on the unspecified baseline hazard of the reference group and when applied to 
human cohorts the resulting effect estimates (β) can directly be interpreted as the additional 
number of people experiencing the event per unit of time. Both models allow for adding 
additional covariates to correct for confounding. Taken together, the Aalen additive model 
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represents an additive semi-parametric technique for survival analysis that is at least as 
flexible as the Cox model. 
statistical and computational aspects
The statistical software programme R has the package “timereg” which has extensive ca-
pabilities for estimating and analyzing additive hazard models and is easily applicable for 
researchers who are familiar with the software.7,11 For those unfamiliar with the R software, 
a tutorial for using the model is provided in the supplemental materials. We studied the ef-
fect of age on mortality from breast cancer in the complete cohort and subgroups of patients 
with specific prognostic disease characteristics. To this end, we used the Cox proportional 
hazard regression to estimate hazard ratio’s, and estimated the absolute risk difference in 
mortality from breast cancer using the Aalen additive hazard regression. Hazard ratios 
indicated the relative increase of mortality when compared to the reference group whereas 
risk differences are presented as the additional number of deaths per 1000 person years. As 
potential confounders we included country, histological grade, tumor stage, lymph node 
status, progesterone receptor status, most extensive surgery, radiotherapy, chemotherapy 
and endocrine therapy. Interaction as deviation from relative effects in the Cox propor-
tional hazards model and interaction as deviation from absolute effects in the Aalen addi-
tive model were tested.  
All statistical tests were two-sided and P-values of less than 0.05 were considered statisti-
cally significant. Proportional differences were compared using a Pearson χ2 test. Median 
follow up and interquartile range (IQR) were calculated using the reversed Kaplan Meier 
estimate.12 All analyses were performed in R Software (version 3.0.0) using the “survival” 
and ”timereg” packages.13 
Results 
9766 women diagnosed with breast cancer were included in the TEAM study; 5349 were 
younger than 65 years, 3060 patients were aged 65 to 74 years and 1357 patients were aged 
75 years or older. Table 1 shows baseline characteristics at time of diagnosis for the three age 
groups separately.  Median follow-up was 5.1 years (IQR 4.1-5.9). 
Increasing age was associated with a higher risk of dying from breast cancer; cumulative 
mortality from breast cancer at five years increased from 5.1% in patients younger than 65 
years, to 5.8% in patients aged 65 to 74 years and 8.3% in patients aged 75 ≥ years (Table 2). 
Five years after inclusion, patients aged ≥ 75 years at baseline were at a 1.7-fold higher risk 
of dying from breast cancer than patients aged under 65 years, in absolute numbers this cor-
responds to an additional number of 6.2 deaths from breast cancer per 1000 patient years.  
160 Chapter 8
Table 1 Patient characteristics by age at diagnosis
< 65 years 65-74 years ≥ 75 years
P value 
    n=5349 n=3060 n=1357  
n % n % n % 
Histological grade and differentation 0.065
G1, well 911 17.0 550 18.0 216 15.9
G2, moderate 2581 48.3 1537 50.2 679 50.0
G3, G4, poor 1377 25.7 732 23.9 329 24.2
Unknown 480 9.0 241 7.9 133 9.8
Tumor size (cm) <0.001
< 2 3298 61.7 1806 59.0 593 43.7
≥ 2 2037 38.1 1247 40.8 764 56.3
Unknown 14 0.3 7 0.2 0 0.0
N stage 0.117
Negative 2800 52.3 1623 53.0 690 50.8
Positive 2518 47.1 1418 46.3 651 48.0
Unknown 31 0.6 19 0.6 16 1.2
Estrogen receptor <0.001
Positive 5219 97.6 3022 98.8 1344 99.0
Negative 128 2.4 35 1.1 13 1.0
Unknown 2 0.0 3 0.1 0 0.0
Progesterone receptor 0.534
Positive 4029 75.3 2268 74.1 1004 74.0
Negative 915 17.1 554 18.1 255 18.8
Unknown 405 7.6 238 7.8 98 7.2
Country <0.001
The Netherlands 1428 26.7 852 27.8 473 34.9
Germany 871 16.3 454 14.8 146 10.8
  United Kingdom/Ireland 696 13.0 413 13.5 166 12.2
Greece 110 2.1 71 2.3 26 1.9
France 722 13.5 403 13.2 105 7.7
United States 1159 21.7 695 22.7 378 27.9
Japan 98 1.8 66 2.2 20 1.5
Belgium/Luxembourg 265 5.0 106 3.5 43 3.2
Most extensive surgery <0.001
Mastectomy 2120 39.6 1372 44.8 841 62.0
Wide local excision 3223 60.3 1685 55.1 515 38.0
Unknown 6 0.1 3 0.1 1 0.1
Radiotherapy <0.001
Yes 3980 74.4 2030 66.3 687 50.6
No 1331 24.9 994 32.5 651 48.0
Unknown 38 0.7 36 1.2 19 1.4
Chemotherapy <0.001
Yes 2742 51.3 700 22.9 71 5.2
No 2607 48.7 2357 77.0 1284 94.6
Unknown 0 0.0 3 0.1 2 0.1
Endocrine therapy 0.384
Tamoxifen followed by exemestane 2667 49.9 1546 50.5 655 48.3
Exemestane 2682 50.1 1514 49.5 702 51.7
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When stratified for tumor size, cumulative mortality from breast cancer at five years was 
higher in the older age groups, both in patients with small and large tumors (Table 2). 
Among patients with small tumors, mortality from breast cancer was 2.0-fold higher in 
patients aged over 75 years when compared to those under 65 years, while among patients 
with large tumors a similar age difference associated with a 1.6-fold increased mortality risk. 
A comparison of these relative risks suggests that the effect of increasing age is less strong in 
patients with larger tumors. On an absolute scale however, this age difference corresponds 
to an additional number of 5.1 deaths per 1000 patient years in patients with small tumors, 
whereas there was an additional number of 9.0 deaths per 1000 patient years in patients 
with large tumors. Apparently, the impact of increasing age is more pronounced in patients 
with larger tumors. 
When stratified for lymph node status, cumulative mortality from breast cancer at five years 
was higher in the older age groups, both in patients with negative and positive lymph node 
status (Table 2). Among patients with a negative lymph node status, older age was associated 
with a 1.7-fold increased risk of dying from breast cancer and this was not different for 
patients with a positive lymph node. These relative risk estimates suggest that the effect of 
increasing age on mortality from breast cancer is not dependent on lymph node status. On 
an absolute scale however, the corresponding absolute risk differences were an additional 
number of 3.1 deaths per 1000 patient years in patients with lymph node negative disease, 
whereas there was an additional number of 10.8 deaths per 1000 patient years in those with 
lymph node positive disease. Apparently, the impact of increasing age is more pronounced 
in patients with a positive lymph node status. 
Figure 1A presents a forest plot of the age specific relative risks of mortality from breast can-
cer when all patients were analyzed as one group and in subgroups stratified for tumor size 
and lymph node status. Comparing the relative risks from top to bottom, the age specific 
risk estimates are similar in the whole group when compared to the risk estimates in strata 
of tumor size and lymph node status. The comparison of the relative risks does not provide 
arguments for effect modification. Statistical testing for interaction provided p-values of 
0.85 for tumor size and 0.99 for lymph node status respectively.
Figure 1B presents a forest plot of the age specific risk differences in mortality from breast 
cancer when all patients were analyzed together, and in subgroups separately. Comparing 
the risk differences from top to bottom, the age specific risk differences are smaller in those 
with smaller tumors and in those with a negative lymph node status. The risk differences are 
largest in those with a positive lymph node status. Statistical testing for interaction provided 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1 Forrest plots presenting relative risks and absolute risks of dying from breast cancer
A) Relative risk of dying due to breast cancer by age group in all patients and by tumor size and lymph 
node status B) Additional number of deaths (per 1000 person years) of dying due to breast cancer in all 
patients and by tumor size and lymph node status
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disCussion
Using the outcomes of a large cohort of women with breast cancer, we show that the relative 
risk of dying from breast cancer increases with increasing age. The relative risk increase 
is similar for those with favorable and unfavorable prognostic characteristics, erroneously 
suggesting that the impact of increasing age is independent of prognosis. At the same time, 
we show that the additional number of older women who die from breast cancer is higher 
among women with a poor prognosis when compared to those with a good prognosis. This 
extra number of patients (per unit of time) affected by the risk factor under study incorpo-
rates both the baseline risk (or hazard) and relative risk increase (or hazard ratio) and thus 
provides a better estimate of the clinical impact. 
Clinicians prefer to target patients for whom the clinical impact of an intervention will be 
high. Although this may appear very straight forward, this crucial piece of information is 
lost when reporting relative risk estimates only. A significant age interaction was observed 
between lymph node negative and lymph node positive status in the additive model, while 
this interaction was not observed in the relative model. Indeed, it is well-known that prov-
ing statistical interaction depends on the underlying scale of the measurement.14 When only 
relative risk measures would have been reported, clinicians may have concluded that the 
effect of age is not depending on the lymph node stage. However, when also presenting risk 
differences the clinical perspective changes: the significant age interaction that was observed 
indicates that older age inflicts more harm in patients with lymph node positive disease. It 
may urge clinicians to specifically address additional interventions in older patients with a 
more severe stage of disease.  
Reporting risk differences together with relative risks will increase the understanding of 
clinical impact of effect sizes found in observational studies and will help target subgroups 
who benefit most from interventions. For no obvious reason, the Aalen additive model 
that we have applied here, has not been applied frequently in medical research. The ap-
pendix provides the codes how to program the analyses in R. In line with our findings, other 
scholars who applied the Aalen model made clear that comparing the difference in absolute 
risk gave rise to new perspectives on effect the effect of risk factors or interventions when 
compared to reporting relative risks only.3,15,16
In cohort studies, absolute outcomes are most often reported as cumulative incidences. 
Although they provide a relevant estimate of absolute effect, there is no possibility to ac-
count for confounding variables. As shown in this paper, the additive hazard model, as 
any other regression model, provides the opportunity to include covariates in the model 
and to address confounding factors. Furthermore, the possibilities to test for statistical 
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interaction are similar to the Cox proportional hazards model. Last, absolute effect of risk 
factors within subgroups can easily be visualized using traditional forest plots to further 
improve the understanding of the findings. It is sobering that the outcome produced by the 
Aalen additive model, the additional number of people affected per unit of time, is not yet 
embraced with enthusiasm.
In conclusion, we have presented an easily applicable model to estimate absolute effect 
measures in time to event analysis while preserving the possibility to adjust for confounders 
and test for statistical interaction. We have shown that interpretation of effect of risk fac-
tors among subgroups can change depending on the relative or absolute scale of the effect 
measure due to variation in underlying baseline risk. This should be taken into account 
when evaluating clinical impact of risk factors. 
Cooperative investigators of the teAM study
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BACKgRound 
Historically, effectiveness of treatment has been measured from a biomedical perspective, 
which is deeply rooted in biology, biochemistry and physiology. It is from this reasoning 
that trial endpoints in cancer research focus on tumor oriented endpoints such as disease 
free survival or progression free survival.1 Determining the effect of treatment on the 
length of life is necessary and this should be considered as the starting point of most new 
medical treatments. However, only measuring the effect of treatment on survival might 
not be sufficient. Especially when approaching the end of life, maintaining a good quality 
of life becomes all the more important.2 Over the last two decades, it has increasingly been 
acknowledged that experience of the patients themselves should be taken into account in 
the estimation of benefit of treatment. An abundance of questionnaires were developed 
to assess quality of life as a representation of patient experience in clinical trials. These 
questionnaires cover various domains of functioning such as physical, cognitive, sexual 
or social functioning, independence in daily living, and disease-related symptoms. These 
domains are chosen and weighted by physicians and researchers and result in a sum score 
that aims to reflect quality of life. 
It is debatable if the assumptions underlying the quality of life questionnaires correspond 
to the needs and wishes of the individual patients. The choices on which domains should be 
included and how to weigh them are defined by researchers, they do not necessarily include 
aspects of life that are considered important for quality of life by an individual patient. 
The patient’s perception of his or her quality of life is highly dependent on the patients’ 
thoughts, feelings, and preferences. Moreover, from the field of sociology it has been firmly 
established that wellbeing reaches its nadir during middle age and subsequently increases 
despite the concomitant loss in functional determinants with ageing. From this ‘disability 
paradox’ it is self-evident that wellbeing is not directly related to functional determinants 
that are currently measured in quality of life questionnaires. Therefore, current quality 
of life questionnaires reflect a state of functioning rather than quality of life as actually 
perceived by the patient perspective. 
If we aim to measure quality of life from a patient perspective, wellbeing would be an appro-
priate candidate to focus on. Wellbeing as an outcome has been used extensively in the field 
of social sciences and economics. The concept of wellbeing encompasses four quadrants 
(Figure 1) depending on whether it relates to passing or enduring experiences of happi-
ness and whether it relates to the entire lifespan or parts thereof.3 Here will focus on two 
quadrants as they are regarded the driving forces of wellbeing: happiness as a measurement 
of how good someone feels within a short time span and life satisfaction as a measure of the 
overall feeling content with his or her life as a whole. Both happiness and life satisfaction are 
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measured from the perspective of the individual: the patient rates their current or overall 
happiness without any predefined assumptions on which domains should be included or 
how they should be weighed. 
Here we introduce new endpoints that can be applied in clinical trials to reflect wellbe-
ing as experienced by patient rather than measuring its functional outcomes. We propose 
to measure happiness, life satisfaction and overall survival. Additionally, we combine the 
measure of happiness with the length of life to develop a balanced estimate of harms and 
benefits in the treatment of older patients with cancer. We provide a statistical approach 
using simulated data from a hypothetical clinical trial. 
Methods 
introducing new endpoints 
Happiness 
To measure wellbeing for this endpoint, we will focus on the left upper part of the quadrant: 
happiness as a measurement of how good someone feels within a short time span. Happiness 
is measured on a single item scale asking patients how happy they feel at that moment. By 
asking patients how they feel at that moment, focus is directed to the affective component 
of their happiness. The answer is rated using a visual faces scale ranging from 0 (extremely 
unhappy) to 10 (extremely happy). Patients are asked to report this on a daily interval using 
the Experience Sampling Method; patients are prompted to rate their happiness using an 
application on their smartphone or other electric device at a random moment of the day.4 
With this method a real-time, day-to-day experience of happiness is recorded during the 
time that patients are alive. 
If happiness is measured for two treatment arms in a randomized clinical trial, for each 
treatment arm it will represent a curve of perceived happiness over time. At the start of 
the study, happiness will be equal between both arms due to randomization. Over time, 
happiness might change between the two arms. The variation between the two arms over 
time can be estimated by comparing all measurements by treatment arm and can be tested 
if there is a statistical difference between the two arms. If a difference is observed further 
analysis regarding the behavior of happiness over time between the two treatment arms is 
required. We propose a way of estimating this further below. 
Life satisfaction 
Life satisfaction (Figure 1, right lower quadrant) is the degree to which an individual rates 
the overall feeling of contentment with his or her life as a whole. This assessment combines 
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both past and future perspectives and is therefore an evaluation over a longer period of 
time. Life satisfaction is measured using the validated Cantril Self-Anchoring scale.5 Th is is 
a single measurement on a visual scale represented as a ladder ranging from 0 to 10 where 0 
represents the worst possible life imaginable and 10 represents the best possible life imagin-
able. Patients are asked where on the ladder they feel to stand at time of randomization and 
at specifi ed time points during the follow-up. Chapter 9  
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Figure 1: Theoretical framework of wellbeing  





















Figure 1: Theoretical framework of wellbeing 
For both treatment arms, at each prespecifi ed time point, the diff erence between life satis-
faction can be measured among the two treatment arms for those patients that are alive at 
that time point (Figure 2). At baseline, life satisfaction should be comparable between the 
two arms as a result of randomization, but it might change between the two treatment arms 
as a result of the diff erent treatments. 
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Life satisfaction for Treatment Arms
Figure 2 Measurement of life satisfaction
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The combined estimate of happiness and length of life: Happy life years 
To quantify the experienced happiness over the duration of being alive we propose to 
combine the measurement of happiness with the length of life by calculating the product 
of overall survival and happiness as an Area Under the Curve (AUC). This AUC is named 
HAPPy life Years (HAPPY’s). The HAPPY is calculated per individual (Figure 3A) and can 
be used to perform a statistical analysis and compare the two randomized arms (Figure 3B). 
In clinical practice, both the shape of the curve and the area of the curve will be valuable for 
decision making. From a mathematical perspective this resembles the calculation of Quality 
Adjusted Life Years (QALY). However, it differs substantially in its conceptual design. The 
HAPPY combines an objective one dimensional endpoint (overall survival) with a subjec-
tive self-anchored single question that reflects the experience and happiness of patients 
regardless the domains that they themselves consider are important. It therefore is a more 
accurate reflection of wellbeing than a QALY. 
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Figure 3 Happy Life Years for (A) two individuals and (B) two treatment arms 
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Results
A statistical example of the new endpoints using simulation data 
disCussion
Ultimately, patients and clinicians aim to maximize both length and quality of life. We 
believe that the newly introduced endpoints reflect this goal better than the traditional 
endpoints used in clinical trials for older patients with cancer. 
In this paper we have discussed the importance of including the patient perspective on 
quality of life in the evaluation of treatment benefit. With these new endpoints, quality of 
life is measured as a function of happiness or life satisfaction, without any underlying as-
sumptions from researchers or clinicians on which aspects define quality of life. Therefore, 
the measurement of quality of life reflects the experience of patients more adequately than 
traditional questionnaires. Measuring the patient perspective on quality of life instead of the 
research perspective is part of  a long-lasting debate in the field of anthropology and healthy 
ageing.6,7 Especially among older patients, it is important to acknowledge the difference 
between the patient’s perspective and the perspective of the researchers when evaluating 
quality of life.8,9
The usefulness of experience sampling method (ESM) for psychiatric and somatic evalua-
tion in clinical trials has been described previously, but to our knowledge it has not been 
applied in clinical research.10 The ESM method is an appealing method for the evaluation 
of happiness as it measurements are made in the natural flow of real life. The collection 
of repeated measures over time improves the validity, reliability and transparency of in-
dividual patterns and this increases the sensitivity to detect changes over time. In the of 
field happiness research, this method is now frequently used to understand the real time 
dynamics of happiness in everyday life. Previously, such  research methods were cumber-
some and expensive. Over the last years several web applications for smartphones have 
been developed that enables researchers to create large databases to study the influence of 
daily activities and experiences on emotional wellbeing.11 We believe that such a research 
method could be applied to evaluate the wellbeing of patients in clinical research and during 
treatment in routine practice.  
Some other methods have been proposed previously to evaluate length of life and quality 
of life in a single endpoint. These methods are the Extended Q-TWiST method and the 
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Quality Adjusted Life Years (QALY).12,13 For both methods, outcomes are calculated using 
an average sum score of a quality of life questionnaire or a predefined weight at one time 
or a few times during follow up. As outlined above, the traditional quality of life question-
naires reflect a state of functioning on various domains and therefore these methods are 
a measurement of functioning over a time period and not necessarily a reflection of the 
experienced quality of life.
Evaluation of life satisfaction using the Cantril’s ladder is an established method with high 
validity and reliability. We could only identify two studies that applied the Cantril’s ladder 
as a tool for life satisfaction among patients with cancer.14,15 However, the tool has been 
extensively used in population based cohort studies in older people to evaluate the relation 
between age and life satisfaction and patterns of life satisfaction over time.16
Already described by Ira Wilson and Paul Cleary in 1995, there is a need to link clinical out-
comes with quality of life in the evaluation of treatment.17 In their conceptual model,17 they 
describe a framework that connects this biomedical model through several levels such as 
physiological factors, symptoms and functioning to overall quality of life. Although overall 
quality of life is considered as the ultimate outcome in their model, traditional question-
naires have focused on the intermediate levels; the domains they assess are comparable to 
the levels in the model of Wilson and Cleary. Our proposed endpoint is the first that directly 
connects the biomedical model in terms of life expectancy with the overall quality of life. 
From our simulation studies, we have shown that these new endpoints are valid under vari-
ous scenarios in clinical trials in older patients with cancer. Moreover, with the introduction 
of the HAPPY endpoint, we provide more insight in the costs and benefits of treatment as 
the shape of the area under the curve reflects the balance of treatment in terms of increasing 
length of life at the cost of possible decrease in quality of life. 
With the introduction of this new endpoint, we do not argue that the domains currently 
assessed in traditional quality of life questionnaires should are not relevant. As outlined in 
the model by Wilson and Cleary, we propose to include these measures of functioning and 
symptoms as explanatory factors for variation in overall quality of life rather than the main 
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suMMARy
Part i: evaluating treatment of older patients with breast cancer
In Chapter 2, data from five population-based national or regional cancer registries in 
Europe provided more insight into treatment strategies and survival outcomes among older 
patients with non-metastatic breast cancer. The design of this study allowed us to explore 
possible patterns between treatment strategies and survival outcomes as some treatment 
differences were most likely based on geographic factors. A notable finding was the low 
proportion of patients receiving adjuvant endocrine therapy in the Netherlands compared 
to the other countries in patients with stage I breast cancer. This reflects a difference in 
the national guidelines: in the Netherlands, endocrine therapy is only recommended in 
hormone receptor positive patients with lymph node positive disease or otherwise unfa-
vourable tumour characteristics (high grade or size ≥ 2 cm),1 while in other countries, ad-
juvant endocrine therapy is prescribed in all patients with hormone receptor positive breast 
cancer. This lower use of endocrine treatment in the Netherlands was not accompanied by 
poorer relative survival in the Netherlands suggesting potential overtreatment in countries 
other than the Netherlands. On the other hand, substantial variation in the omission of 
surgery was observed between the participating countries (Ireland vs Belgium) in patients 
with stage III breast cancer. The increase of omission of surgery was accompanied by a 
decreasing relative survival, potentially indicating undertreatment in this high risk group. 
Overall, these findings underline the lack of consensus in the international community on 
how to optimally treat older patients and reflect the struggle in clinical practice to treat this 
very heterogeneous population. Moreover, the variation in treatment probably contributes 
to variation in survival outcomes in Europe. 
Chapter 3 described the primary outcomes of the long-term follow-up of the TEAM 
trial, investigating the effectiveness of exemestane monotherapy compared to sequential 
therapy with tamoxifen followed by exemestane for a total duration of five years, among 
post-menopausal patients with hormone receptor positive breast cancer. In line with the 
five year results,2 no differences between these two strategies were observed for the primary 
endpoints. When considering cause of death, results of this analyses suggested there might 
be a small benefit of exemestane therapy on breast cancer-specific mortality but this was 
counterbalanced by an increase in non-breast cancer related mortality, resulting in similar 
overall survival rates for both treatment strategies. Literature has noted that tamoxifen 
bears a cardioprotective effect and therefore contributes to lower other cause mortality 
among patients with breast cancer.3 This suggests that although exemestane might be more 
favourable for breast cancer related outcomes, it lacks the cardioprotective effect of tamoxi-
fen. Therefore, tamoxifen might be preferred for patients with a relatively low risk breast 
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cancer and high risk cardiovascular profile, a finding that is particularly important for older 
patients. 
In Chapter 4, we described the ability of physical recovery after surgical treatment and 
during endocrine treatment using two parameters of physical functioning among post-
menopausal patients with breast cancer included in the TEAM trial. Patients aged 70 years 
or older did not improve in physical functioning between one and two years after diagnosis 
to the same extent as younger patients. Impairment in physical functioning could interfere 
with independent living and might influence quality of life. Therefore, these outcomes 
should be described in clinical studies, especially when the majority of the target population 
of the treatment under study is of older age. 
Part ii: Breast cancer prognosis in the presence of competing mortality
In the second part of this thesis we further investigated the prognosis of breast cancer in the 
presence of competing mortality. In Chapter 5, we evaluated the influence of age on breast 
cancer mortality and other cause mortality in ten year follow-up data from the TEAM trial. 
We applied Fine and Gray regression analysis to adjust for competing events. After ten 
years of follow-up, breast cancer mortality continued to increase among postmenopausal 
patients regardless of the increasing other cause mortality. In older patients, breast cancer 
mortality remained higher compared to younger patients and this was not outweighed by 
substantially higher other cause mortality. Chapter 6 provides further insight into the role 
of comorbidities on the long-term risk of breast cancer mortality and other cause mortality 
in postmenopausal patients with early breast cancer, which especially for the older patient 
cohorts is very relevant. Despite the number of comorbidities or increasing age that both 
contributed to higher other cause mortality, no decrease in breast cancer mortality was ob-
served. Most interestingly, we report that older patients without comorbidities are at higher 
risk of dying due to breast cancer, despite a higher other cause mortality. Both Chapter 
5 and Chapter 6 underline the clinical challenge regarding decision making, balancing 
between undertreatment and overtreatment of older patients, and indicate that assessment 
of risk for both breast cancer mortality and other cause mortality is indispensable for treat-
ment decision making in older patients. 
Part iii: From research setting to daily practice: improving methodology in 
studies in older patients 
In the third section of this thesis, we explored some innovative methodological approaches 
to improve our understanding of health and disease among older patients with breast cancer. 
In Chapter 7, we shed further light on how scholars define successful aging using a citation 
network analysis to explore the literature. We described two distinct citation networks that 
form two mutually exclusive concepts of successful aging. The first network focused on suc-
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cessful aging from the perspective of the older person themselves while the second cluster 
based the concept of successful aging on the objective measurements of aging as determined 
by the researchers. These findings emphasize how the concept of successful aging depends 
on whether the individual themselves or the outsider judge the situation. 
In Chapter 8, we reported the use of absolute outcomes next to relative outcomes with 
the Aalen additive hazards model to improve our understanding of the impact of age in 
older patients with breast cancer. We illustrated that this model is easily applicable for time-
to-event analysis while it preserves the possibility to adjust for confounders and test for 
statistical interaction similar to the traditional Cox model. Moreover, our results showed 
that the interpretation of effect of risk factors among subgroups can change depending on 
the relative or absolute scale of the effect measure due to variation in underlying baseline 
risk. As older patients are at higher baseline risk of dying compared to younger patients, it 
is important to take this into account when evaluating the clinical impact of risk factors.
Finally, in Chapter 9 we proposed new endpoints that could be used for the evaluation of 
treatment in older patients with cancer. Ultimately, patients and clinicians aim to maximize 
both length and quality of life. Traditional quality of questionnaires include various domains 
of function (such as physical functioning and social functioning) defined by researchers 
that together sum up to a measurement of quality of life. However, the patient’s perception 
of quality of life is highly dependent on individual thoughts, feelings, and preferences and is 
not necessarily reflected in a quality of life questionnaire based on functional outcomes. The 
proposed endpoints take into account both the perspective of the patient by evaluating the 
experienced happiness and life satisfaction and the objective measure overall survival. We 
combined the measure of happiness with the length of life to develop a balanced estimate 
of harms and benefits in the treatment of older patients with cancer (HAPPY endpoint). 
disCussion 
iMPliCAtions oF the Findings FoR CliniCAl PRACtiCe 
Balancing between undertreatment and overtreatment 
There is a thin line between undertreatment and overtreatment in older patients with breast 
cancer. In Chapter 2, we described examples of both undertreatment and overtreatment. 
First, there is a group of older patients that, based on the breast cancer characteristics, has 
a low risk of disease recurrence and breast cancer mortality. Moreover, due to their older 
age their risk of dying due to other causes is substantially higher. In these patients, the ad-
ditional benefit of adjuvant endocrine therapy might be minimal; despite the large variation 
in prescription of adjuvant endocrine therapy, relative survival was approaching 100% in 
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all participating countries, indicating almost no excess mortality due to breast cancer. Un-
fortunately, there is only circumstantial evidence that supports the omission of endocrine 
therapy in this low risk group. A study comparing treatment and survival in the Netherlands 
and Ireland reported similar findings.4 In addition, a population-based study from Denmark 
identified a subgroup of older patients with low risk breast cancer not treated with adjuvant 
endocrine therapy that were not at increased risk of mortality.5 Recently, a secondary analy-
sis of a Swedish trial that compared adjuvant tamoxifen versus no tamoxifen was also able 
to define a ultralow risk group where adjuvant endocrine therapy did not lead to survival 
benefit over a course of 20 years.6 While the beneficial effects of adjuvant endocrine therapy 
in this subgroup appear to be overestimated, harmful effects appear to be underestimated. 
Tamoxifen increases the risk of trombo-embolic events and is associated with decline in 
cognitive function and increasing risk of depression.2,7,8 Aromatase-inhibitors are strongly 
associated with arthralgia and osteoporosis.2 In a vulnerable older population, this might be 
even more pronounced and may lead to loss of independence, although data to underline 
these implications are lacking. For older patients with low risk breast cancer, the benefit of 
treatment may not outweigh the harms and this should be taken into consideration when 
deciding upon adjuvant endocrine therapy. Moreover, in older patients with cardiovascular 
disease tamoxifen might be more appropriate due to a possible cardioprotective effect but 
further research is needed to aid better profiling. 
Second, there is a group of older patients with unfavourable tumour characteristics that 
have a high risk of recurrence and breast cancer mortality that are vulnerable for under-
treatment: In Chapter 2, we reported that older patients with stage III breast cancer from 
countries that treat a higher proportion of patients with primary endocrine therapy (PET) 
have a poorer relative survival. Growing evidence suggests poor locoregional control with 
PET: a meta-analysis of randomised controlled trials and non-randomised studies has 
shown benefits for surgery over PET in treatment of older patients in better disease control 
and a probable survival benefit in patients with a life expectancy of more than five years.9 
It is therefore that the SIOG only recommends PET for patients with a life expectancy 
of less than 2 years, or for those patients considered unfit for surgery or refuse surgery.10 
Given these recommendations and the knowledge that women who reach the age of 75 
have an average life expectancy of 13 years,11 it is reasonable to assume that in countries 
such as England and Ireland, with up to 39% of the patients treated with PET, some of these 
patients were undertreated. Moreover, Chapter 2 also showed that there is no international 
consensus on the prescription of chemotherapy among older patients. In the Netherlands, 
only very few patients aged over 70 years receive chemotherapy due to an upper age limit in 
our national guidelines. This might lead to undertreatment as the life expectancy of these 
patients may be high enough to gain benefit from chemotherapy. Especially among other-
wise healthy older patients, withholding chemotherapy may contribute to poorer survival 
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outcomes that were described in Chapter 5 and 6. Unfortunately, little evidence exists on the 
efficacy, feasibility and toxicity of chemotherapy among older patients with breast cancer 
as they are often excluded from clinical trials. Only one trial specifically including older 
patients (aged >65 years, good performance score and no major organ dysfunction) com-
pared standard chemotherapy (either cyclophosphamide, methotrexate, and fluorouracil 
(CMF) or cyclophosphamide/doxorubicin) with capecitabine, and noted better outcomes 
for disease recurrence and overall survival in the standard chemotherapy group.12 In both 
therapy arms, however, a substantial percentage of patients experienced toxicity, needed 
dose reduction or stopped therapy early. The chemotherapy toxicity tool in older patients 
with cancer developed by Hurria and colleagues,13 might be helpful in decision making 
regarding adjuvant chemotherapy.
emphasizing the role of life expectancy 
To reduce overtreatment and undertreatment and improve outcomes, treatment should be 
tailored to the needs of the older patient. The goal of many treatment strategies in breast can-
cer is to prevent future disease recurrence. Efficacy of treatment is often evaluated five years 
after initiation of treatment. Therefore, it is of key importance to estimate life expectancy. 
In older patients breast cancer occurs to the background of aging and therefore life expec-
tancy is not only defined by the prognosis of breast cancer. There is a large heterogeneity in 
health status in older patients and calendar age alone is known to be a poor predictor of life 
expectancy. This is illustrated by Figure 1, that indicates how remaining life expectancy is 
influenced by the level of comorbidity in older individuals.14 Many online tools have been 
developed to conceive a better estimation of life expectancy.15 An overview of these tools is 
provided at www.eprognosis.com. In these tools, variables such as comorbidity, frailty and 
subjective health are included to more accurately predict life expectancy. The International 
Society of Geriatric Oncology recommends performing a geriatric assessment in all older 
patients with cancer.10,16 Unfortunately, there is a large variety in tools that are used for 
the geriatric assessment and no consensus has yet been reached which tools should be in-
cluded.16 Nevertheless, several studies have indicated that some form of geriatric assessment 
could be used to predict the risk of toxicities and to provide a profound estimation of breast 
cancer mortality, other cause mortality and benefits and harms of treatment.17 
On the other hand, recently published work by Kusumastuti et al described that the added 
value of geriatric indicators to calendar age to predict mortality decreases with increasing 
age.18 Apparently, the process of aging makes older people intrinsically frail and variation in 
clinically visible signs of frailty do not appear to influence life expectancy. This is also visible 
in Figure 1,14 where variation in life expectancy by comorbidity decreases with increasing 
age groups, especially after the age of 85 years. When extrapolating these findings to the 
treatment of breast cancer, we should question ourselves if there is a certain age threshold 
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at which invasive treatments such as chemotherapy should not be encouraged due to the 
intrinsic aging process, even when a patient is not showing any clinical signs of frailty.  
Fig 1. Estimated life expectancy by age and comorbidity level (none, low/medium, or high). Data adapted.3
Figure 1. Estimated life expectancy by age and comorbidity level (none, low/medium, or high). Adapted 
from Muss et al.14
taking competing mortality into account for breast cancer prognosis
Following the estimation of life expectancy, breast cancer prognosis should be evaluated 
to further define the extent of treatment. However, the tools that are currently available to 
estimate breast cancer prognosis such as Adjuvant! Online and PREDICT are not validated 
for the older population, and they do not incorporate geriatric parameters. Both tools are 
poorly equipped to take the heterogeneous health status of older patients, including comor-
bidity and functional status into account; in validation studies in the Dutch breast cancer 
population both tools overestimated breast cancer outcomes and the impact of treatment in 
older patients.19-21 Therefore, tools specifically designed for older patients to estimate breast 
cancer prognosis are highly needed and they should take competing mortality into account 
to accurately predict breast cancer prognosis. 
Over the last decade, the role of genomic profiling to better predict the value of adjuvant 
treatment in breast cancer is highly debated. In 2016, the results of the Microarray in Node-
Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) 
study were published and described that genetic profiling with the 70-gene signature test 
(MammaPrint) chemotherapy could be safely omitted among patients with a high clinical 
risk and low genomic risk.22 Unfortunately, the MINDACT trial did not include patients 
aged over 70 years and therefore these results cannot easily be extrapolated to the older 
population. It is interesting to elaborate if genomic profiling could improve the predictive 
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value of adjuvant treatment in older patients. Recently, a secondary analysis of a Swedish 
trial that compared adjuvant tamoxifen versus no tamoxifen with a follow-up of twenty 
years showed that the MammaPrint could identify patients with ultra-low long-term risk of 
dying from breast cancer in whom adjuvant endocrine treatment could be safely omitted.6 
iMPliCAtions FoR ReseARCh in the oldeR PoPulAtion with BReAst 
CAnCeR 
include patients that are representative of the target population 
Over the last years, the gap between efficacy observed in cancer trials and outcomes in 
daily practice became apparent.23 Cancer trials aim to establish the efficacy of a drug or 
procedure on the disease of interest. They are performed in a highly controlled environment 
with highly selected and often younger patients.24 Unfortynately, these patients and circum-
stances do not represent the daily practice where older patients carry a considerable burden 
of disease. Therefore, clinical trials ought to be more representative of the populations 
most affected by the disease for which treatments are being tested. This should increase the 
knowledge of effectiveness of treatments and improve translation of trial results to optimal 
care of older cancer patients.25 For this reason, the Food and Drug Administration issued a 
guideline to encourage clinical trials to include patients aged 75 years and older when a dis-
ease is common among older patients.23 Despite the encouragement of both governmental 
institutes and international research organisations, previous attempts have shown that it is 
challenging to include older patients in clinical trials.10 Understandably, clinicians may feel 
uncomfortable with inclusion of frail older patients in trials with treatments with unknown 
efficacy and toxicity profiles. Therefore, ‘level A’ evidence will probably remain scarce for 
older patients. 
To improve evidence based medicine in older patients, a reasonable addition to clinical 
trials are observational studies. They generate a large amount of data that are representative 
of the older population and clinical practice. To prevent bias due to so-called ‘confounding 
by indication’ when comparing treatment strategies, adequate methodological techniques 
should be used.26 Unfortunately, many observational studies use inadequate methods that 
lead to incorrect interpretation of outcomes and thereby reduce the credibility of observa-
tional studies.27 Novel methodological approaches such as the instrumental variable method 
can be applied in observational studies to compare treatment efficacy if certain assump-
tions are met.26 To be able to use this type of research, large and high quality databases are 
necessary. One example is the EURECCA database, that is described in Chapter 2. In this 
project, patient, tumour and treatment variables were collected for all patients aged over 
70 years diagnosed with breast cancer in defined regions or countries. Although only certi-
fied cancer registries were included, the quality of the data was highly variable making it 
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difficult to interpret findings. Moreover, various definitions for staging and treatment were 
applied hampering the possibility to merge and compare data. In the future, quality of these 
databases should be improved by reducing missing information and improving definitions 
of treatment. Furthermore, it would be very relevant to include more information on the 
health status of individual patients, such as comorbidities or polypharmacy, to improve our 
understanding of the interaction between age related factors and cancer outcomes. 
including relevant endpoints for older patients in research 
To measure efficacy of treatment, outcomes in clinical trials in cancer emphasize the phar-
macological or biological efficacy of the drug or surgery. This has resulted in cancer driven 
endpoints, such as progression free survival, disease free survival or pathological complete 
response.28 Clinical trials should not only be concerned with prolonging life, but also focus 
on the needs and desires of patients.28 From the perspective of patients, both length of life 
and quality of life are considered important aspects of treatment decision making and the 
balance might change during life course. In younger patients, increasing length of life might 
be the primary goal of treatment, while in older patients quality of life becomes an increas-
ingly important aspect in treatment decision making.29 
In the evaluation of health care, there has been an increasing awareness to include relevant 
measures for patients. In an influencing paper published in 2010, Michael Porter stated that 
´value should always be defined around the customer´ and introduced value based health 
care that is rapidly being implemented in hospitals worldwide.30 In line with this, Chapter 
7 describes that successful aging can be described from the patient perspective along with 
the researchers perspective of successful aging. In addition, more emphasis has been given 
to so called patient reported outcomes such as functional outcomes, symptoms and quality 
of life to measure the value of care.31 This line of reasoning should be extended to clinical 
research in geriatric oncology.28 The value of treatment should not only be defined in terms 
of effectiveness but should also include the experience of the patient themselves. Current 
guidelines for the treatment of breast cancer do not provide any of this information as they 
are restricted to merely biomedical outcomes and are therefore insufficient for optimal 
treatment of older patients. 
Ultimately, patients and clinicians aim to maximize both length and quality of life. Patient-
related endpoints such as functional status, cognitive status and symptoms are important 
to provide further insight into this balance.28 However, researchers and clinicians should be 
aware that functional outcomes should not be interpreted as a measurement of quality of 
life. As was outlined in Chapter 9, quality of life highly depends on individual needs and 
preferences and among older patients it is not one-to-one related to functional outcomes.32 
If we aim to measure quality of life from a patient perspective, wellbeing would be an ap-
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propriate candidate to focus on. In older patients with cancer, the balance between length 
of life and quality of life should be reflected in the use of endpoints used in clinical trials. 
In Chapter 9, we proposed a new endpoint that includes both measures. In the near future, 
we hope to implement this new endpoint in a study including older patients with cancer to 
provide a better understanding of the balance between harms and benefits of treatment and 
disease from the perspective of the patients themselves. 
develop a prediction model specifically designed for older patients 
The Climb Every Mountain Study is an observational cohort study including patients aged 
over 70 years with non-metastatic breast cancer and it opened in 2013. In addition, the 
Prospective Registration of Issues in Metastasized breast cancer in the Elderly (PRIME) 
study is including patients aged over 70 years with metastatic breast cancer and opened 
in 2014. Both studies collected data on geriatric indicators and tumour characteristics at 
baseline and measured various domains of functioning during follow-up. In the coming 
years, data from both studies will mature and provide us further insight into treatment and 
relevant outcomes in older patients with breast cancer. Another promising research project 
that will integrate data from the Climb study with data from other population based studies 
is the Prediction of Outcome, Risk of Toxicity and quality of life in older patients TREaTed 
for breast cancer (PORTRET) study. In this tool, geriatric indicators will be incorporated to 
predict cancer outcomes in the presence of competing mortality, risk of toxicity and quality 
of life. 
In conclusion, similar to almost all other human malignancies, breast cancer is a disease of 
aging. This will lead to a growing number of older patients for whom optimal care is not yet 
available. It is important to provide studies and tools that are better suited to the needs and 
wishes of older patients. In the near future, important data from several observational stud-
ies will mature, setting foot to a prediction model for older patients with relevant outcomes 
to improve personalized care in older patients with breast cancer. 
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Dit proefschrift had tot doel meer inzicht te verkrijgen in de benadering van behande-
ling van ouderen met borstkanker. Daarbij maakten we gebruik van data van twee grote 
onderzoeksprojecten. Het eerste onderzoeksproject is onderdeel van het internationaal 
multidisciplinair platform European Registration of Cancer Care (EURECCA) waarin 
clinici en epidemiologen tot doel hebben om data en kennis van observationele cohorten 
met elkaar te delen. Binnen het borstkanker project van EURECCA werd data verzameld 
van vier nationale en één regionale kankerregistratie in Europa (Nederland, België, Ierland, 
Engeland en een district in Polen). In totaal werden 236,015 patiënten ouder dan 70 jaar 
met niet-gemetastaseerde borstkanker geïncludeerd. Van deze patiënten was informatie 
bekend over tumorkarakteristieken, stadium van ziekte, lokale behandeling (operatie van 
de borst en oksel, bestraling) en systemische behandeling (hormonale therapie en chemo-
therapie). Tevens was bekend of patiënten gedurende follow-up overleden waren. Daarnaast 
is in dit proefschrift gebruik gemaakt van data van de Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) studie. Dit is een internationale gerandomiseerde studie waarin 
postmenopauzale patiënten met niet-gemetastaseerde borstkanker werden geïncludeerd 
tussen 2001 en 2006. De studiepopulatie met 10 jaar follow-up bedroeg 6,120 patiënten. Bij 
aanvang van de studie werd van deze patiënten informatie verzameld over tumorkarakteris-
tieken, gezondheidsstatus, comorbiditeiten (het hebben van andere ziekten gelijktijdig met 
borstkanker) en gedurende follow-up werd informatie verzameld over terugkeer van ziekte, 
behandeling en oorzaak van overlijden. 
deel i: evaluatie van behandeling van ouderen met borstkanker
Hoofdstuk 2 presenteert de data van vijf Europese nationale of regionale kankerregistra-
ties waarin alle oudere patiënten uit de betrokken landen die gediagnosticeerd zijn met 
borstkanker tussen 2000 en 2013 zijn beschreven. Deze gegevens bieden meer inzicht in de 
verschillen tussen behandelstrategieën en overlevingscijfers bij ouderen met borstkanker in 
de landen die vergeleken worden. De opzet van de studie gaf de mogelijkheid om patronen 
tussen behandelstrategieën en overlevingsuitkomsten nader te bestuderen. De keuze voor 
een bepaalde behandeling blijkt vaak vooral bepaald te worden door geografische verschil-
len, zoals verschillen in behandelrichtlijnen per land. Een van de meest opvallende verschil-
len was wel het verschil in het geven van hormonale therapie bij patiënten met stadium 
I borstkanker. In Nederland kregen weinig patiënten hormonale therapie, terwijl in alle 
andere landen verreweg de meeste  patiënten wel hormonale therapie kregen. Dit verschil in 
behandeling wordt verklaard door verschillen in nationale richtlijnen. In de huidige Neder-
landse richtlijn wordt hormonale therapie alleen gegeven bij patiënten met slechte prognos-
tische kenmerken zoals lymfekliermetastasen, een hooggradige tumor of een tumor groter 
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dan 2 cm.1 In alle andere landen krijgen alle patiënten met een hormoonreceptorgevoelige 
tumor hormonale therapie. Opmerkelijk genoeg werd er tussen de Nederlandse patiënten 
met stadium I borstkanker en de andere patiënten met stadium I borstkanker geen onder-
ling verschil in relatieve overleving geobserveerd. Dit suggereert dat hormonale therapie in 
dit stadium van borstkanker mogelijk weinig toegevoegde waarde heeft en dat er sprake kan 
zijn van overbehandeling van deze patiënten wanneer zij wel hormonale therapie krijgen. 
Ook zien we in dit hoofdstuk een grote variatie tussen de verschillende landen in het wel of 
niet opereren van de tumor bij ouderen met stadium III borstkanker. Dit verschil bleek het 
grootst tussen enerzijds Ierland en Engeland (weinig operaties) en anderzijds België (veel 
operaties). Opvallend genoeg was de relatieve overleving lager in landen waar er minder 
vaak geopereerd werd. Dit suggereert dat het weglaten van de operatie bij patiënten met 
stadium III borstkanker kan leiden tot onderbehandeling. Concluderend laat dit hoofdstuk 
zien dat er sprake is van grote verschillen in behandeling van ouderen met borstkanker tus-
sen verschillende Europese landen. Deze bevindingen van deze internationaal-vergelijkende 
studie bevestigen het gebrek aan consensus dat er in de medische gemeenschap bestaat over 
het zo optimaal mogelijk behandelen van ouderen met borstkanker. 
In hoofdstuk 3 worden de primaire uitkomsten van de lange termijn follow-up van de TEAM 
trial beschreven. Deze gerandomiseerde studie vergeleek gedurende vijf jaar de effectiviteit 
van twee adjuvante hormonale therapieen, exemestaan monotherapie en sequentiële the-
rapie (tamoxifen gedurende twee en half jaar gevolgd door exemestaan gedurende twee en 
half jaar), bij 6120 postmenopauzale patiënten met hormoonreceptor gevoelige borstkan-
ker. Na tien jaar follow-up werd tussen de twee behandelarmen geen verschil in ziektevrije 
overleving geobserveerd. Dit was in lijn met de uitkomsten die werden beschreven na vijf 
jaar follow-up.2  Bij het nader bestuderen van de oorzaak van overlijden werd vastgesteld 
dat de exemestaan monotherapie leidde tot een lagere borstkankergerelateerde mortaliteit 
in vergelijking met sequentiële therapie. Dit effect werd echter weer teniet gedaan door 
een hogere mortaliteit ten gevolge van andere oorzaken van overlijden dan borstkanker in 
de exemestaan monotherapie-arm. Dit resulteerde in een onderling nauwelijks verschil-
lende algehele overleving tussen de twee behandelarmen. In de literatuur wordt beschreven 
dat tamoxifen mogelijk een cardiovasculair beschermend effect hebben en om deze reden 
bijdragen aan een lagere andere oorzaak van overlijden bij patiënten met borstkanker.3 Om 
deze reden zou tamoxifen mogelijk een waardevolle behandeling zijn bij patiënten met 
een laag risico borstkanker en een hoog cardiovasculair risico. Dit is een veel gevallen van 
toepassing op de oudere patiënt. 
In hoofdstuk 4 wordt het fysiek herstel beschreven van postmenopauzale patiënten uit de 
TEAM-trial na het ondergaan van chirurgie en gedurende hormonale therapie waarbij 
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gebruik werd gemaakt van twee parameters van fysiek functioneren. In tegenstelling tot 
patiënten jonger dan 70 jaar, herstelden patiënten ouder dan 70 jaar niet meer tot hun fy-
sieke niveau van voor de operatie. Een gevolg van fysieke achteruitgang bij ouderen kan zijn 
dat zij niet meer in staat zijn om zelfstandig te functioneren en dit kan invloed hebben op 
de kwaliteit van leven. Het is daarom van groot belang dat fysiek functioneren als uitkomst 
wordt beschreven in klinische studies teneinde oudere patiënten in de toekomst beter te 
informeren en een betere behandelkeuze te kunnen maken. 
deel ii: Prognose van borstkanker in de aanwezigheid van andere oorzaken 
van overlijden 
In het tweede deel van dit proefschrift kijken we verder naar de prognose van borstkanker 
wanneer ook andere oorzaken van overlijden een rol spelen. In hoofdstuk 5 wordt de invloed 
van leeftijd op borstkankergerelateerde sterfte en andere sterfteoorzaken onderzocht tien 
jaar na de diagnose van borstkanker bij patiënten die deelnamen aan de TEAM trial. Hierbij 
werd gebruik gemaakt van de Fine and Gray regressieanalyse om de invloed van andere oor-
zaken van overlijden mee te nemen in de schatting van de prognose. Bij oudere patiënten 
was de borstkankerspecifieke mortaliteit hoger dan bij jongere patiënten, ondanks de tevens 
hogere mortaliteit aan andere oorzaken dan borstkanker. Hoofdstuk 6 geeft meer inzicht in 
de rol van comorbiditeiten op borstkankerspecifieke mortaliteit en mortaliteit ten gevolge 
van andere oorzaken dan borstkanker tien jaar na diagnose. Ondanks de toename van het 
aantal comorbiditeiten en toename van de leeftijd daalde de borstkankergerelateerde sterfte 
niet. Bij patiënten ouder dan zeventig jaar zonder comorbiditeiten was de borstkankergere-
lateerde sterfte zelfs hoger dan bij jonge patiënten zonder comorbiditeiten. Zowel hoofdstuk 
5 als hoofdstuk 6 tonen aan dat het kiezen van de juiste behandeling voor de juiste patiënt 
een klinische uitdaging is, waarbij  zowel onderbehandeling als overbehandeling belang-
rijke valkuilen zijn. In voorspellingsmodellen voor de behandeling van borstkanker is het 
derhalve van groot belang om bij de prognose van borstkankergerelateerde sterfte tevens 
rekening te houden met andere oorzaken van sterfte. 
deel iii: van onderzoek naar de klinische praktijk: verbetering van 
methodologie in studies in oudere patiënten 
In het derde gedeelte van dit proefschrift onderzochten we enkele innovatieve methoden 
waarmee we inzichten over ziekte en gezondheid bij oudere patiënten met borstkanker beter 
in kaart konden brengen. In hoofdstuk 7 werd licht geworpen op de definitie van succesvol 
ouder worden zoals deze in de academische wereld steeds meer gebruikt wordt. Hierbij 
werd gebruik gemaakt van een citation network analysis om de literatuur hierover verder in 
kaart te brengen. Aan de hand van deze analyse werden twee afzonderlijke citation networks 
gevonden die onderling heel verschillende definities van succesvol ouder worden blijken 
te hanteren. Het eerste netwerk richt zich met name op succesvol ouder worden vanuit 
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het perspectief van de oudere persoon zelf, terwijl het tweede netwerk zich meer richt op 
objectieve metingen van ouder worden zoals dat gedefinieerd wordt door onderzoekers. 
Deze bevindingen benadrukken dat het concept succesvol ouder worden erg afhankelijk is 
van het diegene die dit beoordeelt; de oudere patiënt vanuit het eigen perspectief als insider 
versus de onderzoeker vanuit het outsider perspectief. 
In hoofdstuk 8 maakten we gebruik van het Aalen Additive Hazards model naast het tra-
ditionele Cox regressiemodel om de meerwaarde van absolute uitkomstmaten naast het 
gebruik van relatieve uitkomstmaten te onderzoeken. In dit hoofdstuk onderzochten we de 
invloed van leeftijd, tumorgrootte en lymfeklierstadium op borstkankerspecifieke overle-
ving. De resultaten laten zien dat het effect van leeftijd op borstkankerspecifieke sterfte in 
subgroepen met verschillende prognostische kenmerken afhankelijk is van het additieve of 
relatieve model. Dit kan verklaard worden door het onderliggende baseline-risico op borst-
kankerspecifieke sterfte. Omdat ouderen een hoger risico hebben op sterfte dan jongere 
patiënten is het van belang ook het absolute risico van risicofactoren te rapporteren. 
In hoofdstuk 9 introduceren we ten slotte een nieuw eindpunt voor de evaluatie van uit-
komsten in klinische studies van ouderen. Het doel van artsen en patiënten is niet om alleen 
de lengte van leven maar ook om de kwaliteit van leven zo veel mogelijk te verbeteren. 
Huidige primaire eindpunten in kankerstudies richten zich met name op de lengte van 
leven. Vragenlijsten naar de kwaliteit van leven meten dit concept veelal als een optelsom 
van verschillende domeinen van functioneren die zijn vastgesteld door onderzoekers (zoals 
fysiek functioneren, cognitief functioneren en sociaal functioneren). Echter, de kwaliteit 
van leven zoals die ervaren wordt door het individu is evenzeer erg afhankelijk van iemands 
eigen gedachten, gevoelens en voorkeuren. De eindpunten die worden gepresenteerd in 
hoofdstuk 9 omvatten zowel de lengte van leven als de kwaliteit van leven en maken ook ge-
bruik van het perspectief van de patiënt ten aanzien van de kwaliteit van leven. Dat gebeurt 
door een combinatie van het meten van de subjectieve geluksbeleving en de tevredenheid 
met het leven enerzijds en de objectieve meting van de overlevingskansen anderzijds. Deze 
twee maten worden vervolgens gecombineerd tot één eindpunt om aldus zo gebalanceerd 
mogelijk de voordelen en nadelen van een behandeling te kunnen vaststellen. 
disCussie 
Adviezen vooR de KlinisChe PRAKtijK 
Balanceren tussen overbehandeling en onderbehandeling 
De scheidslijn tussen onderbehandeling en overbehandeling bij ouderen met borstkanker 
is erg dun. Hoofdstuk 2 liet voorbeelden van beide situaties zien. Allereerst is er een groep 
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oudere patiënten die een laag risico heeft op het ontwikkelen van een (afstands-)recidief 
en het overlijden aan borstkanker. Daarnaast heeft deze groep op basis van haar leeftijd 
een hoger risico op het overlijden aan andere oorzaken dan borstkanker zelf. In deze groep 
patiënten zou de toegevoegde waarde van adjuvante hormonale therapie beperkt kunnen 
zijn. Dit wordt ook ondersteund door de bevindingen in hoofdstuk 2: ondanks de grote 
variatie in het voorschrijven van hormonale therapie tussen de verschillende landen was de 
relatieve overleving in al deze landen niettemin betrekkelijk gelijk en in alle gevallen hoger 
dan 95 procent. Helaas is er weinig direct bewijs beschikbaar dat deze bevinding kan on-
dersteunen. Een population-based studie in Denemarken identificeerde een subgroep van 
oudere patiënten met een laag risico op borstkanker die niet werd behandeld met adjuvante 
hormonale therapie maar tevens geen hoger risico bleek te hebben op sterfte in vergelijking 
met andere onderzochte groepen.4 Recent werd een Zweedse trial opnieuw geanalyseerd 
waarin het al dan niet toedienen van tamoxifen onderling vergeleken werd. In deze analyse 
konden de onderzoekers een groep definiëren met een uitzonderlijk laag risico op borst-
kanker, waarbij tamoxifen geen verbetering gaf in overlijden aan borstkanker gedurende 
twintig jaar follow-up.5 Terwijl de voordelige effecten van adjuvante hormonale therapie in 
deze groep worden overschat, worden de bijwerkingen veelal juist onderschat. Tamoxifen 
verhoogt het risico op trombo-emboliën en wordt tevens geassocieerd met verslechtering 
van de cognitieve functie en een verhoogd risico op depressie.2,6,7 Aromatase-inhibitors zijn 
geassocieerd met artralgiën en osteoporose. In een kwetsbare oudere populatie kunnen 
deze bijwerkingen zelfs versterkt aanwezig zijn en kan dit leiden tot een verlies van zelf-
standigheid en een vermindering van de kwaliteit van leven. Bij oudere patiënten met een 
laag risico op borstkanker wegen de voordelige effecten van adjuvante hormonale therapie 
daarom wellicht niet op tegen de nadelige effecten. 
Daarnaast is er een groep oudere patiënten met slechte prognostische kenmerken die een 
hoog risico heeft op het ontwikkelen van een (afstands-)recidief en het overlijden aan 
borstkanker. In deze groep patiënten kan onderbehandeling een rol spelen. In hoofdstuk 
2 beschrijven we patiënten met stadium III borstkanker waarbij in sommige landen een 
aanzienlijk deel van deze patiënten geen operatie krijgt en enkel behandeld wordt met 
primaire hormonale therapie. In deze landen wordt ook een lagere relatieve overleving 
geobserveerd. In toenemende mate komt er wetenschappelijk bewijs beschikbaar dat 
primaire hormonale therapie leidt tot slechte locoregionale controle van de tumor: een 
meta-analyse van gerandomiseerde en niet-gerandomiseerde klinische studies laat zien dat 
het chirurgisch verwijderen van de tumor in vergelijking met het geven van primaire hor-
monale therapie leidt tot betere locoregionale controle van de ziekte en waarschijnlijk ook 
een betere overleving geeft bij patiënten met een levensverwachting van langer dan vijf jaar.8 
Om die reden adviseert de internationale vereniging voor geriatrische oncologie (SIOG) 
dan ook om primaire hormonale therapie alleen toe te passen bij patiënten die om wat 
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voor reden ook geen operatie kunnen ondergaan of een zeer beperkte levensverwachting 
hebben.9 Vrouwen die de leeftijd van 75 jaar bereiken hebben intussen nog een gemiddelde 
levensverwachting van 13 jaar.10 Daarom is het aannemelijk dat in landen als Engeland en 
Ierland, waarbij tot 39 procent van de patiënten behandeld werd met primaire hormonale 
therapie, er sprake is van onderbehandeling. Daarnaast werd in hoofdstuk 2 ook duidelijk 
dat er geen internationale consensus bestaat over het al dan niet geven van chemotherapie 
bij ouderen met borstkanker. In Nederland wordt een bovenste leeftijdsgrens van 70 jaar 
aangehouden voor het geven van chemotherapie, waardoor in ons land  aan deze groep 
veel minder chemotherapie gegeven wordt dan in andere landen.1 Deze leeftijdsgrens zou 
weleens kunnen leiden tot onderbehandeling, omdat de levensverwachting van een deel 
van deze patiënten inmiddels zo hoog is dat zij wel degelijk voordeel kunnen hebben van 
chemotherapie. Zeker de gezonde oudere patiënt, zoals beschreven in hoofdstuk 5 en 6, zou 
hierdoor een lagere borstkankerspecifieke overleving kunnen hebben. Helaas is er weinig 
klinisch bewijs beschikbaar voor de effectiviteit, haalbaarheid en toxiciteit van chemothera-
pie bij ouderen met borstkanker. Slecht één gerandomiseerde klinische studie includeerde 
ook oudere patiënten met borstkanker (ouder dan 65 jaar, goede performance-scores en 
zonder orgaanfalen) en vergeleek standaard chemotherapie (cyclofosfamide, methotrexaat 
en fluorouracil (CMF) of cyclofosfamide en doxurubicine) met capecitabine. Deze studie 
toonde betere uitkomsten aan voor ziekteterugkeer en -overleving in de standaardgroep. 
In beide behandelarmen ervoer een substantieel percentage van de patiënten bijwerkingen, 
was er noodzaak tot het verlagen van de doseringen of werd de chemotherapie voortijdig 
gestaakt.11 Een recent ontwikkeld voorspellingsmodel voor het optreden van toxiciteit bij 
chemotherapie bij ouderen met kanker zou behulpzaam kunnen zijn bij het selecteren van 
patiënten die naar verwachting maar weinig bijwerkingen zullen ervaren.12 
een grotere rol voor levensverwachting 
Om overbehandeling en onderbehandeling te verminderen zou behandeling zich meer 
moeten richten op de wensen en behoeften van oudere patiënten. Het doel van veel 
behandelingen is het voorkomen van terugkeer of metastasering van borstkanker in de 
toekomst. In klinische studies wordt de effectiviteit van behandeling van borstkanker wordt 
vaak gemeten over een periode van vijf jaar na het starten van behandeling. Daarom is 
het van groot belang om hierbij de levensverwachting in te schatten. Bij oudere patiënten 
is borstkanker vaak niet de enige ziekte die de levensverwachting bepaalt. Er is een grote 
mate van heterogeniteit in de gezondheid van ouderen, en kalenderleeftijd alleen levert 
geen goede voorspelling op van de levensverwachting. Dit wordt geillustreerd in Figuur 1 
waaruit blijkt dat de levensverwachting, naast de variabele leeftijd, ook deels bepaald wordt 
door het aantal comorbiditeiten.13 Er zijn verschillende online hulpmiddelen beschikbaar 
om een realistische inschatting van de levensverwachting te kunnen maken.14 Een over-
zicht van deze tools is te vinden op de website www.eprognosis.com. In deze tools worden 
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variabelen als comorbiditeit, kwetsbaarheid en subjectieve gezondheid meegenomen als 
voorspellers van de levensverwachting. De SIOG raadt aan om een geriatrisch assessment te 
verrichten bij alle ouderen met kanker.9,15 Op dit moment is er nog een te grote variatie in de 
verschillende vragenlijsten en metingen die onderdeel zijn van een geriatrisch assessment.15 
Desalniettemin hebben verschillende studies aangetoond dat een geriatrisch assessment wel 
degelijk behulpzaam is in het voorspellen van toxiciteit, borstkanker specifieke overleving 
en levensverwachting.16 Er er ook literatuur die kritisch staat ten opzichte van het gebruik 
van modellen voor het voorspellen van de levensverwachting. Recent gepubliceerd werk 
door Kusumastuti en collega’s laat zien dat de toegevoegde waarde van geriatrische indica-
toren als toevoeging op de kalenderleeftijd om sterfte te voorspellen bij ouderen beperkter 
wordt naarmate de leeftijd hoger wordt.17 Blijkbaar leidt het proces van veroudering op hoge 
leeftijd tot een intrinsieke biologische kwetsbaarheid en is klinisch zichtbare aanwezigheid 
of afwezigheid van kwetsbaarheid of veroudering niet langer van invloed op de leeftijds-
verwachting. Dit is ook zichtbaar in Figuur 1,13 waarin de variatie in levensverwachting 
op basis van aantal comorbiditeiten afneemt met het toenemen van de leeftijd. Dit is met 
name zichtbaar in de patiënten ouder dan 85 jaar. Wanneer we deze bevindingen extra-
poleren naar de behandeling van borstkanker zouden we ons kunnen afvragen of er niet 
een bepaalde maximumleeftijd is waarop invasieve behandelingen zoals chemotherapie niet 
langer gegeven moeten worden, zelfs wanneer er geen sprake is van klinische tekenen van 
kwetsbaarheid of comorbiditeit. 
 
Fig 1. Estimated life expectancy by age and comorbidity level (none, low/medium, or high). Data adapted.3
Figuur 1. Geschatte levensverwachting op basis van leeftijd en niveau van comorbiditeit (geen, laag/
gemiddeld, hoog). Aangepast van Muss et al.13
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houdt rekening met andere oorzaken van overlijden bij het schatten van de 
prognose van borstkanker 
Om de keuze tot behandeling te maken zal naast het schatten van de levensverwachting ook 
een schatting van de borstkankerprognose gemaakt moeten worden. Predictiemodellen die 
nu beschikbaar zijn voor het schatten van prognose van borstkanker en het effect van be-
handeling, zoals Adjuvant!Online en PREDICT, zijn niet gevalideerd in de oudere populatie. 
Tevens worden daarin geen geriatrische parameters meegenomen. Drie validatiestudies met 
een Nederlandse population-based dataset met oudere patiënten met borstkanker hebben 
aangetoond dat beide predictiemodellen een overschatting gaven van borstkankerspecifieke 
sterfte en het effect van verschillende behandelingen op borstkankerspecifieke sterfte.18-20 
Een goede verklaring voor deze overschatting is het feit dat beide modellen geen rekening 
houden met mortaliteit ten gevolge van andere oorzaken dan borstkanker. Beide predic-
tiemodellen zijn derhalve niet bruikbaar voor de oudere patiënt met borstkanker. Het is 
daarom van groot belang dat er een voorspellingsmodel wordt ontwikkeld dat gericht is op 
en gevalideerd wordt in bij oudere patiënten met borstkanker, waarbij tevens rekening wordt 
gehouden met andere oorzaken van overlijden en waarbij naast borstkankergerelateerde 
uitkomsten ook uitkomsten als het fysiek en cognitief functioneren worden meegenomen. 
In het afgelopen decennium is er veel onderzoek gedaan naar de rol van genetisch profileren 
teneinde de prognose en waarde van adjuvante behandelingen beter te voorspellen. In 2016 
zijn de onderzoeksresultaten van de Microarray in Node-Negative and 1 to 3 Positive Lymph 
Node Disease May Avoid Chemotherapy (MINDACT) trial gepubliceerd. Met behulp van 
het genetisch profileren van de tumor met de 70-gene signature test (Mammaprint) werd 
bij patiënten een hoog klinisch risico op het terugkeren van de ziekte maar een laag ge-
netisch risico chemotherapie veilig achterwegen gelaten kon worden.21 Helaas includeerde 
de MINDACT trial geen patiënten ouder dan 70 jaar en daarom zijn deze uitkomsten niet 
eenvoudig te vertalen naar de oudere populatie met borstkanker. Dit genetisch profileren 
zou heel behulpzaam kunnen zijn in de afweging van het al dan niet geven van chemothe-
rapie bij ouderen met borstkanker. 
Adviezen vooR ondeRzoeK Bij oudeRen Met BoRstKAnKeR 
includeer patiënten in studies die representatief zijn voor de populatie die 
behandeld gaat worden 
In de afgelopen jaren is steeds duidelijker geworden dat de effectiviteit van behandelingen 
zoals die beschreven wordt in klinische trials niet bereikt wordt in maar in beperkte mate 
van toepassing is op de alledaagse klinische praktijk.22 Trials gericht op kanker worden 
uitgevoerd in een zeer gecontroleerde, kunstmatige omgeving waarbij er sterke selectie 
is van overwegend jonge patiënten die naast deze ziekte weinig andere ziekten hebben.23 
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Deze omstandigheden zijn niet representatief voor de klinische praktijk waarbij ouderen 
vaak een groot deel van de patiëntenpopulatie beslaan.24 Daarom zouden klinische trials 
in de toekomst patiënten moeten selecteren die meer representatief zijn voor de populatie 
waarbij de behandeling gegeven gaat worden. Om deze reden heeft de Amerikaanse Food 
and Drug Administration een richtlijn uitgebracht om klinische trials aan te moedigen om 
ook patiënten ouder dan 75 jaar te includeren in studies naar ziekten die veel voorkomen 
bij ouderen.22 Ondanks aanmoedigingen van overheidsinstellingen en internationale on-
derzoeksorganisaties blijkt het lastig te zijn om ouderen in klinische studies te includeren.9 
Waarschijnlijk is het voor artsen ook niet altijd even vanzelfsprekend om kwetsbare oudere 
patiënten te includeren in studies naar nieuwe medicijnen waarvan de effectiviteit en toxici-
teit nog niet geheel bekend zijn. Om deze redenen zal het ‘level A’ bewijs voor behandeling 
van ouderen met kanker schaars blijven. 
Om het evidence based behandelen van ouderen met kanker te verbeteren verdient het 
aanbeveling om meer gebruik te maken van observationele studies. Observationele data zijn 
immers meer representatief voor de algemene, oudere populatie en de klinische praktijk. 
Om bias ten gevolge van confounding by indication te voorkomen bij het vergelijken van be-
handelstrategiën moeten adequate epidemiologische methoden toegepast worden.25 Helaas 
hebben in het verleden veel observationele studies inadequate methoden gebruikt waarbij 
onjuiste conclusies zijn getrokken die op hun beurt hebben geleid tot een lagere geloofwaar-
digheid van dit soort studies.26 Wanneer een studie voldoet aan bepaalde assumpties kan de 
instrumentele variabele-methode gebruikt worden in observationele studies om valide uit-
spraken te doen over de effectiviteit van behandeling.25 Om deze methode toe te passen zijn 
grote datasets, zoals bijvoorbeeld data van de kankerregistraties, nodig met goede kwaliteit 
van data. Om data van verschillende kankerregistraties zinvol te kunnen vergelijken moet 
aan een aantal voorwaarden voldaan worden, zoals het gebruik van eenduidige definities 
voor de gebruikte variabelen en een beperkt percentage aan missende data. Daarnaast is het 
belangrijk om ook data te verzamelen over de algemene gezondheid van de patiënt, zoals 
bijvoorbeeld comorbiteiten en het gebruik van medicatie (polyfarmacie). Op deze manier 
kan een beter inzicht verkregen worden in de interactie tussen kanker en andere ziekten en 
aspecten van de gezondheid. 
gebruik maken van relevante eindpunten voor ouderen 
In klinische trials in kankeronderzoek wordt gebruik gemaakt van tumorgerelateerde eind-
punten om de farmacologische of biologische effectiviteit van het nieuwe medicijn te meten. 
Deze aanpak heeft geresulteerd in eindpunten als progressievrije overleving, ziektevrije 
overleving en pathologische complete respons.27 Klinische trials zouden zich echter niet 
enkel moeten richten op het behandelen van de tumor, maar ook de bredere aspecten van 
het effect van behandeling moeten meenemen. Voor patiënten zijn immers zowel de lengte 
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van leven als de kwaliteit van leven relevante aspecten van de behandeling. Met name bij 
jongere patiënten is lengte van leven mogelijk belangrijker dan kwaliteit van leven, maar 
met het toenemen van de leeftijd verschuift afweging meer en meer in de richting van de 
kwaliteit van leven.28 
In de evaluatie van de gezondheidszorg is er een toenemend besef dat medisch onderzoek 
resultaten uitkomsten moet opleveren die relevant zijn voor patiënten en de behandelaar. 
In een toonaangevende publicatie van Michael Porter in 2010 gaf hij aan dat ‘value should 
always be defined around the customer’.29 Middels deze publicatie introduceerde hij het be-
grip ‘value based healthcare’ wat nu in toenemende mate in ziekenhuizen wereldwijd wordt 
toegepast. Er wordt nu meer nadruk gelegd op deze zogenoemde patient reported outcomes 
zoals fysiek functioneren, symptomen en kwaliteit van leven om de kwaliteit van zorg te 
meten.30 Deze manier van het meten van uitkomsten moet ook zijn vertaalslag vinden naar 
klinisch onderzoek in de geriatrische oncologie.31 De waarde van behandeling moet niet 
alleen gedefinieerd worden door effectiviteit op de tumor maar zou ook de ervaring van 
patiënten die dit middel gebruiken moeten omvatten. 
Uiteindelijk streven artsen en patiënten er naar om zowel lengte van leven als kwaliteit 
van leven te optimaliseren. In klinisch onderzoek naar ouderen met borstkanker zou deze 
beide aspecten als het eindpunt van de studie zichtbaar moeten zijn. Patiëntgerelateerde 
uitkomsten zoals functionele status, cognitieve status en symptomen kunnen hierin bij-
dragen. Onderzoekers en artsen moeten zich ervan bewust zijn dat functionele uitkomsten 
niet geïnterpreteerd moeten worden als adequate maat voor de kwaliteit van leven. Want, 
zoals beschreven in hoofdstuk 9, is kwaliteit van leven evenzeer afhankelijk van iemand 
individuele voorkeuren, verlangens en behoeften en dit is niet altijd rechtstreeks gerelateerd 
aan iemands mate van fysiek functioneren. In hoofdstuk 9 hebben we daarom een nieuw 
eindpunt voorgesteld dat zowel recht doet aan de lengte van leven als aan de kwaliteit van 
leven. Dit nieuwe eindpunt willen we graag zo snel mogelijk introduceren en valideren in 
één van de huidige of toekomstige studies over ouderen met kanker. 
ontwikkelen van een predictiemodel voor ouderen met kanker 
De Climb Every Mountain Study is een observationele cohortstudie waarin patiënten 
ouder dan 70 jaar met niet gemetastaseerde borstkanker zijn geïncludeerd. Daarnaast 
werd in 2014 de Prospective Registration of Issues in Metastatic Breast Cancer (PRIME) 
studie gestart, waarbij vrouwen ouder dan 70 jaar met gemetastaseerde borstkanker zijn 
geincludeerd. Beide studies hebben data verzameld over geriatrische parameters, tumor-
karakteristieken en niveau van functioneren bij aanvang van de studie en gedurende de 
follow-up. In de komende jaren zullen de data van beide studies compleet worden en zal dit 
ons naar verwachting meer inzicht geven in het verloop in de behandeling en in verschil-
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lende domeinen van het functioneren bij ouderen met borstkanker. Tevens is er een nieuw 
onderzoeksproject gestart waarbij data uit bovenstaande studies geïntegreerd worden met 
data van andere studies met het doel om een predictiemodel te creëren voor ouderen met 
borstkanker (Prediction of Outcome, Risk of Toxicity and quality of life in older patients 
TREaTed for breast cancer, PORTRET studie). In dit voorspellingsmodel zullen geriatrische 
indicatoren gecombineerd worden met reeds bekende prognostische factoren om uitkom-
sten met betrekking tot kanker, alsmede de kans op overleving en de kwaliteit van leven 
beter te kunnen voorspellen voor elke individuele patiënt. 
Concluderend kunnen we stellen dat borstkanker, net als vele andere ziekten, een ziekte is 
die hoort bij het ouder worden. Dit zal in de nabije toekomst leiden tot een groei van het 
aantal ouderen met borstkanker voor wie nu nog geen optimale behandeling beschikbaar 
is. Het is daarom belangrijk dat zowel studies als predictiemodellen beter gaan aansluiten 
op de behoeften en wensen van oudere patiënten. Binnenkort zullen de data van enkele 
belangrijke studies klaar zijn voor analyse. Hiermee wordt de basis gelegd voor een nieuw 
predictiemodel dat specifiek gericht is op ouderen met borstkanker en dat eraan zal bijdra-
gen dat de behandeling van deze groep patiënten sterk kan worden verbeterd. 
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